FORM 10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-12-345653.txt : 20120809 0001193125-12-345653.hdr.sgml : 20120809 20120809082808 ACCESSION NUMBER: 0001193125-12-345653 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20120630 FILED AS OF DATE: 20120809 DATE AS OF CHANGE: 20120809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERIDIAN BIOSCIENCE INC CENTRAL INDEX KEY: 0000794172 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 310888197 STATE OF INCORPORATION: OH FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-14902 FILM NUMBER: 121018603 BUSINESS ADDRESS: STREET 1: 3471 RIVER HILLS DR CITY: CINCINNATI STATE: OH ZIP: 45244 BUSINESS PHONE: 5132713700 MAIL ADDRESS: STREET 1: 3471 RIVER HILLS DRIVE CITY: CINCINNATI STATE: OH ZIP: 45244 FORMER COMPANY: FORMER CONFORMED NAME: MERIDIAN DIAGNOSTICS INC DATE OF NAME CHANGE: 19920703 10-Q 1 d370493d10q.htm FORM 10-Q FORM 10-Q

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2012

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 0-14902

MERIDIAN BIOSCIENCE, INC.

Incorporated under the laws of Ohio

31-0888197

(I.R.S. Employer Identification No.)

3471 River Hills Drive

Cincinnati, Ohio 45244

(513) 271-3700

Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.


Class		Outstanding July 31, 2012
Common Stock, no par value		41,272,339

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

INDEX TO QUARTERLY REPORT ON FORM 10-Q


		Page(s)
PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)
	Condensed Consolidated Statements of Operations Three and Nine Months Ended June 30, 2012 and 2011		1

	Condensed Consolidated Statements of Cash Flows Nine Months Ended June 30, 2012 and 2011		2

	Condensed Consolidated Balance Sheets June 30, 2012 and September 30, 2011		3-4

	Condensed Consolidated Statement of Changes in Shareholders’ Equity Nine Months Ended June 30, 2012		5

	Notes to Condensed Consolidated Financial Statements		6-10

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		11-19

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		19

Item 4.	Controls and Procedures		19

PART II.	OTHER INFORMATION

Item 1A.	Risk Factors		19

Item 6.	Exhibits		19

Signature			20

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Meridian relies on proprietary, patented and licensed technologies, and the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian’s main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. The Company cannot predict the possible impact of recently-enacted United States healthcare legislation and any similar initiatives in other countries on its results of operations. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except per share data)


	Three Months Ended				Nine Months Ended
	June 30,				June 30,
	2012		2011		2012		2011
NET SALES	$	42,141	$	40,052	$	129,848	$	118,374
COST OF SALES		14,498		14,701		47,722		43,564

GROSS PROFIT		27,643		25,351		82,126		74,810

OPERATING EXPENSES
Research and development		2,660		2,693		7,441		7,328
Selling and marketing		5,843		5,968		17,192		17,041
General and administrative		6,162		6,559		19,236		19,018
Plant consolidation costs		366		—		1,013		—
Sales and marketing leadership reorganization		—		—		—		1,240

Total operating expenses		15,031		15,220		44,882		44,627

OPERATING INCOME		12,612		10,131		37,244		30,183
OTHER INCOME (EXPENSE)
Interest income		14		26		27		70
Other, net		31		36		304		357

Total other income (expense)		45		62		331		427

EARNINGS BEFORE INCOME TAXES		12,657		10,193		37,575		30,610
INCOME TAX PROVISION		4,063		3,357		12,777		10,489

NET EARNINGS	$	8,594	$	6,836	$	24,798	$	20,121

BASIC EARNINGS PER COMMON SHARE	$	0.21	$	0.17	$	0.60	$	0.49
DILUTED EARNINGS PER COMMON SHARE	$	0.21	$	0.17	$	0.60	$	0.49
AVERAGE NUMBER OF COMMON SHARES
OUTSTANDING - BASIC		41,091		40,737		41,075		40,680
EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARES AND UNITS		593		657		530		673

AVERAGE NUMBER OF COMMON SHARES
OUTSTANDING - DILUTED		41,684		41,394		41,605		41,353

ANTI-DILUTIVE SECURITIES:
Common share options and restricted shares and units		313		160		309		177

DIVIDENDS DECLARED PER COMMON SHARE	$	0.19	$	0.19	$	0.57	$	0.57

The accompanying notes are an integral part of these condensed consolidated financial statements.

Page 1

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited)

(dollars in thousands)


	2012			2011
Nine Months Ended June 30,
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$	24,798		$	20,121
Non-cash items included in net earnings:
Depreciation of property, plant and equipment		2,660			2,525
Amortization of intangible assets		1,608			1,796
Amortization of deferred illumigene instrument costs		587			81
Stock-based compensation		1,670			1,981
Deferred income taxes		(1,491	)		(1,622	)
Loss on disposition and write-down of fixed assets and other assets		203			7
Change in current assets		386			(10,176	)
Change in current liabilities		2,474			2,451
Other, net		(1,007	)		(546	)

Net cash provided by operating activities		31,888			16,618

CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment		(2,985	)		(7,666	)
Proceeds from sale of assets		400			—
Purchases of intangibles and other assets		(1,305	)		(12	)

Net cash used for investing activities		(3,890	)		(7,678	)

CASH FLOWS FROM FINANCING ACTIVITIES
Dividends paid		(23,417	)		(23,192	)
Proceeds and tax benefits from exercises of stock options		399			1,481

Net cash used for financing activities		(23,018	)		(21,711	)

Effect of Exchange Rate Changes on Cash and Equivalents		(668	)		455

Net Increase (Decrease) in Cash and Equivalents		4,312			(12,316	)
Cash and Equivalents at Beginning of Period		23,626			37,879

Cash and Equivalents at End of Period	$	27,938		$	25,563

The accompanying notes are an integral part of these condensed consolidated financial statements.

Page 2

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(dollars in thousands)


ASSETS
	June 30, 2012 (Unaudited)		September 30, 2011


CURRENT ASSETS
Cash and equivalents	$	27,938	$	23,626
Accounts receivable, less allowances of $428 and $310		24,306		24,844
Inventories		33,120		32,689
Prepaid expenses and other current assets		5,081		6,343
Deferred income taxes		3,393		2,852

Total current assets		93,838		90,354

PROPERTY, PLANT AND EQUIPMENT, at Cost
Land		1,172		1,184
Buildings and improvements		26,334		23,033
Machinery, equipment and furniture		35,825		32,408
Construction in progress		1,136		3,887

Subtotal		64,467		60,512
Less: accumulated depreciation and amortization		37,928		33,973

Net property, plant and equipment		26,539		26,539

OTHER ASSETS
Goodwill		22,830		23,124
Other intangible assets, net		10,635		10,947
Restricted cash		1,000		1,000
Deferred illumigene instrument costs, net		3,721		3,304
Other assets		251		225

Total other assets		38,437		38,600

TOTAL ASSETS	$	158,814	$	155,493

The accompanying notes are an integral part of these condensed consolidated financial statements.

Page 3

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(dollars in thousands)


LIABILITIES AND SHAREHOLDERS’ EQUITY
	June 30, 2012 (Unaudited)			September 30, 2011
CURRENT LIABILITIES
Accounts payable	$	6,158		$	5,548
Accrued employee compensation costs		4,640			4,235
Other accrued expenses		5,116			4,692
Income taxes payable		1,626			789

Total current liabilities		17,540			15,264

DEFERRED INCOME TAXES		269			1,705
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY
Preferred stock, no par value, 1,000,000 shares authorized, none issued		—			—
Common shares, no par value, 71,000,000 shares authorized, 41,269,062 and 41,237,120 shares issued, respectively		—			—
Additional paid-in capital		102,012			100,010
Retained earnings		39,446			38,065
Accumulated other comprehensive income		(453	)		449

Total shareholders’ equity		141,005			138,524

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	158,814		$	155,493

The accompanying notes are an integral part of these condensed consolidated financial statements.

Page 4

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Condensed Consolidated Statement of Changes in Shareholders’ Equity (Unaudited)

(dollars and shares in thousands)


	Common Shares Issued			Additional Paid-In Capital		Retained Earnings			Accumulated Other Comprehensive Income (Loss)			Comprehensive Income (Loss)			Total Shareholders’ Equity
Balance at September 30, 2011		41,237		$	100,010	$	38,065		$	449					$	138,524
Cash dividends paid		—			—		(23,417	)		—						(23,417	)
Exercise of stock options		33			332		—			—						332
Issuance of restricted shares, net of forfeitures		(3	)		—		—			—						—
Conversion of restricted stock units		2			—		—			—						—
Stock compensation expense		—			1,670		—			—						1,670
Comprehensive income:
Net earnings		—			—		24,798			—		$	24,798			24,798
Other comprehensive income taxes		—			—		—			483			483			483
Foreign currency translation adjustment		—			—		—			(1,385	)		(1,385	)		(1,385	)

Comprehensive income												$	23,896

Balance at June 30, 2012		41,269		$	102,012	$	39,446		$	(453	)				$	141,005

The accompanying notes are an integral part of these condensed consolidated financial statements.

Page 5

MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Dollars in Thousands, Except Per Share Amounts

(Unaudited)

1.	Basis of Presentation

The interim condensed consolidated financial statements are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, and the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of Management, the interim financial statements include all normal adjustments and disclosures necessary to present fairly the Company’s financial position as of June 30, 2012, the results of its operations for the three and nine month periods ended June 30, 2012 and 2011, and its cash flows for the nine month periods ended June 30, 2012 and 2011. These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company’s fiscal 2011 Annual Report on Form 10-K. Financial information as of September 30, 2011 has been derived from the Company’s audited consolidated financial statements.

The results of operations for interim periods are not necessarily indicative of the results to be expected for the year.

2.	Significant Accounting Policies

(a)

Revenue Recognition and Accounts Receivable –

Revenue is generally recognized from sales when product is shipped and title has passed to the buyer. Revenue for the U.S. Diagnostics segment is reduced at the date of sale for product price adjustments due certain distributors under local contracts. Management estimates accruals for distributor price adjustments based on local contract terms, sales data provided by distributors, estimates of inventories of our products held by distributors, historical statistics, current trends, and other factors. Changes to the accruals are recorded in the period that they become known. Such accruals were $3,871 at June 30, 2012 and $4,176 at September 30, 2011.

Revenue for our Diagnostics segments includes bundled product revenue for our illumigene^® molecular test system. The bundled product includes an instrument, instrument accessories and test kits. If not sold outright, amounts invoiced for the illumigene^® test kits cover the instrument, accessories and test kits. Revenue is recognized based on test kit sales. If not sold outright, costs for the instruments are recognized in cost of sales over the expected instrument utilization period, generally three years.

Life Science revenue for contract services may come from research and development services or manufacturing services, including process development work, or a combination of both. Revenue is recognized based on each of the deliverables in a given arrangement having distinct and separate customer pricing. Pricing is often subject to a competitive bidding process. Contract research and development services may be performed on a “time and materials” basis or “fixed fee” basis. For “time and materials” arrangements, revenue is recognized as services are performed and billed. For “fixed fee” arrangements, revenue is recognized upon completion and acceptance by the customer. For contract manufacturing services, revenue is generally recognized upon delivery of product and acceptance by the customer. In some cases, customers may request that we store on their behalf, clinical grade biologicals that we produce under contract manufacturing agreements. These cases arise when customers do not have clinical grade storage facilities or do not want to risk contamination during transport. For such cases, revenue may be recognized on a bill-and-hold basis. No such bill-and-hold arrangements existed at June 30, 2012 or September 30, 2011.

Page 6

Trade accounts receivable are recorded in the accompanying Condensed Consolidated Balance Sheets at invoiced amounts less provisions for distributor price adjustments and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on current trends and historical write-off experience. The allowance for doubtful accounts and related metrics, such as days’ sales outstanding, are reviewed monthly. Accounts with past due balances over 90 days are reviewed individually for collectibility. Customer invoices are charged off against the allowance when we believe it is probable that the invoices will not be paid. Approximately $5,300 of our accounts receivable at June 30, 2012 is due from Italian hospital customers whose funding ultimately comes from the Italian government. During the fourth quarter of fiscal 2011 and first quarter of fiscal 2012, we experienced a deterioration in the aging of our Italian accounts receivable. While such aging appeared to stabilize during the second and third quarters of fiscal 2012, we continue to monitor such accounts closely.

(b)

Comprehensive Income (Loss) –

Our comprehensive income or loss is comprised of net earnings, foreign currency translation and the related income tax effects.

Assets and liabilities of foreign operations are translated using period-end exchange rates with gains or losses resulting from translation included as a separate component of comprehensive income or loss. Revenues and expenses are translated using exchange rates prevailing during the period. We also recognize foreign currency transaction gains and losses on certain assets and liabilities that are denominated in the Australian dollar, British pound and Euro currencies. These gains and losses are included in other income and expense in the accompanying Condensed Consolidated Statements of Operations.

Comprehensive income for the interim periods was as follows:


	Three Months						Nine Months
	Ended June 30,						Ended June 30,
	2012			2011			2012			2011
Net earnings	$	8,594		$	6,836		$	24,798		$	20,121
Foreign currency translation adjustment		(1,582	)		335			(1,385	)		1,203
Income taxes		554			(117	)		483			(421	)

Comprehensive income	$	7,566		$	7,054		$	23,896		$	20,903

(c)

Income Taxes –

The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between income for financial reporting and income for tax purposes. We prepare estimates of permanent and temporary differences between income for financial reporting purposes and income for tax purposes. These differences are adjusted to actual upon filing of our tax returns, typically occurring in the third and fourth quarters of the current fiscal year for the preceding fiscal year’s estimates.

We account for uncertain tax positions using a benefit recognition model with a two-step approach: (i) a more-likely-than-not recognition criterion; and (ii) a measurement attribute that measures the position as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. If it is not more likely than not that the benefit will be sustained on its technical merits, no benefit is recorded. We recognize accrued interest and penalties related to unrecognized tax benefits as a portion of our income tax provision in the Condensed Consolidated Statements of Operations.

(d)

Stock-based Compensation –

We recognize compensation expense for all share-based awards made to employees, based upon the fair value of the share-based award on the date of the grant. Awards are expensed over their requisite service period.

Page 7

(e)

Cash and Cash Equivalents –

Cash and cash equivalents include the following components:


	June 30, 2012				September 30, 2011
	Cash and Equivalents		Other		Cash and Equivalents		Other
Overnight repurchase agreements	$	13,400	$	—	$	11,784	$	—
Cash on hand –
Restricted		—		1,000		—		1,000
Unrestricted		14,538		—		11,842		—

Total	$	27,938	$	1,000	$	23,626	$	1,000

(f)

Reclassifications –

Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders’ equity.

3.	Inventories

Inventories are comprised of the following:


	June 30, 2012		September 30, 2011
Raw materials	$	7,147	$	7,272
Work-in-process		6,662		7,016
Finished goods - illumigene instruments		2,668		4,179
Finished goods - kits and other		16,643		14,222

Total	$	33,120	$	32,689

4.	Major Customers and Segment Information

Meridian was formed in 1976 and functions as a fully-integrated research, development, manufacturing, marketing and sales organization with primary emphasis in the fields of in vitro diagnostics and life science. Our principal businesses are (i) the development, manufacture and distribution of diagnostic test kits primarily for gastrointestinal, viral, respiratory and parasitic infectious diseases; (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers; and (iii) the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Our reportable segments are U.S. Diagnostics, European Diagnostics and Life Science. Initial segmentation between Diagnostics and Life Science has been determined based upon products and customers, with further segmentation of Diagnostics between U.S. and European being based upon geographic regions served and management responsibility. The U.S. Diagnostics segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the U.S. and countries outside of Australia, Europe, Africa and the Middle East. The European Diagnostics segment consists of the sale and distribution of diagnostic test kits in Australia, Europe, Africa and the Middle East. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad. The Life Science segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Page 8

During the fourth quarter of fiscal 2011, plans were announced to consolidate the Saco, Maine operations into the Memphis, Tennessee facility. This consolidation of facilities is now complete. During the third quarter and nine months ended June 30, 2012, the Company incurred $366 and $1,013, respectively, of costs associated with the facility consolidation, primarily related to employee retention and an additional $210 write-down of the Maine building facility in the third quarter based on a third-party appraisal. To date, $2,070 of total costs have been incurred since the announcement of the consolidation in the fourth quarter of fiscal 2011 ($509 in Cost of Sales and $1,561 in Operating Expenses). Additional costs related to the consolidation totaling approximately $60 are expected to be incurred during the remainder of fiscal 2012, with the majority of such costs to be incurred in connection with retention bonus and other employee-related costs.

Two distributor customers accounted for 48% and 47% of the U.S. Diagnostics segment third-party sales during the three months ended June 30, 2012 and 2011, respectively, and 49% and 50% during the nine months ended June 30, 2012 and 2011, respectively. Two diagnostic manufacturing customers accounted for 11% and 15% of the Life Science segment third-party sales during the three months ended June 30, 2012 and 2011, respectively, and 20% and 14% during the nine months ended June 30, 2012 and 2011, respectively.

Segment information for the interim periods is as follows:


	U.S. Diagnostics		European Diagnostics		Life Science		Eliminations (1)			Total
Three Months Ended June 30, 2012
Net sales -
Third-party	$	26,234	$	5,897	$	10,010	$	—		$	42,141
Inter-segment		2,464		5		133		(2,602	)		—
Operating income (2)		9,442		998		2,118		54			12,612
Goodwill (June 30, 2012)		1,381		—		21,449		—			22,830
Other intangible assets, net (June 30, 2012)		2,423		—		8,212		—			10,635
Total assets (June 30, 2012)		81,911		16,930		97,150		(37,177	)		158,814
Three Months Ended June 30, 2011
Net sales -
Third-party	$	23,829	$	6,612	$	9,611	$	—		$	40,052
Inter-segment		2,875		9		141		(3,025	)		—
Operating income (3)		8,399		978		797		(43	)		10,131
Goodwill (September 30, 2011)		1,381		—		21,743		—			23,124
Other intangible assets, net (September 30, 2011)		1,604		—		9,343		—			10,947
Total assets (September 30, 2011)		73,850		19,390		92,467		(30,214	)		155,493
Nine Months Ended June 30, 2012
Net sales -
Third-party	$	80,091	$	18,326	$	31,431	$	—		$	129,848
Inter-segment		7,428		9		793		(8,230	)		—
Operating income (2)		29,377		2,398		5,526		(57	)		37,244

Page 9


Nine Months Ended June 30, 2011
Net sales -
Third-party	$	72,007	$	18,926	$	27,441	$	—		$	118,374
Inter-segment		7,938		16		459		(8,413	)		—
Operating income (3)		26,780		1,781		1,499		123			30,183

(1)	Eliminations consist of inter-segment transactions.

(2)	Life Science includes $366 and $1,013 of costs related to consolidation of the Maine operations into the Tennessee facility during the three and nine months ended June 30, 2012, respectively.

(3)	U.S. Diagnostics and European Diagnostics include $365 and $875, respectively, in the nine months ended June 30, 2011 related to sales and marketing leadership reorganization costs.

Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation.

5.	Intangible Assets

A summary of our acquired intangible assets subject to amortization, as of June 30, 2012 and September 30, 2011 is as follows:


	June 30, 2012				September 30, 2011
	Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization
Manufacturing technologies, core products and cell lines	$	11,625	$	9,117	$	11,626	$	8,545
Trademarks, licenses and patents		4,842		1,667		3,538		1,337
Customer lists and supply agreements		12,219		7,267		12,222		6,557

	$	28,686	$	18,051	$	27,386	$	16,439

The actual aggregate amortization expense for these intangible assets was $545 and $595 for the three months ended June 30, 2012 and 2011, respectively, and $1,608 and $1,796 for the nine months ended June 30, 2012 and 2011, respectively. The estimated aggregate amortization expense for these intangible assets for each of the fiscal years through fiscal 2017 is as follows: remainder of fiscal 2012 – $549, fiscal 2013 – $2,179, fiscal 2014 – $1,743, fiscal 2015 – $1,495, fiscal 2016 – $1,153 and fiscal 2017 – $911.

Page 10

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Refer to “Forward Looking Statements” following the Index in front of this Form 10-Q. In the discussion that follows, all amounts are in thousands (both tables and text), except per share data and percentages.

Following is a discussion and analysis of the financial statements and other statistical data that management believes will enhance the understanding of Meridian’s financial condition, changes in financial condition and results of operations. This discussion should be read in conjunction with the financial statements and notes thereto beginning on page 1.

Results of Operations

Three Months Ended June 30, 2012

Net earnings for the third quarter of fiscal 2012 increased 26% to $8,594, or $0.21 per diluted share, from net earnings for the third quarter of fiscal 2011 of $6,836, or $0.17 per diluted share. This increase reflects the combined effects of increased sales and stable operating expense levels. The fiscal 2012 third quarter includes $366 of costs associated with the consolidation of the Saco, Maine operations into the Memphis, Tennessee facility (impact on earnings of $238, or less than $0.01 per diluted share). Consolidated sales increased 5% to $42,141 for the third quarter of fiscal 2012 compared to the same period of the prior year. Sales increases in our C. difficile and Foodborne diagnostic focus product families, and our Life Science businesses, contributed to this increase, while sales in our H. pylori focus product family were flat compared to the fiscal 2011 third quarter.

Sales for the U.S. Diagnostics segment for the third quarter of fiscal 2012 increased 10% compared to the third quarter of fiscal 2011, reflecting growth across all of our focus product families – 6% growth in our H. pylori products, 9% growth in our foodborne products, and 25% growth in our C. difficile products. Third quarter 2012 sales for our European Diagnostics segment decreased 11% compared to the third quarter of fiscal 2011. On an organic basis, which excludes the effects of currency translation, sales of our European Diagnostics segment were flat compared to the 2011 third quarter. Solid 10% growth in European sales of our C. difficile products – resulting in large part from the continued acceptance of our C. difficile GDH product, which was introduced internationally during the first quarter of fiscal 2011 – served to offset a decrease in H. pylori and foodborne product sales within this segment. Primarily reflecting growth in our molecular reagent business, sales of our Life Science segment increased by 4% during the third quarter of fiscal 2012 compared to the third quarter of fiscal 2011.

Nine Months Ended June 30, 2012

For the nine month period ended June 30, 2012, net earnings increased 23% to $24,798, or $0.60 per diluted share, from net earnings for the comparable fiscal 2011 period of $20,121, or $0.49 per diluted share. This increase reflects the combined effects of increased sales and stable operating expense levels. The 2012 year-to-date period includes $1,013 of costs associated with the consolidation of the Saco, Maine operations into the Memphis, Tennessee facility (impact on earnings of $659, or $0.02 per diluted share), while the 2011 period includes $1,240 of costs related to the reorganization of our European and global sales and marketing leadership during the second quarter of fiscal 2011 (impact on earnings of $872 or $0.02 per diluted share). Consolidated sales increased 10% to $129,848 for the first nine months of fiscal 2012 compared to the same period of the prior fiscal year, reflecting increases in sales across all of our diagnostic focus product families: C. difficile, Foodborne and H. pylori, and our Life Science businesses.

During the first nine months of fiscal 2012, sales for the U.S. Diagnostics segment increased 11% from the comparable fiscal 2011 period. This increase reflects growth across all of our focus product families – 12% growth in our H. pylori products, 17% growth in our foodborne products and 30% growth in our C. difficile products. Sales of our European Diagnostics segment for the first nine months of fiscal 2012 decreased 3% compared to the first nine months of fiscal 2011. On an organic basis, which excludes the effects of currency translation, sales of our European Diagnostics segment increased 3% during the fiscal 2012 year-to-date period, reflecting growth in our C. difficile and H. pylori focus product families being partially offset by a decline in sales of our foodborne products. With growth in both its core bulk reagent and molecular reagent businesses, sales of our Life Science segment increased by 15% during the first nine months of fiscal 2012 over the comparable fiscal 2011 period.

Page 11

Non-GAAP Information

The tables below provide information on net earnings, basic earnings per share and diluted earnings per share, excluding the effect of costs associated with the consolidation of our Saco, Maine operations into our Memphis, Tennessee facility (fiscal 2012) and the reorganizing of our sales and marketing leadership (fiscal 2011), each of which is a non-GAAP financial measure, as well as reconciliations to amounts reported under U.S. Generally Accepted Accounting Principles. We believe that this information is useful to those who read our financial statements and evaluate our operating results because:

These measures help to appropriately evaluate and compare the results of operations from period to period by removing the impact of non-routine costs related to consolidating the Maine operations (fiscal 2012) and reorganizing our sales and marketing leadership (fiscal 2011); and

These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our Board of Directors, and as a basis for strategic planning and forecasting.


	Three Months				Nine Months
	Ended June 30,				Ended June 30,
	2012		2011		2012		2011
Net Earnings -
U.S. GAAP basis	$	8,594	$	6,836	$	24,798	$	20,121
Facility consolidation costs (1)		238		—		659		—
Sales & marketing leadership reorganization (2)		—		—		—		872

Adjusted earnings	$	8,832	$	6,836	$	25,457	$	20,993

Net Earnings per Basic Common Share -
U.S. GAAP basis	$	0.21	$	0.17	$	0.60	$	0.49
Facility consolidation costs (1)		0.01		—		0.02		—
Sales & marketing leadership reorganization (2)		—		—		—		0.02

Adjusted Basic EPS (3)	$	0.21	$	0.17	$	0.62	$	0.52

Net Earnings per Diluted Common Share -
U.S. GAAP basis	$	0.21	$	0.17	$	0.60	$	0.49
Facility consolidation costs (1)		0.01		—		0.02		—
Sales & marketing leadership reorganization (2)		—		—		—		0.02

Adjusted Diluted EPS (4)	$	0.21	$	0.17	$	0.61	$	0.51

(1)	These facility consolidation costs are net of income tax effects of $128 and $354 for the three and nine month periods, respectively, which were calculated using the effective tax rates of the jurisdictions in which the costs were incurred.

(2)	These leadership reorganization costs are net of the $368 income tax effect for the nine month period, which was calculated using the effective tax rates of the jurisdictions in which the costs were incurred.

(3)	Net Earnings per Basic Common Share for the three months ended June 30, 2012 and the nine months ended June 30, 2011 do not sum to the total due to rounding.

(4)	Net Earnings per Diluted Common Share for the three and nine months ended June 30, 2012 do not sum to the total due to rounding.

Page 12

Revenue Overview

Our Diagnostics segments provided the largest share of our consolidated revenues, 76% for the third quarters of both fiscal 2012 and fiscal 2011, and 76% and 77% for the first nine months of fiscal 2012 and 2011, respectively. Sales from our focus families (C. difficile, Foodborne and H. pylori) comprised 63% and 61% of our Diagnostics segments’ revenues during the third quarters of fiscal 2012 and 2011, respectively, and 62% and 57% for the nine month periods ended June 30, 2012 and 2011, respectively.

Revenue for the fiscal 2012 third quarter for both of our Diagnostics segments combined increased 6%, reflecting growth in our foodborne (6%) and C. difficile (19%) product families, and flat sales in our H. pylori product family compared to the prior year quarter. Respiratory product sales, including influenza respiratory products, decreased 2%. On an organic basis, sales for our European Diagnostics segment were flat compared to the prior year third quarter, with the growth in our C. difficile product family being offset by sales declines in our H. pylori, foodborne and respiratory products.

For the first nine months of fiscal 2012, revenue for both of our Diagnostics segments combined increased 8% from the comparable fiscal 2011 period. This increase reflects growth across all of our focus product families – 7% growth in our H. pylori products, 15% growth in our foodborne products and 24% growth in our C. difficile products. Excluding the effects of currency translation, our European Diagnostics segment’s sales during the nine months ended June 30, 2012 increased 3% relative to the comparable fiscal 2011 period, reflecting the combined effects of growth in our C. difficile and H. pylori product families, partially offset by a decline in the sales of our foodborne and respiratory products.

As an enterprise with global operations and markets, our business and financial performance are in part dependent upon global economic conditions, and we could be negatively impacted by a global, regional or national economic crisis, including sovereign risk in the event of deterioration in the credit worthiness of, or a default by, local governments. We are particularly susceptible to the economic conditions in countries where government-sponsored healthcare systems are the primary payers for healthcare, including those countries within the European Union that are reducing their public expenditures in an effort to achieve cost savings. While to-date such factors have not had a significant negative impact on our results or operations, we continue to monitor and plan for the potential impact of these global economic factors.

In addition, there have been a number of media reports questioning the longevity of the Euro currency, and whether certain countries might exit the Euro currency. We express no opinion on either of these matters. In the event that the Euro currency would completely dissolve, or in the event certain countries exited the Euro currency, the carrying value of our assets and liabilities in European countries where we have a direct presence could be materially affected as legacy currencies are re-implemented. We continue to monitor this situation and have begun to prepare contingency plans.

C. difficile Products

Our illumigene^® molecular C. difficile product has now been available in markets around the world for over 24 months. Sales of this product were approximately $6,200 and $16,300 in the three and nine months ended June 30, 2012, respectively. We have approximately 900 customers providing service to in excess of 1,000 hospitals and laboratories worldwide. It generally takes a customer 60-90 days from purchase order placement to become revenue producing – a timeframe we are continually working to reduce. Our illumigene^® molecular C. difficile product has restored the C. difficile product family to positive sales growth, 19% and 24% during the three and nine months ended June 30, 2012, respectively, and has allowed us to continue to recover lost toxin test volume.

Our major competitors in this product family are Cepheid and Becton Dickinson (molecular) and Alere (immunoassay). We believe that we have several principal advantages versus our competition. First, our molecular instrumentation package has a smaller footprint and significantly lower cost than either Cepheid or Becton Dickinson. We believe that this advantage allows our product to fit into virtually any size hospital or reference laboratory. We believe that our second principal advantage is the breadth of our C. difficile product offerings. With the launch of our molecular product and FDA clearance of our common antigen C. difficile products – Premier C. difficile GDH received FDA clearance in May 2011, and ImmunoCard C. difficile GDH received FDA clearance in December 2011 – unlike our primary competitors, we are in a position to offer a full line of testing solutions to our clinical laboratory customers around the world to counter the competitive pressures surrounding this market. Additionally, we hold the only FDA-approved claim for C. difficile testing in the pediatric population. These advantages, along with the performance features of the products in our C. difficile portfolio, give us a compelling product offering for any hospital testing method preference.

Page 13

During December 2011, we received FDA clearance for our second molecular test for the illumigene^® molecular platform, illumigene^® Group B Streptococcus (GBS). Our GBS test has been placed with over 100 customers, most of which are current C. difficile customers. During the quarter, we generated approximately $300 in GBS revenues; approximately $600 during the fiscal year-to-date nine month period. Regarding additional tests being developed for the platform: the test for Group A Streptococcus has cleared clinical trials and was submitted to the FDA for marketing clearance in July 2012; and the test for Mycoplasma pneumoniae is currently in clinical trials and is expected to be submitted to the FDA for marketing clearance later this year. Following these, we expect an illumigene^® platform-based test for Bordetella pertussis to clear formal clinical trials and be submitted to the FDA for marketing clearance.

In addition to Cepheid, Becton Dickinson and Alere, other competitors are beginning to enter the C. difficile market. Quest Diagnostics and Great Basin recently received FDA clearance for a molecular C. difficile test and Quidel received CE marking approval for a molecular C. difficile test for sale within the European Union. Although we believe that the breadth of our C. difficile product offerings and our low cost molecular platform provide key advantages to the offerings of our competitors, selling prices may come under pressure as more competitors enter the market.

Foodborne Products

Although our foodborne products are marketed and sold on a global basis, most of our sales volume is within the U.S. Diagnostics segment. We continue to see demand increases in the United States, as laboratories realize the benefits of increased sensitivity and faster turnaround time with our tests for Enterohemorrhagic E. coli (EHEC) and Campylobacter, compared to traditional culture methods. Sales increases for these products within the U.S. Diagnostics segment were 9% and 17% for the three and nine month periods ended June 30, 2012, respectively.

H. pylori Products

During the third quarter of fiscal 2012, sales of our H. pylori products grew 6% for our U.S. Diagnostics segment; 12% during the nine month fiscal year-to-date period. This increase in our U.S. Diagnostics segment continues to reflect the benefits of our partnerships with managed care companies in promoting the health and economic benefits of a test and treat strategy, and the ongoing effects of such strategy moving physician behavior away from serology-based testing toward direct antigen testing. Compared to the third quarter of fiscal 2011, sales of H. pylori products for our European Diagnostics segment declined 3% on an organic basis for the third quarter of fiscal 2012, due in large part to order patterns of certain distributors. Such sales grew 3% for the year-over-year nine month periods ended June 30.

Group Purchasing Organizations and Integrated Delivery Networks

In our U.S. Diagnostics segment, consolidation of the U.S. healthcare industry over the last several years has led to the creation of group purchasing organizations (GPOs) and integrated delivery networks (IDNs) that aggregate buying power for hospital groups and put pressure on our selling prices. We have multi-year supply agreements with several GPOs and IDNs. These agreements help secure our products with these customers and lead to new business.

Life Science Segment

Sales for our Life Science segment increased 4% for the third quarter of fiscal 2012 and 15% for the nine month fiscal year-to-date period, reflecting increases in both our core bulk reagent business (1% quarterly and 16% year-to-date) and our molecular reagent business (9% quarterly and 13% year-to-date). The year-to-date increase in the core bulk reagent business largely results from the completion of certain contract manufacturing projects and increased orders for Rubella and Hepatitis A proteins. Our molecular reagent business, operated through our Bioline Group, continues to benefit from its new product launches and advancements during recent months – most notably its new SensiFAST™ and MyTaq™ PCR components. Revenues for our Life Science segment are inherently dependent upon customer order patterns and timing of contract manufacturing work. We expect revenues for the fourth quarter of fiscal 2012 to be in the range of $9,000 to $10,000.

Page 14

Foreign Currency

During the third quarter of fiscal 2012, currency exchange rates had an approximate $800 unfavorable impact on revenue; $650 within the European Diagnostics segment and $150 in the Life Science segment. This compares to currency exchange having an approximate $650 favorable impact on revenue in the third quarter of fiscal 2011. On a nine month year-to-date basis, currency exchange rates had an approximate $1,040 unfavorable impact on fiscal 2012 revenue; $890 within the European Diagnostics segment and $150 in the Life Science segment. This compares to currency exchange having an approximate $165 favorable impact on revenue in the first nine months of fiscal 2011.

The volatility in the Euro-USD exchange rate increased significantly during the quarter, and this may continue into the foreseeable future until such time as the sovereign debt crisis situation in Europe is resolved. Each one-point decline in the Euro-USD exchange rate (e.g., 1.28 to 1.27) negatively affects the revenues of our European Diagnostics segment by approximately $170. However, we would not expect such exchange rate fluctuations to have a significant impact on operating income. This results from the fact that we are also exposed to foreign currency risk related to the supply of certain European-manufactured diagnostic test kits, which serves to provide a natural hedge against the impact on European Diagnostics revenue.

Significant Customers

Two national distributors in our U.S. Diagnostics segment accounted for 48% and 47% of total sales for this segment for the third quarters of fiscal 2012 and 2011, respectively, and 49% and 50% during the nine months ended June 30, 2012 and 2011, respectively.

Two diagnostic manufacturing customers in our Life Science segment accounted for 11% and 15% of total sales for this segment for the third quarters of fiscal 2012 and 2011, respectively, and 20% and 14% during the nine months ended June 30, 2012 and 2011, respectively. The fluctuation in the percentage of sales in both periods reflects the inherent volatility in the buying patterns of these customers.

Segment Revenues

Revenues for the Diagnostics segments, in the normal course of business, may be affected from quarter to quarter by buying patterns of major distributors, seasonality and strength of certain diseases, and foreign currency exchange rates. Revenues for the Life Science segment, in the normal course of business, may be affected from quarter to quarter by the timing and nature of arrangements for contract services work, which may have longer production cycles than bioresearch reagents and bulk antigens and antibodies, as well as buying patterns of major customers, and foreign currency exchange rates. We believe that the overall breadth of our product lines serves to reduce the variability in consolidated revenues.

Page 15

Revenues for each of our segments are shown below.


	Three Months Ended June 30,									Nine Months Ended June 30,
	2012			2011			Inc (Dec)			2012			2011			Inc (Dec)
U.S. Diagnostics	$	26,234		$	23,829			10	%	$	80,091		$	72,007			11	%
European Diagnostics		5,897			6,612			(11	)%		18,326			18,926			(3	)%
Life Science		10,010			9,611			4	%		31,431			27,441			15	%

Consolidated	$	42,141		$	40,052			5	%	$	129,848		$	118,374			10	%

International -
U.S. Diagnostics	$	1,420		$	1,845			(23	)%	$	4,637		$	5,058			(8	)%
European Diagnostics		5,897			6,612			(11	)%		18,326			18,926			(3	)%
Life Science		5,737			5,365			7	%		18,535			15,238			22	%

Total	$	13,054		$	13,822			(6	)%	$	41,498		$	39,222			6	%

% of total sales		31	%		35	%					32	%		33	%

Gross Profit


	Three Months Ended June 30,									Nine Months Ended June 30,
	2012			2011			Change			2012			2011			Change
Gross Profit	$	27,643		$	25,351			9	%	$	82,126		$	74,810			10	%
Gross Profit Margin		66	%		63	%		+3 points			63	%		63	%		None

The overall gross profit margin increase for the third quarter of fiscal 2012 results primarily from the combined effects of the mix of products sold, as well as the mix of sales from the Company’s segments.

Our overall operations consist of the sale of diagnostic test kits for various disease states and in alternative test formats, as well as bioresearch reagents, bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, proficiency panels, contract research and development, and contract manufacturing services. Product sales mix shifts, in the normal course of business, can cause the consolidated gross profit margin to fluctuate by several points.

Page 16

Operating Expenses


	Three Months Ended June 30, 2012
	Research & Development			Selling & Marketing			General & Administrative			Other (1)			Total Operating Expenses
2011 Expenses	$	2,693		$	5,968		$	6,559		$	—		$	15,220

% of Sales		7	%		15	%		16	%		—	%		38	%
Fiscal 2012 Increases (Decreases):
U.S. Diagnostics		(30	)		(274	)		(124	)		—			(428	)
European Diagnostics		—			(89	)		182			—			93
Life Science		(3	)		238			(455	)		366			146

2012 Expenses	$	2,660		$	5,843		$	6,162		$	366		$	15,031

% of Sales		6	%		14	%		15	%		1	%		36	%
% Increase (Decrease)		(1	)%		(2	)%		(6	)%		NMF			(1	)%

	Nine Months Ended June 30, 2012
	Research & Development			Selling & Marketing			General & Administrative			Other (1)			Total Operating Expenses
2011 Expenses	$	7,328		$	17,041		$	19,018		$	1,240		$	44,627

% of Sales		6	%		14	%		16	%		1	%		38	%
Fiscal 2012 Increases (Decreases):
U.S. Diagnostics		361			(676	)		884			(365	)		204
European Diagnostics		—			22			366			(875	)		(487	)
Life Science		(248	)		805			(1,032	)		1,013			538

2012 Expenses	$	7,441		$	17,192		$	19,236		$	1,013		$	44,882

% of Sales		6	%		13	%		15	%		1	%		35	%
% Increase (Decrease)		2	%		1	%		1	%		(18	)%		1	%

(1)	Comprised of costs related to reorganizing our sales and marketing leadership (2011) and consolidating our Maine and Tennessee operations (2012).

Overall, the relative stability in total operating expense during both the third quarter and first nine months of fiscal 2012 continues to result in large part from the combined effects of our (i) ongoing efforts to control spending in each of our segments while investing the necessary resources in our strategic areas of growth; (ii) beginning to realize cost savings from the consolidation of our Core Life Science operations into one facility; (iii) incurring costs in connection with the consolidation of our Saco, Maine operations into our Memphis, Tennessee location during the three and nine months ended June 30, 2012 of approximately $366 and $1,013, respectively; and (iv) incurring during the second quarter of fiscal 2011 approximately $1,240 of costs in connection with the reorganization of our European and Global Sales and Marketing Leadership. The Maine and Tennessee facility consolidation costs incurred during the third quarter of fiscal 2012 and year-to-date period relate primarily to retention bonus costs for personnel scheduled to terminate at varying times during fiscal 2012 and an additional write-down of the Maine building facility.

Page 17

Operating Income

Operating income increased 24% to $12,612 for the third quarter of fiscal 2012, and increased 23% to $37,244 for the first nine months of fiscal 2012, as a result of the factors discussed above.

Other Income and Expense

The decrease in other income, net, during the nine month year-to-date period can primarily be attributed to the net effects of an improvement in net currency exchange gains/losses of approximately $100 and a decrease in grant income from a foreign governmental agency of approximately $170.

Income Taxes

The effective rate for income taxes was 32% for the third quarter and 34% for the first nine months of fiscal 2012, which on a quarterly basis is one percentage point lower than the corresponding prior year period and flat on a year-to-date basis. The decrease in rates primarily results from the effect of adjusting, upon filing of the federal tax return, the previously estimated permanent and temporary differences between income for financial reporting purposes and income for tax purposes. For the fiscal year ending September 30, 2012, we expect the effective tax rate to approximate 35%.

Liquidity and Capital Resources

Comparative Cash Flow Analysis

Our cash flow and financing requirements are determined by analyses of operating and capital spending budgets, consideration of acquisition plans, and consideration of common share dividends. We have historically maintained a credit facility to augment working capital requirements and to respond quickly to acquisition opportunities. Our investment portfolio presently contains overnight repurchase agreements.

We have an investment policy that guides the holdings of our investment portfolio. Our objectives in managing the investment portfolio are to (i) preserve capital; (ii) provide sufficient liquidity to meet working capital requirements and fund strategic objectives such as acquisitions; and (iii) capture a market rate of return commensurate with market conditions and our policy’s investment eligibility criteria. As we look forward, we will continue to manage the holdings of our investment portfolio with preservation of capital being the primary objective.

At the present time, we do not expect current conditions in the financial markets, or overall economic conditions to have a significant impact on our liquidity needs, financial condition, or results of operations, although no assurances can be made in this regard. We intend to continue to fund our working capital requirements and dividends from current cash flows from operating activities and cash on hand. If needed, we also have an additional source of liquidity through our $30,000 bank credit facility, which we expect to renew prior to its expiration on September 15, 2012. Approximately $5,300 of our accounts receivable at June 30, 2012 is due from Italian hospital customers whose funding ultimately comes from the Italian government. During the fourth quarter of fiscal 2011 and first quarter of fiscal 2012, we experienced a deterioration in the aging of our Italian accounts receivable. While such aging appeared to stabilize during the second and third quarters of fiscal 2012, we continue to monitor such accounts closely. Our liquidity needs may change if overall economic conditions worsen and/or liquidity and credit within the financial markets remains tight for an extended period of time, and such conditions impact the collectibility of our customer accounts receivable or credit terms with our vendors, or disrupt the supply of raw materials and services.

Net cash provided by operating activities increased 92% for the first nine months of fiscal 2012 to $31,888, reflecting the 23% increase in net earnings and the effects of net working capital changes related to our investments in illumigene^® inventory and the timing of payments with suppliers. Net cash flows from operating activities and cash on hand are anticipated to be adequate to fund working capital requirements, capital expenditures and dividends during the next 12 months. During the third quarter of fiscal 2012, our $0.19 per share cash dividend approximated 90% of our quarterly diluted earnings per share, nearly in line with the Company’s long-standing policy of setting a payout ratio of between 75% and 85% of each fiscal year’s expected net earnings. We believe that this positive dividend payout relationship will continue, although no assurances can be made in this regard. During the first nine months of fiscal 2012, cash generated from the Company’s operating activities exceeded the quarterly dividend by 36%.

Page 18

Capital Resources

We have a $30,000 credit facility with a commercial bank that expires on September 15, 2012, which we expect to renew. As of July 31, 2012, there were no borrowings outstanding on this facility and we had 100% borrowing capacity available to us. We have had no borrowings outstanding under this facility during the first nine months of fiscal 2012, or during the full year of fiscal 2011.

Our capital expenditures are estimated to range between approximately $3,000 to $5,000 for fiscal 2012, with the actual amount depending upon actual operating results and the phasing of certain projects. Such expenditures may be funded with cash and equivalents on hand, operating cash flows, and/or availability under the $30,000 credit facility discussed above.

We do not utilize any special-purpose financing vehicles or have any undisclosed off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes in the Company’s exposure to market risk since September 30, 2011.

ITEM 4. CONTROLS AND PROCEDURES

As of June 30, 2012, an evaluation was completed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) and 15d-15(b) promulgated under the Securities Exchange Act of 1934, as amended. Based on that evaluation, our management, including the CEO and CFO, concluded that our disclosure controls and procedures were effective as of June 30, 2012. There have been no changes in our internal control over financial reporting identified in connection with the evaluation of internal control that occurred during the third quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, or in other factors that could materially affect internal control subsequent to June 30, 2012.

PART II. OTHER INFORMATION

ITEM 1A. RISK FACTORS

There have been no material changes from risk factors as previously disclosed in the Registrant’s Form 10-K in response to Item 1A to Part I of Form 10-K.

ITEM 6. EXHIBITS

The following exhibits are being filed or furnished as a part of this Quarterly Report on Form 10-Q.



31.1		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)

31.2		Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)

32		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101		The following financial information from Meridian Bioscience Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 filed with the SEC on August 9, 2012, formatted in XBRL includes: (i) Condensed Consolidated Statements of Operations for the three and nine months ended June 30, 2012 and 2011, (ii) Condensed Consolidated Statements of Cash Flows for the nine months ended June 30, 2012 and 2011, (iii) Condensed Consolidated Balance Sheets as of June 30, 2012 and September 30, 2011, (iv) Condensed Consolidated Statement of Shareholders’ Equity for the nine months ended June 30, 2012, and (v) the Notes to Condensed Consolidated Financial Statements

Page 19

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		MERIDIAN BIOSCIENCE, INC.

Date: August 9, 2012		/s/ Melissa A. Lueke
		Melissa A. Lueke
		Executive Vice President and Chief Financial Officer

Page 20

EX-31.1 2 d370493dex311.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER Certification of Principal Executive Officer

Exhibit 31.1

Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a)

I, John A. Kraeutler, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Meridian Bioscience, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2012

/s/ John A. Kraeutler

John A. Kraeutler

Chief Executive Officer

EX-31.2 3 d370493dex312.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER Certification of Principal Financial Officer

Exhibit 31.2

Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a)

I, Melissa A. Lueke, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Meridian Bioscience, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2012

/s/ Melissa A. Lueke

Melissa A. Lueke

Executive Vice President and Chief Financial Officer

EX-32 4 d370493dex32.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER Certification of Chief Executive Officer and Chief Financial Officer

Exhibit 32

Meridian Bioscience, Inc.

Certification of Chief Executive Officer and Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the filing with the Securities and Exchange Commission of the Quarterly Report of Meridian Bioscience, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2012 (the “Report”), the undersigned officers of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ John A. Kraeutler

John A. Kraeutler

Chief Executive Officer

August 9, 2012

/s/ Melissa A. Lueke

Melissa A. Lueke

Executive Vice President and

Chief Financial Officer

August 9, 2012

EX-101.INS 5 vivo-20120630.xml XBRL INSTANCE DOCUMENT 0000794172 us-gaap:CommonStockMember 2011-10-01 2012-06-30 0000794172 us-gaap:RetainedEarningsMember 2012-06-30 0000794172 us-gaap:AdditionalPaidInCapitalMember 2012-06-30 0000794172 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-06-30 0000794172 us-gaap:RetainedEarningsMember 2011-09-30 0000794172 us-gaap:AdditionalPaidInCapitalMember 2011-09-30 0000794172 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-09-30 0000794172 us-gaap:CommonStockMember 2012-06-30 0000794172 us-gaap:CommonStockMember 2011-09-30 0000794172 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-10-01 2012-06-30 0000794172 vivo:UnitedStatesDiagnosticsMember 2012-04-01 2012-06-30 0000794172 vivo:LifeScienceMember 2012-04-01 2012-06-30 0000794172 vivo:EuropeanDiagnosticsMember 2012-04-01 2012-06-30 0000794172 us-gaap:BusinessIntersegmentEliminationsMember 2012-04-01 2012-06-30 0000794172 vivo:UnitedStatesDiagnosticsMember 2011-10-01 2012-06-30 0000794172 vivo:LifeScienceMember 2011-10-01 2012-06-30 0000794172 vivo:EuropeanDiagnosticsMember 2011-10-01 2012-06-30 0000794172 us-gaap:BusinessIntersegmentEliminationsMember 2011-10-01 2012-06-30 0000794172 vivo:UnitedStatesDiagnosticsMember 2011-04-01 2011-06-30 0000794172 vivo:LifeScienceMember 2011-04-01 2011-06-30 0000794172 vivo:EuropeanDiagnosticsMember 2011-04-01 2011-06-30 0000794172 us-gaap:BusinessIntersegmentEliminationsMember 2011-04-01 2011-06-30 0000794172 vivo:UnitedStatesDiagnosticsMember 2010-10-01 2011-06-30 0000794172 vivo:LifeScienceMember 2010-10-01 2011-06-30 0000794172 vivo:EuropeanDiagnosticsMember 2010-10-01 2011-06-30 0000794172 us-gaap:BusinessIntersegmentEliminationsMember 2010-10-01 2011-06-30 0000794172 vivo:KitsAndOtherMember 2012-06-30 0000794172 vivo:IllumigeneInstrumentsMember 2012-06-30 0000794172 vivo:KitsAndOtherMember 2011-09-30 0000794172 vivo:IllumigeneInstrumentsMember 2011-09-30 0000794172 vivo:TrademarksLicensesAndPatentsMember 2012-06-30 0000794172 vivo:ManufacturingTechnologiesCoreProductsAndCellLinesMember 2012-06-30 0000794172 vivo:CustomerListsAndSupplyAgreementsMember 2012-06-30 0000794172 vivo:TrademarksLicensesAndPatentsMember 2011-09-30 0000794172 vivo:ManufacturingTechnologiesCoreProductsAndCellLinesMember 2011-09-30 0000794172 vivo:CustomerListsAndSupplyAgreementsMember 2011-09-30 0000794172 us-gaap:RetainedEarningsMember 2011-10-01 2012-06-30 0000794172 us-gaap:ComprehensiveIncomeMember 2011-10-01 2012-06-30 0000794172 us-gaap:OtherInvestmentsMember 2012-06-30 0000794172 us-gaap:OtherInvestmentsMember 2011-09-30 0000794172 2011-06-30 0000794172 2010-09-30 0000794172 vivo:UnitedStatesDiagnosticsMember 2012-06-30 0000794172 vivo:LifeScienceMember 2012-06-30 0000794172 vivo:EuropeanDiagnosticsMember 2012-06-30 0000794172 us-gaap:BusinessIntersegmentEliminationsMember 2012-06-30 0000794172 vivo:UnitedStatesDiagnosticsMember 2011-09-30 0000794172 vivo:LifeScienceMember 2011-09-30 0000794172 vivo:EuropeanDiagnosticsMember 2011-09-30 0000794172 us-gaap:BusinessIntersegmentEliminationsMember 2011-09-30 0000794172 2012-04-01 2012-06-30 0000794172 2011-04-01 2011-06-30 0000794172 2010-10-01 2011-06-30 0000794172 us-gaap:AdditionalPaidInCapitalMember 2011-10-01 2012-06-30 0000794172 2012-06-30 0000794172 2011-09-30 0000794172 2012-07-31 0000794172 2011-10-01 2012-06-30 vivo:Customer xbrli:pure iso4217:USD xbrli:shares xbrli:shares iso4217:USD

<table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">1.</td> <td align="left" valign="top">Basis of Presentation </td> </tr> </table> The interim condensed consolidated financial statements are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, and the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of Management, the interim financial statements include all normal adjustments and disclosures necessary to present fairly the Company’s financial position as of June 30, 2012, the results of its operations for the three and nine month periods ended June 30, 2012 and 2011, and its cash flows for the nine month periods ended June 30, 2012 and 2011. These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company’s fiscal 2011 Annual Report on Form 10-K. Financial information as of September 30, 2011 has been derived from the Company’s audited consolidated financial statements. The results of operations for interim periods are not necessarily indicative of the results to be expected for the year.

<table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">2.</td> <td align="left" valign="top">Significant Accounting Policies </td> </tr> </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">(a)</td> <td align="left" valign="top"> Revenue Recognition and Accounts Receivable – </td> </tr> </table> Revenue is generally recognized from sales when product is shipped and title has passed to the buyer. Revenue for the U.S. Diagnostics segment is reduced at the date of sale for product price adjustments due certain distributors under local contracts. Management estimates accruals for distributor price adjustments based on local contract terms, sales data provided by distributors, estimates of inventories of our products held by distributors, historical statistics, current trends, and other factors. Changes to the accruals are recorded in the period that they become known. Such accruals were $3,871 at June 30, 2012 and $4,176 at September 30, 2011. Revenue for our Diagnostics segments includes bundled product revenue for our illumigene ® molecular test system. The bundled product includes an instrument, instrument accessories and test kits. If not sold outright, amounts invoiced for the illumigene® test kits cover the instrument, accessories and test kits. Revenue is recognized based on test kit sales. If not sold outright, costs for the instruments are recognized in cost of sales over the expected instrument utilization period, generally three years. Life Science revenue for contract services may come from research and development services or manufacturing services, including process development work, or a combination of both. Revenue is recognized based on each of the deliverables in a given arrangement having distinct and separate customer pricing. Pricing is often subject to a competitive bidding process. Contract research and development services may be performed on a “time and materials” basis or “fixed fee” basis. For “time and materials” arrangements, revenue is recognized as services are performed and billed. For “fixed fee” arrangements, revenue is recognized upon completion and acceptance by the customer. For contract manufacturing services, revenue is generally recognized upon delivery of product and acceptance by the customer. In some cases, customers may request that we store on their behalf, clinical grade biologicals that we produce under contract manufacturing agreements. These cases arise when customers do not have clinical grade storage facilities or do not want to risk contamination during transport. For such cases, revenue may be recognized on a bill-and-hold basis. No such bill-and-hold arrangements existed at June 30, 2012 or September 30, 2011.   Trade accounts receivable are recorded in the accompanying Condensed Consolidated Balance Sheets at invoiced amounts less provisions for distributor price adjustments and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on current trends and historical write-off experience. The allowance for doubtful accounts and related metrics, such as days’ sales outstanding, are reviewed monthly. Accounts with past due balances over 90 days are reviewed individually for collectibility. Customer invoices are charged off against the allowance when we believe it is probable that the invoices will not be paid. Approximately $5,300 of our accounts receivable at June 30, 2012 is due from Italian hospital customers whose funding ultimately comes from the Italian government. During the fourth quarter of fiscal 2011 and first quarter of fiscal 2012, we experienced a deterioration in the aging of our Italian accounts receivable. While such aging appeared to stabilize during the second and third quarters of fiscal 2012, we continue to monitor such accounts closely.   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">(b)</td> <td align="left" valign="top"> Comprehensive Income (Loss) – </td> </tr> </table> Our comprehensive income or loss is comprised of net earnings, foreign currency translation and the related income tax effects. Assets and liabilities of foreign operations are translated using period-end exchange rates with gains or losses resulting from translation included as a separate component of comprehensive income or loss. Revenues and expenses are translated using exchange rates prevailing during the period. We also recognize foreign currency transaction gains and losses on certain assets and liabilities that are denominated in the Australian dollar, British pound and Euro currencies. These gains and losses are included in other income and expense in the accompanying Condensed Consolidated Statements of Operations. Comprehensive income for the interim periods was as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="70%"> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center">Three Months</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center">Nine Months</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center">Ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center">Ended June 30,</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Net earnings </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,594</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,836</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24,798</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,121</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Foreign currency translation adjustment </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,582</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">335</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,385</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,203</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Income taxes </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">554</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(117</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">483</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(421</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> Comprehensive income </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,566</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,054</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,896</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,903</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">(c)</td> <td align="left" valign="top"> Income Taxes – </td> </tr> </table> The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between income for financial reporting and income for tax purposes. We prepare estimates of permanent and temporary differences between income for financial reporting purposes and income for tax purposes. These differences are adjusted to actual upon filing of our tax returns, typically occurring in the third and fourth quarters of the current fiscal year for the preceding fiscal year’s estimates. We account for uncertain tax positions using a benefit recognition model with a two-step approach: (i) a more-likely-than-not recognition criterion; and (ii) a measurement attribute that measures the position as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. If it is not more likely than not that the benefit will be sustained on its technical merits, no benefit is recorded. We recognize accrued interest and penalties related to unrecognized tax benefits as a portion of our income tax provision in the Condensed Consolidated Statements of Operations.   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">(d)</td> <td align="left" valign="top"> Stock-based Compensation – </td> </tr> </table> We recognize compensation expense for all share-based awards made to employees, based upon the fair value of the share-based award on the date of the grant. Awards are expensed over their requisite service period.   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">(e)</td> <td align="left" valign="top"> Cash and Cash Equivalents – </td> </tr> </table> Cash and cash equivalents include the following components:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="66%"> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">June 30, 2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">September 30, 2011</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Cash and Equivalents</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Other</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Cash and Equivalents</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Other</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Overnight repurchase agreements </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,400</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,784</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Cash on hand – </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Restricted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Unrestricted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,538</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,842</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,938</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,626</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">(f)</td> <td align="left" valign="top"> Reclassifications – </td> </tr> </table> Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders’ equity.

<table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">3.</td> <td align="left" valign="top">Inventories </td> </tr> </table> Inventories are comprised of the following:   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="76%"> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="6%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">June 30, 2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">September 30, 2011</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Raw materials </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,147</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,272</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Work-in-process </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,662</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,016</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Finished goods - illumigene instruments </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,668</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,179</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Finished goods - kits and other </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,643</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,222</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33,120</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32,689</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

<table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">4.</td> <td align="left" valign="top">Major Customers and Segment Information </td> </tr> </table> Meridian was formed in 1976 and functions as a fully-integrated research, development, manufacturing, marketing and sales organization with primary emphasis in the fields of in vitro diagnostics and life science. Our principal businesses are (i) the development, manufacture and distribution of diagnostic test kits primarily for gastrointestinal, viral, respiratory and parasitic infectious diseases; (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers; and (iii) the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Our reportable segments are U.S. Diagnostics, European Diagnostics and Life Science. Initial segmentation between Diagnostics and Life Science has been determined based upon products and customers, with further segmentation of Diagnostics between U.S. and European being based upon geographic regions served and management responsibility. The U.S. Diagnostics segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the U.S. and countries outside of Australia, Europe, Africa and the Middle East. The European Diagnostics segment consists of the sale and distribution of diagnostic test kits in Australia, Europe, Africa and the Middle East. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad. The Life Science segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.   During the fourth quarter of fiscal 2011, plans were announced to consolidate the Saco, Maine operations into the Memphis, Tennessee facility. This consolidation of facilities is now complete. During the third quarter and nine months ended June 30, 2012, the Company incurred $366 and $1,013, respectively, of costs associated with the facility consolidation, primarily related to employee retention and an additional $210 write-down of the Maine building facility in the third quarter based on a third-party appraisal. To date, $2,070 of total costs have been incurred since the announcement of the consolidation in the fourth quarter of fiscal 2011 ($509 in Cost of Sales and $1,561 in Operating Expenses). Additional costs related to the consolidation totaling approximately $60 are expected to be incurred during the remainder of fiscal 2012, with the majority of such costs to be incurred in connection with retention bonus and other employee-related costs. Two distributor customers accounted for 48% and 47% of the U.S. Diagnostics segment third-party sales during the three months ended June 30, 2012 and 2011, respectively, and 49% and 50% during the nine months ended June 30, 2012 and 2011, respectively. Two diagnostic manufacturing customers accounted for 11% and 15% of the Life Science segment third-party sales during the three months ended June 30, 2012 and 2011, respectively, and 20% and 14% during the nine months ended June 30, 2012 and 2011, respectively. Segment information for the interim periods is as follows:   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="62%"> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">U.S. Diagnostics</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">European Diagnostics</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Life Science</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000">Eliminations (1)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Total</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Three Months Ended June 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Net sales - </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Third-party </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,234</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,897</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,010</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">42,141</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Inter-segment </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,464</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">133</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,602</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Operating income (2) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,442</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">998</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,118</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">54</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,612</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Goodwill (June 30, 2012) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,381</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,449</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,830</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Other intangible assets, net (June 30, 2012) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,423</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,212</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,635</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Total assets (June 30, 2012) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">81,911</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,930</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">97,150</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(37,177</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">158,814</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Three Months Ended June 30, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Net sales - </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Third-party </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,829</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,612</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,611</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40,052</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Inter-segment </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,875</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">141</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,025</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Operating income (3) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,399</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">978</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">797</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(43</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,131</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Goodwill (September 30, 2011) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,381</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,743</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,124</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Other intangible assets, net (September 30, 2011) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,604</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,343</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,947</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Total assets (September 30, 2011) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">73,850</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19,390</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,467</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30,214</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">155,493</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Nine Months Ended June 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Net sales - </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Third-party </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">80,091</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,326</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,431</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">129,848</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Inter-segment </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,428</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">793</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,230</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Operating income (2) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,377</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,398</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,526</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(57</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,244</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table>   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="67%"> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Nine Months Ended June 30, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Net sales - </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Third-party </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">72,007</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,926</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,441</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">118,374</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Inter-segment </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,938</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">459</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,413</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Operating income (3) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">26,780</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,781</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,499</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">123</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,183</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">(1)</td> <td align="left" valign="top">Eliminations consist of inter-segment transactions. </td> </tr> </table> <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">(2)</td> <td align="left" valign="top">Life Science includes $366 and $1,013 of costs related to consolidation of the Maine operations into the Tennessee facility during the three and nine months ended June 30, 2012, respectively. </td> </tr> </table> <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">(3)</td> <td align="left" valign="top">U.S. Diagnostics and European Diagnostics include $365 and $875, respectively, in the nine months ended June 30, 2011 related to sales and marketing leadership reorganization costs. </td> </tr> </table> Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation.

<table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">5.</td> <td align="left" valign="top">Intangible Assets </td> </tr> </table> A summary of our acquired intangible assets subject to amortization, as of June 30, 2012 and September 30, 2011 is as follows:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="60%"> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">June 30, 2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">September 30, 2011</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Gross Carrying Value</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Gross Carrying Value</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Accumulated Amortization</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Manufacturing technologies, core products and cell lines </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,625</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,117</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,626</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,545</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Trademarks, licenses and patents </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,842</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,667</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,538</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,337</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Customer lists and supply agreements </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,219</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,267</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,222</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,557</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td valign="top"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">28,686</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,051</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,386</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,439</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table> The actual aggregate amortization expense for these intangible assets was $545 and $595 for the three months ended June 30, 2012 and 2011, respectively, and $1,608 and $1,796 for the nine months ended June 30, 2012 and 2011, respectively. The estimated aggregate amortization expense for these intangible assets for each of the fiscal years through fiscal 2017 is as follows: remainder of fiscal 2012 – $549, fiscal 2013 – $2,179, fiscal 2014 – $1,743, fiscal 2015 – $1,495, fiscal 2016 – $1,153 and fiscal 2017 – $911.

<table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td align="left" valign="top"> Cash and Cash Equivalents – </td> </tr> </table> Cash and cash equivalents include the following components:   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="66%"> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">June 30, 2012</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000">September 30, 2011</td> <td valign="bottom"> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Cash and Equivalents</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Other</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Cash and Equivalents</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Other</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Overnight repurchase agreements </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,400</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,784</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Cash on hand – </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Restricted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Unrestricted </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,538</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,842</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Total </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,938</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,626</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,000</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr style="font-size:1px"> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr>  </table>

<table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="62%"> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">U.S. Diagnostics</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">European Diagnostics</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Life Science</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000">Eliminations (1)</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000">Total</td> <td valign="bottom"> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Three Months Ended June 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Net sales - </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Third-party </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">26,234</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,897</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10,010</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">42,141</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Inter-segment </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,464</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">133</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,602</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Operating income (2) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,442</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">998</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,118</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">54</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,612</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Goodwill (June 30, 2012) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,381</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,449</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,830</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Other intangible assets, net (June 30, 2012) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,423</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,212</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,635</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Total assets (June 30, 2012) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">81,911</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,930</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">97,150</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(37,177</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">158,814</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Three Months Ended June 30, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Net sales - </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Third-party </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,829</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,612</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,611</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40,052</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Inter-segment </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,875</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">141</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,025</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Operating income (3) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,399</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">978</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">797</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(43</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,131</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Goodwill (September 30, 2011) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,381</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">21,743</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,124</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Other intangible assets, net (September 30, 2011) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,604</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,343</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,947</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Total assets (September 30, 2011) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">73,850</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">19,390</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">92,467</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30,214</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">155,493</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Nine Months Ended June 30, 2012 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Net sales - </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Third-party </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">80,091</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,326</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,431</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">129,848</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Inter-segment </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,428</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">793</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,230</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Operating income (2) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,377</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,398</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,526</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(57</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37,244</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table>   <table cellspacing="0" cellpadding="0" width="100%" border="0" style="border-collapse:collapse; text-align: left" align="center">  <tr> <td width="67%"> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> </tr>   <tr bgcolor="#cceeff"> <td valign="top"> Nine Months Ended June 30, 2011 </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr> <td valign="top"> Net sales - </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Third-party </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">72,007</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,926</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">27,441</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">118,374</td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr> <td valign="top"> Inter-segment </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,938</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">459</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,413</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">—  </td> <td nowrap="nowrap" valign="bottom"> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> Operating income (3) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">26,780</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,781</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,499</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">123</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,183</td> <td nowrap="nowrap" valign="bottom"> </td> </tr>  </table>   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">(1)</td> <td align="left" valign="top">Eliminations consist of inter-segment transactions. </td> </tr> </table> <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">(2)</td> <td align="left" valign="top">Life Science includes $366 and $1,013 of costs related to consolidation of the Maine operations into the Tennessee facility during the three and nine months ended June 30, 2012, respectively. </td> </tr> </table> <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">(3)</td> <td align="left" valign="top">U.S. Diagnostics and European Diagnostics include $365 and $875, respectively, in the nine months ended June 30, 2011 related to sales and marketing leadership reorganization costs. </td> </tr> </table>

false --09-30 Q3 2012 2012-06-30 10-Q 0000794172 41272339 Large Accelerated Filer MERIDIAN BIOSCIENCE INC

5548000

6158000

789000

1626000

4692000

5116000

33973000

37928000

449000

-453000

100010000

102012000

1670000

310000

428000

1796000

1608000

177000

160000

309000

313000

155493000

-30214000

19390000

92467000

73850000

158814000

-37177000

16930000

97150000

81911000

90354000

93838000

38600000

38437000

23033000

26334000

11842000

14538000

37879000

25563000

23626000

1000000

27938000

1000000

-12316000

4312000

0.57

0.19

0.57

0.19

71000000

41237120

41269062

20903000

7054000

23896000

7566000

3887000

1136000

43564000

14701000

47722000

14498000

-1622000

-1491000

2852000

3393000

1705000

269000

2525000

2660000

23417000

0.49

0.17

0.60

0.21

0.49

0.17

0.60

0.21

455000

-668000

4235000

4640000

16439000

6557000

8545000

1337000

18051000

7267000

9117000

1667000

1796000

595000

1608000

545000

27386000

12222000

11626000

3538000

28686000

12219000

11625000

4842000

549000

911000

1153000

2179000

1495000

1743000

-7000

-203000

19018000

6559000

19236000

6162000

23124000

21743000

1381000

22830000

21449000

1381000

74810000

25351000

82126000

27643000

30610000

10193000

37575000

12657000

10489000

3357000

12777000

4063000

10947000

9343000

1604000

10635000

8212000

2423000

4179000

14222000

2668000

16643000

32689000

33120000

7272000

7147000

7016000

6662000

70000

26000

27000

14000

1184000

1172000

155493000

158814000

15264000

17540000

-21711000

-23018000

-7678000

-3890000

16618000

31888000

427000

62000

331000

45000

44627000

15220000

44882000

15031000

30183000

123000

1781000

1499000

26780000

10131000

-43000

978000

797000

8399000

37244000

-57000

2398000

5526000

29377000

12612000

54000

998000

2118000

9442000

225000

251000

1203000

335000

-1385000

-1582000

421000

117000

-483000

-554000

357000

36000

304000

31000

23192000

23417000

12000

1305000

7666000

2985000

1000000

6343000

5081000

400000

20121000

6836000

24798000

8594000

60512000

64467000

26539000

24844000

24306000

7328000

2693000

7441000

2660000

1000000

38065000

39446000

-8413000

16000

459000

7938000

-3025000

9000

141000

2875000

-8230000

9000

793000

7428000

-2602000

5000

133000

2464000

118374000

18926000

27441000

72007000

40052000

6612000

9611000

23829000

129848000

18326000

31431000

80091000

42141000

5897000

10010000

26234000

17041000

5968000

17192000

5843000

1981000

1670000

41237000

41269000

138524000

449000

100010000

38065000

141005000

-453000

102012000

39446000

2000

3000

33000

332000

673000

657000

530000

593000

41353000

41394000

41605000

41684000

40680000

40737000

41075000

41091000

4176000 3871000 60000 210000 2070000 81000 587000 -2451000 -2474000 -10176000 386000 1013000 1013000 366000 366000 3304000 3721000 5300000 P3Y 1240000 0.50 32408000 35825000 509000 1561000 2 2 546000 1007000 11784000 13400000 P90D 0.14 0.50 0.15 0.47 0.20 0.49 0.11 0.48 1013000 366000 1481000 399000 875000 365000 Greater than 50% likelihood of being realized upon ultimate settlement

EX-101.SCH 6 vivo-20120630.xsd XBRL TAXONOMY EXTENSION SCHEMA 0202 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0204 - Disclosure - Major Customers and Segment Information link:presentationLink link:calculationLink link:definitionLink 06051 - Disclosure - Intangible Assets (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0605 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0505 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 0205 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0201 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 06041 - Disclosure - Major Customers and Segment Information (Details Textual) link:presentationLink link:calculationLink link:definitionLink 0604 - Disclosure - Major Customers and Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 0504 - Disclosure - Major Customers and Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 06022 - Disclosure - Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 06021 - Disclosure - Significant Accounting Policies (Details 1) link:presentationLink link:calculationLink link:definitionLink 0603 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0503 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 0602 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 0502 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0401 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0140 - Statement - Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0203 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0131 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0130 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0120 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0110 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vivo-20120630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 vivo-20120630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 vivo-20120630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Document and Entity Information [Abstract] Document and entity information. Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Cumulative Effects of Changes in Accounting Principles, Noncontrolling Interest EARNINGS BEFORE INCOME TAXES Other Nonoperating Income (Expense) Other, net Nonoperating Income (Expense) Total other income (expense) Investment Income, Interest and Dividend Interest income Other Nonoperating Income (Expense) [Abstract] OTHER INCOME (EXPENSE) Operating Income (Loss) OPERATING INCOME Operating income Operating Expenses Total operating expenses General and Administrative Expense General and administrative Research and Development Expense Research and development Gross Profit GROSS PROFIT Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Common Stock, Dividends, Per Share, Declared DIVIDENDS DECLARED PER COMMON SHARE Cash and Cash Equivalents, at Carrying Value Cash and Equivalents at End of Period Cash and Equivalents at Beginning of Period Total Cash and equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net Increase (Decrease) in Cash and Equivalents Effect of Exchange Rate on Cash and Cash Equivalents Effect of Exchange Rate Changes on Cash and Equivalents Net Cash Provided by (Used in) Financing Activities Net cash used for financing activities Net Cash Provided by (Used in) Operating Activities Net cash provided by operating activities Proceeds and Tax Benefits from Exercises of Stock Options Proceeds and tax benefits from exercises of stock options The cash inflow associated with the amount received from holders exercising their stock options and reductions in the entity's income taxes that arise when compensation cost (from non-qualified share-based compensation) recognized on the entity's tax return exceeds compensation cost from share-based compensation recognized in financial statements. This element represents the cash inflow reported in the enterprise's financing activities. Payments to Acquire Intangible Assets Purchases of intangibles and other assets Other Cash Flows from Operating Activities Other, net The net change during the reporting period in the amount due within one year (or one business cycle) of receivables and payables that were originally due beyond one year (or one business cycle) and the net change during the reporting period in other operating assets and liabilities not otherwise defined in the taxonomy. Change in Accounts Payable Accrued Expenses and Income Taxes Payable Change in current liabilities Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services, the net change during the reporting period in other expenses incurred but not yet paid, and the net change during the period in the amount of cash payments due to taxing authorities for taxes that are based on the reporting entity's earnings. Change in Accounts Receivable Inventory and Prepaid Expenses Change in current assets The net change during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities, the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities, and the net change during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. Amortization of Intangible Assets Amortization of intangible assets Gain (Loss) on Disposition of Assets Loss on disposition and write-down of fixed assets and other assets ASSETS [Abstract] Receivables, Net, Current Accounts receivable, less allowances of $428 and $310 Inventory, Net Total Inventories Deferred Tax Assets, Net, Current Deferred income taxes Assets, Current Total current assets Construction in Progress, Gross Construction in progress Property, Plant and Equipment, Gross Subtotal Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization Intangible Assets, Net (Excluding Goodwill) Other intangible assets, net Other Assets, Noncurrent Other assets Assets, Noncurrent Total other assets Assets TOTAL ASSETS Total assets LIABILITIES AND STOCKHOLDERS' EQUITY [Abstract] Liabilities, Current Total current liabilities Preferred Stock, Value, Issued Preferred stock, no par value, 1,000,000 shares authorized, none issued Common Stock, Value, Issued Common shares, no par value, 71,000,000 shares authorized, 41,269,062 and 41,237,120 shares issued, respectively Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Ending balance Beginning balance Total shareholders' equity Preferred Stock, Shares Authorized Preferred stock, shares authorized Machinery Equipment and Furniture Machinery, equipment and furniture Carrying amount as of the balance sheet date of long-lived, depreciable assets used in production process to produce goods and services and depreciable assets commonly used in offices and stores. Examples include desks, chairs, and store fixtures. Inventory Disclosure [Text Block] Inventories Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited) [Abstract] Ending balance, Shares Beginning balance, Shares Shares, Issued Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of restricted shares, net of forfeitures Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Value Stock compensation expense Other Comprehensive Income, Foreign Currency Transaction and Translation Adjustment, before Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Tax Other comprehensive income taxes Comprehensive Income, Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive income Common Stock [Member] Common Shares Issued Retained Earnings [Member] Retained Earnings Comprehensive Income [Member] Comprehensive Income (Loss) Statement [Table] Statement, Equity Components [Axis] Equity Component [Domain] Statement [Line Items] Cash Cash on hand - Unrestricted Income Tax, Policy [Text Block] Income Taxes Investment Type [Axis] Comprehensive Income Loss, [Policy Text Block] Comprehensive Income (Loss) Describes an entity's accounting policy for recording comprehensive income. Investment Portfolio [Abstract] Investment portfolio Investment portfolio. Significant Accounting Policies (Textual) [Abstract] Significant Accounting Policies (Textual) [Abstract] Significant accounting policies. Inventory, Net [Abstract] Inventories Finished goods Inventory, Finished Goods Inventory, Work in Process Work-in-process Inventory, Raw Materials Raw materials Preferred Stock, Shares Issued Preferred stock, shares issued Restricted Cash and Cash Equivalents, Noncurrent Cash on hand - Restricted Restricted cash Tax Benefits Recognized from Uncertain Tax Positions Measurement Tax benefits recognized from uncertain tax positions measurement Tax benefits recognized from uncertain tax positions measurement. Finite-Lived Intangible Assets, Major Class Name [Domain] United States Diagnostics [Member] U.S. Diagnostics [Member] United States diagnostics. European Diagnostics [Member] European Diagnostics [Member] European diagnostics. Life Science [Member] Life Science [Member] Life science. Major Customers and Segment Information (Textual) [Abstract] Major Customers and Segment Information (Textual) [Abstract] Major customers and segment information. Schedule of Segment Reporting Information by Segment [Abstract] Segment information for the interim periods Schedule of segment reporting information by segment. Statement, Business Segments [Axis] Segment Reporting Information [Line Items] Overnight Repurchase Agreements at Carrying Value Overnight repurchase agreements Overnight repurchase agreements at carrying value. Inventories [Table] Inventories. Inventories [Line Items] Inventories. Kits and Other [Member] Kits and other [Member] Kits and other. Illumigene Instruments [Member] Illumigene instruments [Member] Illumigene instruments. Products and Services [Axis] Products And Services [Domain] Segment [Domain] Revenues From Transactions With Other Operating Segments Of Same Entity Net sales - Inter-segment Investment Type Categorization [Domain] Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options, Shares Business Intersegment, Eliminations [Member] Eliminations [Member] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Text Block] Compensation Related Costs, Policy [Text Block] Stock-based Compensation Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive income: Antidilutive securities excluded from Computation [Abstract] ANTI-DILUTIVE SECURITIES: Antidilutive securities excluded from Computation. Inventories [Abstract] Schedule of Restricted Cash and Cash Equivalents [Table Text Block] Investment portfolio Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Comprehensive income: Depreciation Depreciation of property, plant and equipment Payments of Dividends, Common Stock Dividends paid Schedule of Comprehensive Income (Loss) [Table Text Block] Comprehensive income Accrued Income Taxes, Current Income taxes payable Accrued Liabilities, Current Other accrued expenses Employee-related Liabilities, Current Accrued employee compensation costs Segment information Schedule of Inventory, Current [Table Text Block] Inventories Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Plant Consolidation Costs Plant consolidation costs. Plant consolidation costs Stock Issued During Period, Shares, Conversion of Units Conversion of restricted stock units Selling and Marketing Expense Selling and marketing Deferred Income Tax Expense (Benefit) Deferred income taxes Payments to Acquire Property, Plant, and Equipment Purchases of property, plant and equipment Prepaid Expense, Current Prepaid expenses and other current assets Land Land Buildings and Improvements, Gross Buildings and improvements Property, Plant and Equipment, Net Net property, plant and equipment Goodwill Goodwill Accounts Payable, Current Accounts payable Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Retained earnings Allowance for Doubtful Accounts Receivable, Current Allowances for accounts receivable Reclassifications [Policy Text Block] Reclassifications Reclassifications. Common share options and restricted shares and units Preferred Stock, No Par Value Preferred stock, par value Weighted Average Number of Shares Outstanding, Diluted AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED Weighted Average Number of Shares Outstanding, Basic AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC Net Cash Provided by (Used in) Investing Activities Net cash used for investing activities Dividends, Common Stock, Cash Cash dividends paid Revenue Recognition, Policy [Text Block] Revenue Recognition and Accounts Receivable Basis of Presentation [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Basis of Presentation Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block] Summary of acquired intangible assets subject to amortization Trademarks Licenses and Patents [Member] Trademarks, licenses and patents [Member] Trademarks, licenses and patents. Customer Lists and Supply Agreements [Member] Customer lists and supply agreements [Member] Customer lists and supply agreements. Finite-Lived Intangible Assets, Net [Abstract] Summary of acquired intangible assets subject to amortization Intangible Assets (Textual) [Abstract] Intangible assets. Intangible Assets (Textual) [Abstract] Finite-Lived Intangible Assets, Amortization Expense Amortization expense for intangible assets Future Amortization Expense, Year One Estimated amortization expense for intangible assets fiscal year 2013 Future Amortization Expense, Year Two Estimated amortization expense for intangible assets fiscal year 2014 Future Amortization Expense, Year Three Estimated amortization expense for intangible assets fiscal year 2015 Future Amortization Expense, Year Four Estimated amortization expense for intangible assets fiscal year 2016 Future Amortization Expense, Year Five Estimated amortization expense for intangible assets fiscal year 2017 Schedule of Finite-Lived Intangible Assets by Major Class [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets [Line Items] Condensed Consolidated Statements of Operations [Abstract] Condensed Consolidated Statements of Cash Flows (Unaudited) [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Cost of Goods Sold COST OF SALES Operating Expenses [Abstract] OPERATING EXPENSES Income Tax Expense (Benefit) INCOME TAX PROVISION Earnings Per Share, Basic BASIC EARNINGS PER COMMON SHARE Earnings Per Share, Diluted DILUTED EARNINGS PER COMMON SHARE Assets, Current [Abstract] CURRENT ASSETS Property, Plant and Equipment [Abstract] PROPERTY, PLANT AND EQUIPMENT, at Cost Other Assets, Noncurrent [Abstract] OTHER ASSETS Liabilities, Current [Abstract] CURRENT LIABILITIES Deferred Tax Liabilities, Noncurrent DEFERRED INCOME TAXES Commitments And Contingencies COMMITMENTS AND CONTINGENCIES Stockholders' Equity Attributable to Parent [Abstract] SHAREHOLDERS' EQUITY Liabilities and Stockholders' Equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, No Par Value Common stock, par value Past Due Balance Period for Review of Accounts Individually Minimum Period of review of accounts individually Past due balance period for review of accounts individually minimum. Percentage of Sales to Third Party Percentage of third-party sales Percentage of segment's third-party sales to two customers. EX-101.PRE 10 vivo-20120630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 R9.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Jun. 30, 2012

Inventories [Abstract]

Inventories

3.	Inventories

Inventories are comprised of the following:


	June 30, 2012		September 30, 2011
Raw materials	$	7,147	$	7,272
Work-in-process		6,662		7,016
Finished goods - illumigene instruments		2,668		4,179
Finished goods - kits and other		16,643		14,222

Total	$	33,120	$	32,689

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

EXCEL 13 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\T8S-B-F9F-E\R9&$Q7S1F83A?8C@P8E]A-3`U M8C`Y,V4V96,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?0F%L86YC M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7 M;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-I9VYI9FEC86YT7T%C8V]U;G1I;F=?4&]L:6-I93$\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN=&%N9VEB;&5?07-S971S7U1A8FQE#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-I9VYI9FEC86YT7T%C8V]U;G1I M;F=?4&]L:6-I93,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN=F5N=&]R:65S7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I%>&-E M;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/DEN=&%N9VEB;&5?07-S971S M7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K'0\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H M965T&-E;"!84"!O M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\T8S-B-F9F-E\R9&$Q7S1F83A?8C@P8E]A-3`U8C`Y,V4V96,- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&,S8C9F9C9?,F1A,5\T M9F$X7V(X,&)?834P-6(P.3-E-F5C+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!);F9O2!);F9O2!296=I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^2G5N(#,P+`T*"0DR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^+2TP.2TS M,#QS<&%N/CPO3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T8S-B-F9F-E\R9&$Q7S1F83A?8C@P M8E]A-3`U8C`Y,V4V96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M-&,S8C9F9C9?,F1A,5\T9F$X7V(X,&)?834P-6(P.3-E-F5C+U=O'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$F%T:6]N/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'!E;G-E7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA&5D(&%S"!B96YE M9FET7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,Y M,SQS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-RPY,C@\6%B;&4\ M+W1D/@T*("`@("`@("`\=&0@8VQAF5D+"`T,2PR-CDL,#8R(&%N9"`T,2PR,S3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^)FYB'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYBF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P M,"PP,#`\'0^)FYB'0^ M)FYB'0^)FYB'0^)FYBF5D/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,2PP,#`L,#`P/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5R8VES92!O9B!S=&]C:R!O<'1I;VYS+"!3:&%R97,\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XT.#,\'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T8S-B-F9F-E\R9&$Q7S1F83A? M8C@P8E]A-3`U8C`Y,V4V96,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO-&,S8C9F9C9?,F1A,5\T9F$X7V(X,&)?834P-6(P.3-E-F5C+U=O'0O:'1M;#L@ M8VAA'0^/"$M+41/0U194$4@:'1M;"!0 M54),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A M;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E M9"!.;W1E(#$@+2!U3IT:6UE MF4],T0R/CQB/CPO8CX\+V9O;G0^#0H@("`\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0R/@T*("`@/&(^/"]B/CPO9F]N=#X-"B`@(#QF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$)V)O3IT:6UEF4],T0R/CQB M/C$N/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L M:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP M<'@^/&9O;G0@&-H86YG92!#;VUM:7-S:6]N+B8C,38P.T-E6QE/3-$;6%R9VEN+71O<#HQ,G!X.VUA6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@F4Z M,3AP>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\ M+W`^#0H\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@/"$M+2!" M96=I;B!";&]C:R!486=G960@3F]T92`R("T@=7,M9V%A<#I3:6=N:69I8V%N M=$%C8V]U;G1I;F=0;VQI8VEE'1";&]C:RTM/@T*("`@/'1A8FQE('-T M>6QE/3-$)V)O3IT:6UEF4],T0R/CQB/C(N/"]B M/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$ M=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V)O3IT:6UEF4],T0R/CQB/BAA*3PO M8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS M1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/@T*("`@/"]B/CQB/CQI/E)E=F5N=64@4F5C;V=N M:71I;VX@86YD($%C8V]U;G1S(%)E8V5I=F%B;&4@)B,X,C$Q.R`\+VD^/"]B M/B`\+V9O;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\+W1A8FQE/@T*("`@/'`@ M3IT:6UE MF4],T0R/@T*("`@4F5V96YU92!I2!D:7-T M6QE/3-$)VUA3IT:6UEF4],T0R/E)E M=F5N=64@9F]R(&]U6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@65A3IT:6UEF4],T0R/DQI9F4@4V-I96YC92!R979E;G5E(&9OF5D('5P;VX@8V]M<&QE=&EO;B!A;F0@ M86-C97!T86YC92!B>2!T:&4@8W5S=&]M97(N($9O2!R96-O M9VYI>F5D('5P;VX@9&5L:79E2!T:&4@8W5S=&]M97(N($EN('-O;64@8V%S97,L#0H@("!C=7-T;VUE M2!B92!R96-O9VYI>F5D(&]N(&$@ M8FEL;"UA;F0M:&]L9"!B87-I&ES=&5D(&%T($IU;F4F(S$V,#LS,"P@,C`Q,B!O6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T M=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P M.C!P>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z-"4G/CQF;VYT M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@2!F;W(@8V]L;&5C=&EB:6QI='DN($-U&EM871E;'D@)#4L,S`P(&]F(&]UF4@9'5R:6YG('1H92!S96-O;F0@ M86YD('1H:7)D('%U87)T97)S(&]F(&9I2X@/"]F;VYT/CPO M<#X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C$X<'@[;6%R9VEN+71O<#HP M<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE('-T M>6QE/3-$)V)O3IT:6UEF4],T0R/CQB/BAB*3PO M8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS M1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/CQB/@T*("`@/"]B/CQB/CQI/D-O;7!R96AE;G-I=F4@ M26YC;VUE("A,;W-S*2`F(S@R,3$[(#PO:3X\+V(^(#PO9F]N=#X\+W1D/@T* M("`@/"]T#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z-"4G/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)VUAF4@ M9F]R96EG;B!C=7)R96YC>2!T3IT M:6UEF4],T0R/D-O;7!R96AE;G-I=F4@:6YC;VUE M(&9OF4Z,3)P>#MM87)G:6XM M=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B M;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR M)2!B;W)D97(],T0P('-T>6QE/3-$)V)OF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/E1HF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI M9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/DYI;F4@36]N=&AS/"]B/CPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/D5N9&5D($IU M;F4F(S$V,#LS,"P\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]LF4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@"!S;VQI9"`C,#`P,#`P)SX\9F]N M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4] M,T0Q/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$ M)V)O6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V M86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0Q/CQB/C(P,3$\+V(^/"]F;VYT/CPO=&0^(`T*("`@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O M;G0^/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!(96%D("TM M/@T*("`@/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*("`@/'1R(&)G8V]L M;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S M='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C@L-3DT/"]F;VYT/CPO=&0^(`T*("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT M:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0R M/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$3IT:6UEF4],T0R/B8C,38P M.SPO9F]N=#X\+W1D/@T*("`@/"]T6QE/3-$)VUAF4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4] M,T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UE MF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B@Q+#,X-3PO9F]N=#X\+W1D/B`-"B`@(#QT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C$L,C`S M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@&5S/"]F;VYT M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V)O6QE/3-$)V)O M"!S;VQI9"`C,#`P,#`P)SXF M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`- M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4] M,T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE M=R!R;VUA;B<@3IT:6UEF4],T0R/C(S+#@Y-CPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@6QE/3-$)V9O;G0M M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4] M,T0R/C(P+#DP,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V)O6QE M/3-$)V)O6QE/3-$)V)O6QE/3-$ M)V)O6QE/3-$9F]N="US:7IE.C$X<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O M='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE('-T>6QE/3-$)V)O3IT M:6UEF4],T0R/CQB/BAC*3PO8CX\+V9O;G0^/"]T M9#X@#0H@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<#X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R M/CQB/@T*("`@/"]B/CQB/CQI/DEN8V]M92!487AE6QE/3-$)VUA6%B;&4@86YD M('1H;W-E(&1E9F5R"!P=7)P;W-E"!P=7)P;W-E2!O8V-U3IT:6UEF4],T0R/E=E(&%C8V]U;G0@9F]R('5N8V5R=&%I;B!T87@@<&]S:71I M;VYS('5S:6YG(&$@8F5N969I="!R96-O9VYI=&EO;B!M;V1E;"!W:71H(&$- M"B`@('1W;RUS=&5P(&%P<')O86-H.B`H:2DF(S$V,#MA(&UO2!O9B!B96EN9R!R96%L M:7IE9"!U<&]N('5L=&EM871E#0H@("!S971T;&5M96YT+B!)9B!I="!IF4Z,3AP>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)VUA'0M86QI9VXZ(&QE9G0G M(&)O6QE/3-$)VUA6QE/3-$ M9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP M<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL M<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL93TS1"=B M;W)D97(M8V]L;&%P'0M86QI9VXZ(&QE9G0G(&%L M:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T* M("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#8V)3XF(S$V,#L\+W1D/B`-"B`@ M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D/B`- M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@ M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@ M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@ M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT M9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]TF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@8V]LF4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/@T*("`@/"]TF4],T0Q/B8C,38P.SPO9F]N M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT@8V]L6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B0\+V9O;G0^ M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA M;B<@3IT:6UEF4] M,T0R/D-AF4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT^/&9O;G0@'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\ M=&0@;F]W3IT:6UEF4],T0R/B8C M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O M;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C$L,#`P M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/E5N3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3IT:6UEF4],T0R/C$T+#4S.#PO9F]N=#X\+W1D M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V9O M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE M/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@ M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*("`@/'`@6QE/3-$)V)O6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@ M/"]T6QE/3-$)VUA3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@ M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY.G1I M;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C(S+#8R-CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/C$L,#`P/"]F;VYT/CPO M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@ M"!D;W5B M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*("`@/'`@"!D;W5B;&4@ M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*("`@/'`@2`M M+3X-"B`@(#PO=&%B;&4^(`T*("`@/'`@F4Z,3AP M>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^ M#0H@("`\=&%B;&4@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY M.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/D-E6QE/3-$9F]N="US:7IE M.C$X<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[ M/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\T8S-B-F9F-E\R9&$Q7S1F83A?8C@P8E]A-3`U8C`Y,V4V96,-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-&,S8C9F9C9?,F1A,5\T9F$X7V(X M,&)?834P-6(P.3-E-F5C+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO M+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L M+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#,@ M+2!U41I'0M86QI9VXZ(&QE9G0G(&)O3IT:6UE MF4],T0R/CQB/CQU/DEN=F5N=&]R:65S/"]U/B`\ M+V(^/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"]T86)L93X-"B`@(#QP M('-T>6QE/3-$;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O M;G0@6QE/3-$)V)O M6QE/3-$ M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@F4],T0Q M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@ M8V]L2`M+3X-"B`@(#QT3IT:6UEF4],T0R/E)A=R!M871EF4],T0Q/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/E=O M3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C8L-C8R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ M3IT:6UEF4],T0R/D9I;FES:&5D(&=O;V1S("T@:6QL=6UI9V5N M92!I;G-T3IT:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C(L-C8X/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@F4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@ MF4],T0R M/D9I;FES:&5D(&=O;V1S("T@:VETF4] M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@3IT:6UEF4],T0R/B8C,38P.SPO9F]N=#X\ M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UEF4],T0R/C$T+#(R,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$ M)V)O6QE M/3-$)V)O3IT:6UE MF4],T0R/E1O=&%L/"]F;VYT/CPO<#X-"B`@(#PO M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@3IT:6UE MF4],T0R/C,S+#$R,#PO9F]N=#X\+W1D/B`-"B`@ M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S M(&YE=R!R;VUA;B<@3IT:6UEF4],T0R/C,R+#8X.3PO M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R M;VUA;B<@6QE/3-$)V)O6QE/3-$)V)O XML 14 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

9 Months Ended

Jun. 30, 2012

Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Significant Accounting Policies

(a)

Revenue Recognition and Accounts Receivable –

Revenue for our Diagnostics segments includes bundled product revenue for our illumigene ^® molecular test system. The bundled product includes an instrument, instrument accessories and test kits. If not sold outright, amounts invoiced for the illumigene^® test kits cover the instrument, accessories and test kits. Revenue is recognized based on test kit sales. If not sold outright, costs for the instruments are recognized in cost of sales over the expected instrument utilization period, generally three years.

(b)

Comprehensive Income (Loss) –

Our comprehensive income or loss is comprised of net earnings, foreign currency translation and the related income tax effects.

Comprehensive income for the interim periods was as follows:


	Three Months						Nine Months
	Ended June 30,						Ended June 30,
	2012			2011			2012			2011
Net earnings	$	8,594		$	6,836		$	24,798		$	20,121
Foreign currency translation adjustment		(1,582	)		335			(1,385	)		1,203
Income taxes		554			(117	)		483			(421	)

Comprehensive income	$	7,566		$	7,054		$	23,896		$	20,903

(c)

Income Taxes –

(d)

Stock-based Compensation –

(e)

Cash and Cash Equivalents –

Cash and cash equivalents include the following components:


	June 30, 2012				September 30, 2011
	Cash and Equivalents		Other		Cash and Equivalents		Other
Overnight repurchase agreements	$	13,400	$	—	$	11,784	$	—
Cash on hand –
Restricted		—		1,000		—		1,000
Unrestricted		14,538		—		11,842		—

Total	$	27,938	$	1,000	$	23,626	$	1,000

(f)

Reclassifications –

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

XML 15 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Condensed Consolidated Statements of Operations [Abstract]
NET SALES	$ 42,141	$ 40,052	$ 129,848	$ 118,374
COST OF SALES	14,498	14,701	47,722	43,564
GROSS PROFIT	27,643	25,351	82,126	74,810
OPERATING EXPENSES
Research and development	2,660	2,693	7,441	7,328
Selling and marketing	5,843	5,968	17,192	17,041
General and administrative	6,162	6,559	19,236	19,018
Plant consolidation costs	366		1,013
Sales and marketing leadership reorganization				1,240
Total operating expenses	15,031	15,220	44,882	44,627
OPERATING INCOME	12,612	10,131	37,244	30,183
OTHER INCOME (EXPENSE)
Interest income	14	26	27	70
Other, net	31	36	304	357
Total other income (expense)	45	62	331	427
EARNINGS BEFORE INCOME TAXES	12,657	10,193	37,575	30,610
INCOME TAX PROVISION	4,063	3,357	12,777	10,489
NET EARNINGS	$ 8,594	$ 6,836	$ 24,798	$ 20,121
BASIC EARNINGS PER COMMON SHARE	$ 0.21	$ 0.17	$ 0.60	$ 0.49
DILUTED EARNINGS PER COMMON SHARE	$ 0.21	$ 0.17	$ 0.60	$ 0.49
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	41,091	40,737	41,075	40,680
EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARES AND UNITS	593	657	530	673
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	41,684	41,394	41,605	41,353
ANTI-DILUTIVE SECURITIES:
Common share options and restricted shares and units	313	160	309	177
DIVIDENDS DECLARED PER COMMON SHARE	$ 0.19	$ 0.19	$ 0.57	$ 0.57

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited) (USD $) In Thousands, unless otherwise specified	Total USD ($)	Common Shares Issued	Additional Paid-In Capital USD ($)	Retained Earnings USD ($)	Accumulated Other Comprehensive Income (Loss) USD ($)	Comprehensive Income (Loss) USD ($)
Beginning balance at Sep. 30, 2011	$ 138,524		$ 100,010	$ 38,065	$ 449
Beginning balance, Shares at Sep. 30, 2011		41,237
Cash dividends paid	(23,417)			(23,417)
Exercise of stock options	332		332
Exercise of stock options, Shares		33
Issuance of restricted shares, net of forfeitures		(3)
Conversion of restricted stock units		2
Stock compensation expense	1,670		1,670
Comprehensive income:
Net earnings	24,798			24,798		24,798
Other comprehensive income taxes	483				483	483
Foreign currency translation adjustment	(1,385)				(1,385)	(1,385)
Comprehensive income	23,896					23,896
Ending balance at Jun. 30, 2012	$ 141,005		$ 102,012	$ 39,446	$ (453)
Ending balance, Shares at Jun. 30, 2012		41,269

XML 17 R22.htm IDEA: XBRL DOCUMENT

Major Customers and Segment Information (Details Textual) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012 Customer	Jun. 30, 2011
Segment Reporting Information [Line Items]
Consolidation of the Maine operations into the Tennessee facility	366		1,013
Major Customers and Segment Information (Textual) [Abstract]
Cost incurred, total			2,070
Cost of sales			509
Operating expenses			1,561
Additional cost expected to be incurred	60		60
Additional Write Down Cost Related to Facility Consolidation	210		210
U.S. Diagnostics [Member]
Segment Reporting Information [Line Items]
Percentage of third-party sales	48.00%	47.00%	49.00%	50.00%
Number of customers			2
Sales and marketing leadership reorganization costs				365
Life Science [Member]
Segment Reporting Information [Line Items]
Consolidation of the Maine operations into the Tennessee facility	366		1,013
Percentage of third-party sales	11.00%	15.00%	20.00%	14.00%
Number of customers			2
European Diagnostics [Member]
Segment Reporting Information [Line Items]
Sales and marketing leadership reorganization costs				$ 875

XML 18 R24.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Textual) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Intangible Assets (Textual) [Abstract]
Amortization expense for intangible assets	$ 545	$ 595	$ 1,608	$ 1,796
Estimated amortization expense for intangible assets remainder of fiscal year 2012			549
Estimated amortization expense for intangible assets fiscal year 2013			2,179
Estimated amortization expense for intangible assets fiscal year 2014			1,743
Estimated amortization expense for intangible assets fiscal year 2015			1,495
Estimated amortization expense for intangible assets fiscal year 2016			1,153
Estimated amortization expense for intangible assets fiscal year 2017			$ 911

XML 19 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 20 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Jun. 30, 2012

Basis of Presentation [Abstract]

Basis of Presentation

1.	Basis of Presentation

The results of operations for interim periods are not necessarily indicative of the results to be expected for the year.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6921930&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6970148&loc=SL6228881-111685

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Name Statement of Position (SOP)

-Publisher AICPA

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Name FASB Interpretation (FIN)

-Publisher FASB

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6359553&loc=d3e288-107754

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

+ Details

XML 21 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 24,798	$ 20,121
Non-cash items included in net earnings:
Depreciation of property, plant and equipment	2,660	2,525
Amortization of intangible assets	1,608	1,796
Amortization of deferred illumigene instrument costs	587	81
Stock-based compensation	1,670	1,981
Deferred income taxes	(1,491)	(1,622)
Loss on disposition and write-down of fixed assets and other assets	203	7
Change in current assets	386	(10,176)
Change in current liabilities	2,474	2,451
Other, net	(1,007)	(546)
Net cash provided by operating activities	31,888	16,618
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment	(2,985)	(7,666)
Proceeds from sale of assets	400
Purchases of intangibles and other assets	(1,305)	(12)
Net cash used for investing activities	(3,890)	(7,678)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends paid	(23,417)	(23,192)
Proceeds and tax benefits from exercises of stock options	399	1,481
Net cash used for financing activities	(23,018)	(21,711)
Effect of Exchange Rate Changes on Cash and Equivalents	(668)	455
Net Increase (Decrease) in Cash and Equivalents	4,312	(12,316)
Cash and Equivalents at Beginning of Period	23,626	37,879
Cash and Equivalents at End of Period	$ 27,938	$ 25,563

XML 22 R17.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Comprehensive income:
Net earnings	$ 8,594	$ 6,836	$ 24,798	$ 20,121
Foreign currency translation adjustment	(1,582)	335	(1,385)	1,203
Other comprehensive income taxes	554	(117)	483	(421)
Comprehensive income	$ 7,566	$ 7,054	$ 23,896	$ 20,903

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the economic entity, including both controlling (parent) and noncontrolling interests. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, including any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References+ Details

- Definition

Pre tax adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains (losses). Includes gain (loss) on foreign currency forward exchange contracts. Includes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements. Includes the gain (loss) on a derivative instrument or nonderivative financial instrument that may give rise to a foreign currency transaction gain (loss) that has been designated and qualified as a hedging instrument for hedging of the foreign currency exposure of a net investment in a foreign operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 35

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6939497&loc=d3e30304-110892

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 24

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 14, 17, 19, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 45

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b),(d)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 52

-Paragraph 13, 20, 31

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 55

-Paragraph 2

-Subparagraph (a)-(c)

-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

+ Details

- Definition

Tax effect of the change in accumulated other comprehensive income (loss), that is, the tax effect on items included in other comprehensive income (loss) during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 24

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 36

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 20

-Section 45

-Paragraph 11

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6909487&loc=d3e39076-109324

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=6922042&loc=SL4591551-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A1, A4, A5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=6921930&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=6922042&loc=SL4591552-111686

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 5

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4569616-111683

+ Details

XML 23 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Jun. 30, 2012	Jul. 31, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	MERIDIAN BIOSCIENCE INC
Entity Central Index Key	0000794172
Document Type	10-Q
Document Period End Date	Jun. 30, 2012
Amendment Flag	false
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--09-30
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		41,272,339

XML 24 R18.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details 1) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Sep. 30, 2011	Jun. 30, 2011	Sep. 30, 2010
Investment portfolio
Overnight repurchase agreements	$ 13,400	$ 11,784
Cash on hand - Restricted	1,000	1,000
Cash on hand - Unrestricted	14,538	11,842
Total	27,938	23,626	25,563	37,879
Other [Member]
Investment portfolio
Cash on hand - Restricted	1,000	1,000
Total	$ 1,000	$ 1,000

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

XML 25 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Sep. 30, 2011
CURRENT ASSETS
Cash and equivalents	$ 27,938	$ 23,626
Accounts receivable, less allowances of $428 and $310	24,306	24,844
Inventories	33,120	32,689
Prepaid expenses and other current assets	5,081	6,343
Deferred income taxes	3,393	2,852
Total current assets	93,838	90,354
PROPERTY, PLANT AND EQUIPMENT, at Cost
Land	1,172	1,184
Buildings and improvements	26,334	23,033
Machinery, equipment and furniture	35,825	32,408
Construction in progress	1,136	3,887
Subtotal	64,467	60,512
Less: accumulated depreciation and amortization	37,928	33,973
Net property, plant and equipment	26,539	26,539
OTHER ASSETS
Goodwill	22,830	23,124
Other intangible assets, net	10,635	10,947
Restricted cash	1,000	1,000
Deferred illumigene instrument costs, net	3,721	3,304
Other assets	251	225
Total other assets	38,437	38,600
TOTAL ASSETS	158,814	155,493
CURRENT LIABILITIES
Accounts payable	6,158	5,548
Accrued employee compensation costs	4,640	4,235
Other accrued expenses	5,116	4,692
Income taxes payable	1,626	789
Total current liabilities	17,540	15,264
DEFERRED INCOME TAXES	269	1,705
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY
Preferred stock, no par value, 1,000,000 shares authorized, none issued
Common shares, no par value, 71,000,000 shares authorized, 41,269,062 and 41,237,120 shares issued, respectively
Additional paid-in capital	102,012	100,010
Retained earnings	39,446	38,065
Accumulated other comprehensive income	(453)	449
Total shareholders' equity	141,005	138,524
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 158,814	$ 155,493

XML 26 R12.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

9 Months Ended

Jun. 30, 2012

Significant Accounting Policies [Abstract]

Revenue Recognition and Accounts Receivable

Revenue Recognition and Accounts Receivable –

Revenue for our Diagnostics segments includes bundled product revenue for our illumigene ^® molecular test system. The bundled product includes an instrument, instrument accessories and test kits. If not sold outright, amounts invoiced for the illumigene^® test kits cover the instrument, accessories and test kits. Revenue is recognized based on test kit sales. If not sold outright, costs for the instruments are recognized in cost of sales over the expected instrument utilization period, generally three years.

Comprehensive Income (Loss)

Comprehensive Income (Loss) –

Our comprehensive income or loss is comprised of net earnings, foreign currency translation and the related income tax effects.

Income Taxes

Income Taxes –

Stock-based Compensation

Stock-based Compensation –

Cash and Cash Equivalents

Cash and Cash Equivalents –

Cash and cash equivalents include the following components:


	June 30, 2012				September 30, 2011
	Cash and Equivalents		Other		Cash and Equivalents		Other
Overnight repurchase agreements	$	13,400	$	—	$	11,784	$	—
Cash on hand –
Restricted		—		1,000		—		1,000
Unrestricted		14,538		—		11,842		—

Total	$	27,938	$	1,000	$	23,626	$	1,000

Reclassifications

Reclassifications –

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 8, 9, 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Technical Practice Aid (TPA)

-Number 2110

-Paragraph 6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122427

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

- Definition

Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.

+ References+ Details

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144681

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 6-34, 43, 47, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 4

-Paragraph 11

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e32280-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 48

-Paragraph 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2144749

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e32247-109318

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

+ Details

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References+ Details

XML 27 R11.htm IDEA: XBRL DOCUMENT

Intangible Assets

9 Months Ended

Jun. 30, 2012

Intangible Assets [Abstract]

Intangible Assets

5.	Intangible Assets

A summary of our acquired intangible assets subject to amortization, as of June 30, 2012 and September 30, 2011 is as follows:


	June 30, 2012				September 30, 2011
	Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization
Manufacturing technologies, core products and cell lines	$	11,625	$	9,117	$	11,626	$	8,545
Trademarks, licenses and patents		4,842		1,667		3,538		1,337
Customer lists and supply agreements		12,219		7,267		12,222		6,557

	$	28,686	$	18,051	$	27,386	$	16,439

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References+ Details

XML 28 R23.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Sep. 30, 2011
Summary of acquired intangible assets subject to amortization
Gross Carrying Value	$ 28,686	$ 27,386
Accumulated Amortization	18,051	16,439
Manufacturing technologies, core products and cell lines [Member]
Summary of acquired intangible assets subject to amortization
Gross Carrying Value	11,625	11,626
Accumulated Amortization	9,117	8,545
Trademarks, licenses and patents [Member]
Summary of acquired intangible assets subject to amortization
Gross Carrying Value	4,842	3,538
Accumulated Amortization	1,667	1,337
Customer lists and supply agreements [Member]
Summary of acquired intangible assets subject to amortization
Gross Carrying Value	12,219	12,222
Accumulated Amortization	$ 7,267	$ 6,557

XML 29 R19.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details Textual) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Jun. 30, 2012	Sep. 30, 2011
Significant Accounting Policies (Textual) [Abstract]
Accrued distributor price adjustments	$ 3,871	$ 4,176
Expected instrument utilization period	3 years
Period of review of accounts individually	90 days
Accounts receivable from Italian hospital customers	$ 5,300
Tax benefits recognized from uncertain tax positions measurement	Greater than 50% likelihood of being realized upon ultimate settlement
Likelihood percentage of tax benefit being recognized upon ultimate settlement	50.00%

XML 30 R15.htm IDEA: XBRL DOCUMENT

Major Customers and Segment Information (Tables)

9 Months Ended

Jun. 30, 2012

Major Customers and Segment Information [Abstract]

Segment information


	U.S. Diagnostics		European Diagnostics		Life Science		Eliminations (1)			Total
Three Months Ended June 30, 2012
Net sales -
Third-party	$	26,234	$	5,897	$	10,010	$	—		$	42,141
Inter-segment		2,464		5		133		(2,602	)		—
Operating income (2)		9,442		998		2,118		54			12,612
Goodwill (June 30, 2012)		1,381		—		21,449		—			22,830
Other intangible assets, net (June 30, 2012)		2,423		—		8,212		—			10,635
Total assets (June 30, 2012)		81,911		16,930		97,150		(37,177	)		158,814
Three Months Ended June 30, 2011
Net sales -
Third-party	$	23,829	$	6,612	$	9,611	$	—		$	40,052
Inter-segment		2,875		9		141		(3,025	)		—
Operating income (3)		8,399		978		797		(43	)		10,131
Goodwill (September 30, 2011)		1,381		—		21,743		—			23,124
Other intangible assets, net (September 30, 2011)		1,604		—		9,343		—			10,947
Total assets (September 30, 2011)		73,850		19,390		92,467		(30,214	)		155,493
Nine Months Ended June 30, 2012
Net sales -
Third-party	$	80,091	$	18,326	$	31,431	$	—		$	129,848
Inter-segment		7,428		9		793		(8,230	)		—
Operating income (2)		29,377		2,398		5,526		(57	)		37,244


Nine Months Ended June 30, 2011
Net sales -
Third-party	$	72,007	$	18,926	$	27,441	$	—		$	118,374
Inter-segment		7,938		16		459		(8,413	)		—
Operating income (3)		26,780		1,781		1,499		123			30,183

(1)	Eliminations consist of inter-segment transactions.

(2)	Life Science includes $366 and $1,013 of costs related to consolidation of the Maine operations into the Tennessee facility during the three and nine months ended June 30, 2012, respectively.

(3)	U.S. Diagnostics and European Diagnostics include $365 and $875, respectively, in the nine months ended June 30, 2011 related to sales and marketing leadership reorganization costs.

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details

XML 31 R13.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

9 Months Ended

Jun. 30, 2012

Significant Accounting Policies [Abstract]

Comprehensive income


	Three Months						Nine Months
	Ended June 30,						Ended June 30,
	2012			2011			2012			2011
Net earnings	$	8,594		$	6,836		$	24,798		$	20,121
Foreign currency translation adjustment		(1,582	)		335			(1,385	)		1,203
Income taxes		554			(117	)		483			(421	)

Comprehensive income	$	7,566		$	7,054		$	23,896		$	20,903

Investment portfolio


	June 30, 2012				September 30, 2011
	Cash and Equivalents		Other		Cash and Equivalents		Other
Overnight repurchase agreements	$	13,400	$	—	$	11,784	$	—
Cash on hand –
Restricted		—		1,000		—		1,000
Unrestricted		14,538		—		11,842		—

Total	$	27,938	$	1,000	$	23,626	$	1,000

- Definition

Tabular disclosure of components of comprehensive income (loss) including, but not limited to: (a) foreign currency translation adjustments; (b) gains (losses) on foreign currency transactions that are designated as, and are effective as, economic hedges of a net investment in a foreign entity; (c) gains (losses) on intercompany foreign currency transactions that are of a long-term-investment nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; (d) change in the market value of a futures contract that qualifies as a hedge of an asset reported at fair value; (e) unrealized holding gains (losses) on available-for-sale securities and that resulting from transfers of debt securities from the held-to-maturity category to the available-for-sale category; (f) a net loss recognized as an additional pension liability not yet recognized as net periodic pension cost; and (g) the net gain (loss) and net prior service cost or credit for pension plans and other postretirement benefit plans.

+ References+ Details

- Definition

Tabular disclosure of the cash and cash items which are restricted as to withdrawal or usage. The provisions of any restrictions are described in a note to the financial statements. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.

+ References+ Details

XML 32 R14.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

9 Months Ended

Jun. 30, 2012

Inventories [Abstract]

Inventories


	June 30, 2012		September 30, 2011
Raw materials	$	7,147	$	7,272
Work-in-process		6,662		7,016
Finished goods - illumigene instruments		2,668		4,179
Finished goods - kits and other		16,643		14,222

Total	$	33,120	$	32,689

XML 33 R16.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

9 Months Ended

Jun. 30, 2012

Intangible Assets [Abstract]

Summary of acquired intangible assets subject to amortization


	June 30, 2012				September 30, 2011
	Gross Carrying Value		Accumulated Amortization		Gross Carrying Value		Accumulated Amortization
Manufacturing technologies, core products and cell lines	$	11,625	$	9,117	$	11,626	$	8,545
Trademarks, licenses and patents		4,842		1,667		3,538		1,337
Customer lists and supply agreements		12,219		7,267		12,222		6,557

	$	28,686	$	18,051	$	27,386	$	16,439

- Definition

Tabular disclosure of amortizable intangibles assets, in total and by major class, including the gross carrying amount and accumulated amortization. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.

+ References+ Details

XML 34 R21.htm IDEA: XBRL DOCUMENT

Major Customers and Segment Information (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Sep. 30, 2011
Segment information for the interim periods
Net sales - Third-party	$ 42,141	$ 40,052	$ 129,848	$ 118,374
Operating income	12,612	10,131	37,244	30,183
Goodwill	22,830		22,830		23,124
Other intangible assets, net	10,635		10,635		10,947
Total assets	158,814		158,814		155,493
U.S. Diagnostics [Member]
Segment information for the interim periods
Net sales - Third-party	26,234	23,829	80,091	72,007
Net sales - Inter-segment	2,464	2,875	7,428	7,938
Operating income	9,442	8,399	29,377	26,780
Goodwill	1,381		1,381		1,381
Other intangible assets, net	2,423		2,423		1,604
Total assets	81,911		81,911		73,850
European Diagnostics [Member]
Segment information for the interim periods
Net sales - Third-party	5,897	6,612	18,326	18,926
Net sales - Inter-segment	5	9	9	16
Operating income	998	978	2,398	1,781
Total assets	16,930		16,930		19,390
Life Science [Member]
Segment information for the interim periods
Net sales - Third-party	10,010	9,611	31,431	27,441
Net sales - Inter-segment	133	141	793	459
Operating income	2,118	797	5,526	1,499
Goodwill	21,449		21,449		21,743
Other intangible assets, net	8,212		8,212		9,343
Total assets	97,150		97,150		92,467
Eliminations [Member]
Segment information for the interim periods
Net sales - Inter-segment	(2,602)	(3,025)	(8,230)	(8,413)
Operating income	54	(43)	(57)	123
Total assets	$ (37,177)		$ (37,177)		$ (30,214)

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References+ Details

- Definition

Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph e

-Clause 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 68

-Subparagraph l

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph e

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 72

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 35 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Jun. 30, 2012	Sep. 30, 2011
Condensed Consolidated Balance Sheets [Abstract]
Allowances for accounts receivable	$ 428	$ 310
Preferred stock, par value
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued
Common stock, par value
Common stock, shares authorized	71,000,000	71,000,000
Common stock, shares issued	41,269,062	41,237,120

- Definition

Issuance value per share of no-par value, nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References+ Details

XML 36 R10.htm IDEA: XBRL DOCUMENT

Major Customers and Segment Information

9 Months Ended

Jun. 30, 2012

Major Customers and Segment Information [Abstract]

Major Customers and Segment Information

4.	Major Customers and Segment Information

Segment information for the interim periods is as follows:


	U.S. Diagnostics		European Diagnostics		Life Science		Eliminations (1)			Total
Three Months Ended June 30, 2012
Net sales -
Third-party	$	26,234	$	5,897	$	10,010	$	—		$	42,141
Inter-segment		2,464		5		133		(2,602	)		—
Operating income (2)		9,442		998		2,118		54			12,612
Goodwill (June 30, 2012)		1,381		—		21,449		—			22,830
Other intangible assets, net (June 30, 2012)		2,423		—		8,212		—			10,635
Total assets (June 30, 2012)		81,911		16,930		97,150		(37,177	)		158,814
Three Months Ended June 30, 2011
Net sales -
Third-party	$	23,829	$	6,612	$	9,611	$	—		$	40,052
Inter-segment		2,875		9		141		(3,025	)		—
Operating income (3)		8,399		978		797		(43	)		10,131
Goodwill (September 30, 2011)		1,381		—		21,743		—			23,124
Other intangible assets, net (September 30, 2011)		1,604		—		9,343		—			10,947
Total assets (September 30, 2011)		73,850		19,390		92,467		(30,214	)		155,493
Nine Months Ended June 30, 2012
Net sales -
Third-party	$	80,091	$	18,326	$	31,431	$	—		$	129,848
Inter-segment		7,428		9		793		(8,230	)		—
Operating income (2)		29,377		2,398		5,526		(57	)		37,244


Nine Months Ended June 30, 2011
Net sales -
Third-party	$	72,007	$	18,926	$	27,441	$	—		$	118,374
Inter-segment		7,938		16		459		(8,413	)		—
Operating income (3)		26,780		1,781		1,499		123			30,183

(1)	Eliminations consist of inter-segment transactions.

(2)	Life Science includes $366 and $1,013 of costs related to consolidation of the Maine operations into the Tennessee facility during the three and nine months ended June 30, 2012, respectively.

(3)	U.S. Diagnostics and European Diagnostics include $365 and $875, respectively, in the nine months ended June 30, 2011 related to sales and marketing leadership reorganization costs.

Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 131

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

+ Details

ZIP 37 0001193125-12-345653-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-12-345653-xbrl.zip M4$L#!!0````(`(Y#"4&.8E?,:ET``*(6!@`1`!P`=FEV;RTR,#$R,#8S,"YX M;6Q55`D``^NL(U#KK"-0=7@+``$$)0X```0Y`0``[#UI<]NVMM_?S/L/N+IM M)YW1:CM>D]Y)'/?>W"9-)G:G?9\\$`E):"B2!4C+ZJ]_YQP`)+0YWF0M9C[$ M(@D"9\/9`!Z\^M?U,&)70FF9Q*]KG6:[QD0<)*&,^Z]KN6YP'4A9^]=/__L_ MK_[1:+`_WG[YP/XM8J%X)D(VDMF`[GWDZBL[3=*QDOU!QEZ<_LBZ8_;E"WN7 MQ+&((C%FC8;KY"W7\&X2F]YVFAW[[+JK(@;PQ/IU;9!EZ7&K-1J-FGB[F:A^ M:Z?=WFW)6&<\#D3-M#R.9/SUAN;XN`OCN>;7,^U'N]2ZT?J9&^GP%(W.<\+5[H M<=VEQO8!CM!IM#N-W4Z!`O0G[T`A?!J6+_B-]UOF8=%4RWFT@9:=UA\?/YP' M`S'DC>D!0C'5NQ9!LY]"!#S_PF+%72.)C33U]$3U&)#_.QJEX7=-RF$;8 M+=T;*-%[74,N-!R9F][P\38;#)+X\SY+@Z^5',>P*98"$'D20Q_%W:*AB$/7;*?1 MWF_LMK'KT&OTJN5U_JIE63?+Q[<\0JE[HS_U/!Y^$1D'!H>79US%H+7T=C'2 MH>>P6PXWS8S.)ICD[CT&D]Z$H<3YR:/+SUR&E^_CRU.>R@RNMXI;)9Z(YOO8 M(KFA3`N"?)A':.@O/V4#H5!?IDH,D#A7`I@(%E!L&0-+G`GE"8P-PIO%S'.1 MHH*NU.0C,PE\FJ-'9U*E)C>1:96:7(F:?%1F5A'!VENPBC5K,&L6Q]*5&GQ" M-;B"Z/MBH,0"UO\62^0Z$4U?OI.\'RTOGIT'MF<]-1 M!,QK)I3%Y/(LDD,9EU]DIB_?Q&Z9 M?C-8^UDE81YDG]2Y4%<2<"HG+>(#Z!`VF[6UQ7'D?13E0]D7,6Z3T)G*26@W MGS,E7AY:F\4BM_NHFC3KLE7/<:2:-&O+(J?7+A0/Q9"KKQJ\_P!H(,P<^@RF M;'-X];/$F.V#O!(A>`P\[LMN!)AJD>FWXX_\ST2=1ES[;F2)MT,;L+9(;Y;Z MYSI(AV+L/4EOFGN=I&HTOW_25$)ND<>_.8X<\X0ZH M&\Q+Q#>+IV53EZE3E[:]Q/5!YJ;N7ODQNH2 M6_[]RS9_[S+?(3;9G_?QE=#9)FG:$N*+<2HFN4@X>2AMIE];<6;UUFW>G.DL MG0%WP^^Q):^]3OBUEY'%J[9E;(@JK+XA6&^^5)LG-H-/U7Z(I]@/L6R'L#); M&^(G.H959FL]^5*9K0/&Y5OJ#'4'"=*S&Y9O^JY6Z;(?#UJ8X^ MP].93NB\@^,4?MZBA]_.WYU]/B_Z".45$+6D`[;[-1_B\15)J2&]P>SQ#,?0 MS^1HAD;SWZ=NWXDX(=]S?L<&"SW@2NA%/<]V\:KE83`7X7/J<0'1Y@VWB&PS M72PDA=\#'L)P%I$)FSF$@<[Z$'T9L[=1$GQE%[S?%R'[-<]B61(%[A+"W"`_NGR4^]G(%`<2!X5ME._DSJ($H3O`F36#&8%^`N> M(;%P^OX092<`Y;M/IQ?_]_F,#;)AQ#[_]O;#^U-6:[1:O^^>MEKO+MZQ/_YS M\?$#ZS3;[$)Q,.'&%K=:9[_6V)SS,BZ^M*ZQKPZ^;'\V,N_-9IB%-:#!#_WL MA*AN`5E(K@YKL&61:@X8*#WU6,^#T#RZGG[4`W(SG8TC4'7XN]'C0QF-CS/P M>32+Q8BI9,CC&M/R;VBR4\.W\<6N^]$J?V$'#^^]>'MY0ZP3`AGO1L*-T4U4 M*%0C2**(IUHR'Q^S2/2R&C-M7]?:-1:(*$IY:$[_L=#`23F'.10]2R(6ZF#?&7U41PT7.* M!SIWFH>!*6)YS/,0<]:,QR'=295(X6$73(>!""+Z$F:DZ7P.@<'*.Y#,PD= MII'0A&Z?CJ"*HC&V$6EFWL\`,I,29R8GCJ1_@TMRW.KH,!C_N"815GJ3&\:_[`A^G) M/SO[[9-3H7#?FS\,O=5+DBQ&Q1X6^ACHC4T0)T`URD.#4P$JX>V1\R;"S2'/ M7%JR`;\2K"M$['$2Z`1>2(8O@=.E#^93Q\'UOF)"D,D94@60? M>`C^S(GVQDX38Y(9)_Z"EU`'TA3.Q-'.?P^XM($Y7A>7`_`\L9!#&_>!+U\[RI:MA%9#A'\<9\ MQPSV'9!N;80;[!MN,F8]4&<+07.:Z9N:K,EFM77Z34WM93G!7C0#LKTX7KE+3',.;@5$\P$HT#>%]OV<8(Y. MZ&V-5':\2.5V!)CJ_!G[L3OKZL=ZC&0E)YECY?(]VE*%[#],@U1"]H+_N%Y2 M5@I`=T;Z)/[X(JY$G`MP%(($Y+!PHJTD:GP@Y!6QM+#H'2N+OG*4.9OY^)HCF[Z:`"N3VH^?,/V>B#3U(9> MF-YFW0X+9)27L%F*0/,!N,VJ* M?A/Z$0@#O>\@@+`#XI-I?SZ$40(;)8%?GRG9S;-$:0@58:(Q,!#@>Z&)5#Q` MUZN,)Y@`4(84YD%PH\"5-+ZRU\OLF*SK#A^>[!FFNAKJNJ4G8H!\KSP(W7!S\-;\;@S>%'.NQKG(SB M)CO'D*[H8`1>//MNMWYXT$%>WA!1?+=7[QSL8Z,;O._[>LQ32$43G,WW@+\SF2K4>5H8 M/PC1S4#NIL\/3SL.DT@$$,S#5`?)9GJL@:=>"'9!>F$2Y8(6'),;KDY)W?M- MJ0>MS<0@E0.=$YQ?(<#U\/'TQ+TO M78F:7RF:3ZX$06]CLI)>\X@T32!/Y7N*OE!D[A6CNYIL/CT#D.8REU""4"H. MVR\E`J!'J$!J5G8RSC08W*>R!F8%JA*T,?1R,+IXZVWR8B$KU+Y@Q30`8Y7OAZ.^T3Y"Z] MCF990;"OBX?@"'9-&E[Y;_3D-2H5(68:-C$/=?O./0*"P59S.<)UB0LEO0M$ ML-LN*#`1TK!F(GP#RMN,F*=)3"R(1.$OFUPP98F[)CGJ>&I0+H1]@<#Z0\WU M/6E0*VAC%#QG+;XU^GN0'9Q3`4BNG1CNH6&^$G_EJ.;(DQEAY)8`&1/RE;2J5/`8!@@K>*SANH25HS0`?5O#"RB77H\ZM!&8#A;OLJ.,8$"B5C M,$%J>$19>$.F@AUV=GB,H.F!8M4`RC<&:`FL:/]J$_F3#WV)`C4/\]_X\PM\ M0(#C<1P_+S,X&=;?L&QU4U@_SWS,S1`\KOF@VC)NA<6$-:H,2>743SW;357L?"`$FNFL](6<'/Z1BD[R;]?*H@)B$ M'!==DA&-2-U,-P(<[/**)B?7!4%VGG<15R/&$!""-Q(E6ENG1GIAUV2$0X^] M6&BD9"8:2:]'SH8B@WP[Z,R:%)W%R88"*(#A%(DZQWAN7.CLSL&)# MH66J6RY=23'"#G"5)1HWRQ0#K8=`J)Q1P-HUK+&^T5&;!L`N+.]M-YA8AQ`R M)SUIW`G0]$$FNZ@-H'NW-2G%"[4! MC(PT07^(T'^?\4A"6#!(-.U2]53E".Y!RYQHSO(H<^.C1Z7+Y1G711_I&Z/D M-MD[JP]Q30J`!';\E7,%!AFA]I>5:'%**B#:W`8[=:1<*5XPF\!FH6%/S.)) M,4?[.)XEB8-H#FF:[/>!M+)O!(Y>Y&DJ:'T6UTXSCBS_6Q1:'?K7`M=<[:*S M5*$#5\^#%VV#1&4/O8%TRLS9@@(@7-$0*+,K6)>ILJHONIN659THWL),]1;V MX@-H[1^W.HOZ*5?6V_+QEP;_1)'=0IU&SR59+0BH10;1E"E=5$=5+H!=UI8% M8^.D1>7V#K.&:HR1[3GCUTST>B*X[_KQ$Y#&E-XB#$#9=0N7M5=@[*TPHZ5R M>*/OKRG`HQ1``TP[:%B[,491IM3L2T%CYH@LM%UGQA<+Z^&3LMA0`":<>Y&H M^TH"(;N)C46`;'!"G1]KL0#T*7BATRL.%,!XN-39!C_0^&B-=5+ZW`MD@IO= M%`9OHJM!'!TAF_3F1/1B;XM/>++C"&SH-@:7'N0;,*K*V*00-:NJL[>X+4F# MFP(&P=@5_+;1021%$%>P?W\OH[CRBT9TVD]-FU%K"HYWO)ZSM/6RUM52!0(I, M)I_+?0$7!-1_<&/1]/+^0BM]8"WZ%+9S3*>SEH9,!7*[MWS_B1M5X#YS<*>= MHAM=UBET)C6:OR@Q.=*WO,VGZ18#7-!"<&-_GJ)XT`H,.9[TE3`S'X/>T=^N M"'L38?$;VU73M9HGC\;.L_F;@JLIL\4T?H[39V>:M5,>K76D.^DUH\B$_;-- M_QY)!#`]]SSGU.H)WZD(7TG\LR+\ZB1^85K7?3"Q.-Z?S@F\3<+Q;$Z`=?M`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`5&>`Z+H MN!*J\!2'$V4B^#4>F)/"6)HJA-@3>B;+1:="`4&H/BZ5>[7C$];W@,$->#,P MINR'WSW"9389F@I56/H0.J8*CCU3]L16OL*>E,AR%>LZR\8IUFD#^B8!TIK* M?\;V]!NL865.AO'+4U"/L42VI183"O13$-\(26@I!K M6T/D]Z(,(*&6QZ[*"_'#'C:D;<49#DR.14]FKHP,;?T<)J&([/E7A$XV2AK` MIA0KBJF$!X-C]D)Z:T(<7E&B$\SP+)Z"GZ=$(->R*GW MS>&.IFIS9JH'VBIR]I$VU6^\TY+P.L(Z=3JSY0B)SX"F0XK>QU*A2F#=5+R. MV+NG<. M!"I[UP4#"'(.7#`5"+$@#81G5."G>LI54L5XCS>.RR`_52J<2 M.8`080[43$7,(ZK7XTH^P7S*8Z\T>,(-\WC.,_P_!U3FQ/7`$#&S/[S;W@?$SUMOD,R,<<#GPZN[A4J M`&VJ"HV["N.JN^-&8J<"0-16)1EA[ZQ.C+HBTRX6LU%G;+[Z(%)->"KA4H/ MW$X/B$W3`Z=XVB#:,OIQ!M($0)!=\10!V[8X!)$E&!!S.G!1>)B[LRA-P5DL M\X:^2E%[L*KY5F8\[E_S;7__@37?]M:GS%<%;@7NPW:!;'B%C)DZ2T];(6-^ M>?([6N**%8_!BAM.AU@9/Y[CC%QQS1KG5M(-Q5IXSW,NG^?47#%//F%IYXKR MU6RH>++RV7#+9>3G4%;K$Q[T@INZ<&TK5\&`:^$=PS5+P6HS\F-\5[U;WVNW M;P5$M;EQDQA;I.UV?"K)XYU._>"PVH"^?8S=_*E\K\A[U5]$H;.> MQ&R`:P/3JZ'KZX@\V;;/^[U485UAO=%8WZ3*'CW8VEV69@97<_O9LGY3YO82(Z^E.2>_Q:IR3YY*CO?J+W>K MRNU;S.'*2#U;UGY[.2@;7]MB.^N;572LZ%C1$'#((E[B1JZ=Z8J MYMF74R4TW*71FNP\#P9S@4#?C\DA2'N&&YECD3'!50RBKQE`0B6(!DD$4T47 MO#HXH1(H_\_>U3:W;2OKOX+KF\RD,]0+J?>X[4QBIVW.Q$DF=F_/^92A2$C" M,46R(&E%_?5W=T%2E"S+LFQ9(HU^:&B1!';W62P6X.XBGA^D@MC/C22JC6T[ M?'L)^DO,^/$[54X/R/X:>,(1/+J"$?_>"YSK7Y&8GS.[13^!]1J/NW? M_Y7XM583KZV37U-;>O[E[.H_7S^P23SUV-<_WW_Z>,9.:HW&7ZVS1N/\ZIS] M^X^KBT_,K#?9%1[\3(7U;*_1^/#YA)U,XCA\VVC,9K/ZK%4/Y+AQ]:WQ`]LR M\>7TLA87WJR[L7MR=YK@;=9;K,:V87LUJ_#EVN56_;C,,EXD>)'!)](#.Y.% MA=U([%YL[>.8*[!"]-\6JE^Y_JT00W4EK,;S<:D$'1F5]M:`5:(ZG<-`=*^:74*7A MFSUC6)M9PM)%UV38S]Y^SS#;AS\S^B@M5LEQM7IEB,;,A5C[N-9O%$LDRK7P#H:I;?`JNGHM@H#W#;,WJ`$`)?1`[MEPZ[IK!M8 M'0=YB45MN_87$`8N6;L,A]EJA'=/U;6L,CC=&WVRLL?\53/U0\M1I]#H%)KG ML.*MEF%:98C'2U0^!;!="(+?@7D=">FG(1OM8(R$O[/\&DITE$0PT/'L<=Z!29-E' M"JZF`&DBL\11DA=<"E?8/IO9$1Y..Z5#J9DYZ'75$>R)[ZA`<#IN>I1XWKR& MIU:/)9T"$`5D,.@G&>%1\'BP._XIKWE^U'UD>WB$O1S; MOOB'I$A"5!.\!@8%`-HEO@/R"N$*S3&V#8Q'MK21LOC M`&\CCN).(NR4VT#OZIT.+8U1R,B#4_%`$&`;(S0+FU1 M1`5B972:,PU9@T0NHF3 M;NP[F9$UR`80.Z-$$K!+/0/VQ4XS0H@];"CG:LC1UA3Z&_,`#%8X`7V4,(6C M/<,3KO'4;*5?`#RI&XY/N"N&PJ/LE:O);?%E1*'"@HF*R2PM63P&9,@T@0:T MZ0S-D._##P;[,A&!0;W2^=U@"O,AL96=2>UASC,EM5"0>Y#$$0QB?/,=2!3, MC;`SI`WV;B1A`.0=7PC7A:X_@)U23*[5B'6,%LG>FN2-!!'S:XE:4JF'2OT" MYQ`!2G7%?;+]X$*]#Z#+;V!^?8/]Y@4P]]FG[%/@N_C#!W_L`3GP0^)<R[0^3NHK^W/3Y4','=]/C>*_*Q"^0!K3(P_F45V80Q%9.4\FEN8/92![6Z0 M)%C+(#N>.F(/,<'.[Q=?F>,)GXPJ#"V7;V^6B>TC,Y;&@K61_)[8$4XOHJ#0_(@G75`8+0:\C-N/D+_A@,1R0I4H3 MI%UL<.6HJ4O;`>-T88,0EP=3FD=X>T@Q4(K<5(*[MF@QU?[T/H((M_U@1JAZ MH-%@4Q=,Q!,AW9P'!--'(J8@CPG"[P+!Z\_E->C],U*5.6HSYCJZ[%6KVR4) M8%NO3*-IMI3WA0X6Z#8,8M3C``V)'46!(\B?)2>4I)KRMKMT6_::& M?EDP:DK#YM6-&OB.\*P=AM(68($`!7",@2QE6UY91K/7I)YP+SYE=Y%7FDL+ MO&-'J4"F'S3R4Q*708E.?TI&)VNB?>^*!4# MKC_\",$X\NBG.GNWD)@BMR#GV\007[2P`!$$/P0&E7O*PKSJ-LG[X3\0<]7` MD"]X=A?:)_G4QB\?*VQ8QD(?IK@>1%S@B0A3915Q*VT"4T"?3TZ\KUY>J,0P M\).B=F5]Y-0L6,QI87&>Q(E8)M4`W6N)V_S6QUNZ]SM3F3K^I MJ+IJ,>@6+8'D6PU\ZD[9M^5Q360,%#F=YNM"X\31MH;ECO;KJ4C6+'"PE[OD M8YJ*(+.3RV?MG+Q_V:3S0DI.NRB?Q\OF6'0WVZH1BZT:@@&9Q&4Y6/$T#9[F M)3M2JPY*"8U*DQ!*NWG'FA':M1Z9$=HZGA1+3:XFMZSD[A0%JA-1'Y.(BIX/ M_9&FG1:V>:6QN1X,$'OMXA'Z@B_6"Q6HWD..EX\,16^VOU9 ML/C&?&@UL>J@.A$):MK6*WV5D3H#+0R`=LQ^@-=-ZYZN)I-HVGJE-'J`:M8 M+_/IO1KQ!Q8@L@RS;98`V#UN`.S-=?R(6_RU-!ZKHL[C([^,/*$7:;2[VHFL M,,`=#6YUP35;NE18A>%]8QG=YN%+A?VD(=9KAYU, M44R_!X$[$Y['WF!@*LOB4;5/N6^E-EK],FS,:X!?[()90[^KOVG"@K$,I7DU MPGIP:^@?.+@MH]\J0W1,1?8[J0*.\&/;'PO,#;.CB%/M,QYKG_79O\%;^CM> MA0'6T]J+A;YO6*788]$`Z[&MH7]P0'>W58;XJC)NH%+1A=0KU0[I,T]:IC$P M]2YJA1$VN\:@%*MMC?"NL1<]P^QHA"N,\)L60-P[?*:@#@_=HYWN](V^688P MC&ILB^*+0W(_MZPPI;RD82Z,X_5*=2V'(WQ)X/C2ALJL_VU005QUC\-(0 M;S>-9J<,)GJ/ZW]=8.I@0_))@UO[O3+$R&B`=W4Z-+C5!;<<50XUO#N'$!A- MZ_#664<0Z+5#U2,+;A>8:NDXUKTG7[0&VCVI,,"#GJX_5&%X>_HUVRR#^FN`]=RF MH7]H]&=+^ZU5!EB/[1<+O=DT!NTR?`PIXU;JE/]GNTTYV.T1Z48159C0U2?'&( M%Y^%OTVY*942-LQE<;Q.J2[L<(0O::XUUZ7FNHS;"[K MNBXWM3.'AZYYT6\:S8&.JJT>L&;?:%E=#6SE@&V91KL4"1X:6!UIH!'?:*.M M@=%OER&;=H];`+KBU,'&Y%-&$QAMJPR*K`'>]5.S!K>ZX/9*\?51P[MK$$'? ML([@X#D=0Z`7#U6/+;A=<4J?G+IOW8=55.L(CN33UFU_"!NM@5Y=5!C@CM'1 MF]55!OA-Y_`&6ON?>_PJT3.L]N'#E!_N9N9__T^MAD&@[,K&G/GW@3MGM=K* M&WAKF9]PB40DY:T9_CA-?4UP1M^:UN)OQ>+;9OAC';7+7B%UQASN>5%H.^!1 M_G+2/*&_0]MUL[]GPHTGH(C-YNL3-@RDRR7]GE*E?JF!\^S98<3?9A>IYTN2 M?\O0)&X;WIR2S;O.7"02N26B=PM3=^ZP;UJ`-:9QS(MT_'%(5YLF0*@3YS6P7:::\WU2^5ZC]__ M=0J`UNAC?$ESK;DN-=?/^D%-IP#LS.&AHQ![EM%L'GYWMGJ;LX<&UNP;`_U5 MI8+`6CVCK<\(K""PY8_BT8@_T$9CGE:OC!_.GG`+0*<`'&Q,/FD*P*"E@W0J M#+"I?>@8++UZ>'DY`/K4Z7WKOM4U>OW#ISAI MZ[8_[Q,`UGM>E0:XK0^.KS3`UN']3PWO_E(`FH;9+P/"6\;!;DX!N.U;$H64 M`=!=S@!H/B8!8(=`_D(:P&JZP&HZ03%]8-7AOH5:^G#[]'A5ZUNE]DP^E^91M-L(?). M$,41D]RS8^ZR.""M"#SADI+@$_&$LPL;8\@#M>A#W0&%">C.%?=]'D6P1Q\;F`84A,XQ")UDL+X6O0'T1"$'!;SAWEQKX*X: MN&Y)_FP:^&?]LL[.A3WV0<.$$Y$6?$@D*)'M+]U(U1.ULZ.TL]_K+.N``0^1 M0MU2HSMR&8H:K0)DL6&8H:XY[5IXW`90HXD(21*2!W)L^^(?I?4T*!ZE=W=N MR]R7+K>KN*\*-IL->3SCW&>I00?F)8Q"QPD2'V4R"B2S8\8C)%=$$_B))@`G MF(:V/V>A%`[TA(_1[SZ>8D;B\^TQIRDB3&081#PR0(WC":B01QPO-6-/L3_` M*9UTJ)ME^[).QN%Z^2U<#[/_.-_CYT82U<:V';Z]5/+YQL-`HEJR;C_FYQ:_H[/A MUG2+8D)3](V/?CGYXL2UIEE#O?X.ZEYK-?':.ODU=>C.OYQ=_>?K!S:)IQ[[ M^N?[3Q_/V$FMT?BK==9HG%^=LW__<77QB9GU)B,U$2AZVVLT/GP^82>3.`[? M-AJSV:P^:]5A'#2NOC5^8%LFOIQ>UN+"FW4W=D_NSI^Z+8$.J[$'<+^:=?7B M3#>^.,2+3ITT=YB/CL,8\YP>O$CP8H$B4S`2072+W4_R8RUH]^D-Z#L6)5-H MWUWLU9$+S0R#7 M3%D"['1$;(]`IX-9]'8GZV@]X9AL^67Q9=08>?"]I.1[<3I]P[N3'P@ M?"QP6]0))&>A#-S$B=7F,ZZ=F2=\'MT6;24"Y0Z?9V1TK]J)89DZL:C""/<,2WLE5088 MA["E%Q851KAK=([@A*!'NB6WXPW3:,)[\7NV2K&W_:#TJQW%WJ__9+B;SOJ@X3K-L0)UB`83R6?&S'?"GEF/$?(88`4;&&>,(COB9=>69'[%6G MG1;7Z`PZV=-I?9;[ZVE8Q#F^C@E6J[4YTHHRW68_N^P-NGD?6Y;LL.YHOLY0 M"#P".5$)B4?(`>]QVYED56U&(G)`LG-NRPA%$23C2?8C$-);EY$M^=3&KZ<2 M&UD\:S'%4-\RS5,4]L`HW&TMW[4,L[=TO[U\'^37;A7O=U;OMP>=XOWNZGVS MTR)Q%IE9>F1@FAMJ;RPJ9&Q1K.&1%3+>J;(D&$'_-?"$,W_+;L1-0!4NFMU6 M\[L/C5C?[?RQ[R$]]IV&I;E:6^,;O^%^PK]Q)QC[5*Y"M5K!RAJ/E%RA),>] M0CN"@APK.U_%R2:=:];7O,@?W,D`YV\/E^>$839D\@N!%ZD@64&2-`Y3J"*\ MP<4-B:\X'JE-D0]#:G3-\+QG+GM,\8Q35@P6:;]^W+Q%_6?"`"LZYCZ7MN?- MP7Z29/[!,D3P8EJ<:3;A?I8M@\]C8:80C3W(+A8Q2&L"@0M8C0KU0+JJ)!3>#+D4`6`[4=C,V9!37?%K6,+[=7:9P+2= M-S#C$LN%&?V>B5AN\"=>M6&N[>)#&Q+&'U"%ZJ'#Z#0U<<5''C>TBOJ."*Y1 M]6A1\6\(NNF!E#/-EBMOWS9APO.2J5AGD/)'<#3O0+^Y;%&C),S==?#H5$?9 MCT4\"M9Q&GC<23P;ACIH-HOF$6!:7R!Z179AF>5<%K8/UZ#=""QC(B^8_CAC,J?C!!W0]B6E/R\CKG,'P"H23UE=#G7Y^X>XJ M5Y(F,@M6YH83]<1_45[KA+0JH(+)+QCZW)!EKRC;56?KY:E*4F9"7)"P,!QI MNT)5ZLM,.!BUE'9:#3BJX%P.HBXO*'Z?5-[SLB&TD0+:RI@#JTH8.?"BUX0DESRYZ&1Z5)&:W;' M2'4!QQ'^#B,+56&IE5D@KPULPL8^AVF1680&)#&ILWLTH[@L<[D'*S^)O@P. M*FAQ#'_#OU+B?$+=3>P;I`1G*Z`K5E&G/+0E3NE.%I&*_+3^ZN?&"`",C5YYE1.QHP0L. MMP4CV.P0#!AWJ5LU$.ZADY`J;DY#C^?^,MJ:$%:>H./#.2E%AJEB.5?V M.Q2VV-5:WY,Z316-*KYEL\5]O7\$W<$QY=A1-C"RFPI\R?].T,R1)S/#51)F M@@?DY0@)NC&QO1$8.4_XY%.-,9\+!$N9XPYZ-]F;BB2>NI=WL+R(L::-DBBE M#"0OX)K\Z@5];D#V%@8/7R4`R01O-:OB*Y0]2%^8V3X-%6CS6K$,Q-A9)>F\ MX"^N8[&2IL(H0I=-B2F'(QT=!2!H>*!:U4#RM0G.!*EJ?PY4$\LWBQH%9A[& MO_+G[_`!@8ZG<;E>*<-/FY;KI8VVIOJ>=/BA[,"L%JY8U>8 MX[-4SQ4A!D/HXC:;BU=I&5?XX[WMT6BYG'#<9[/CA2^4.4<>3ABT3HFH1.W] MRQ\RL4$RC$>)EU.L=@-MW(RC'JF9U8>`AQ`M-5ZBDYLM@M)Q/D1>E1K#@A"\ M$2^(LB1*45AV+:]PZ'9A+323(N:U8#0B9T/2A+P===A05IYXRD$"N)PB5;=Q M/3?/;;;9.\T/,Y.1HG0C^`P;P(U5W"7-MQBH("\LE6-:L`X5-*EO M-&A2!]A$BGW:C("V80F9D)U4[@18>B<60ZKI#6NY;$Y-D56S@S,!W41I@1CL ML8W>EE*:7`1D@<"8#<'6@A%@@A;B&0KY>F_1[`R&.QD=G$5M`9/-NQ`>_T$( M`G'_S]ZU/C>*)/GO%W'_`^?;B?!$H#8O(>2=F0B_>M=[W7:O[;ZY_>3`4++8 M0:#E8;?WK[_*`B0D81DA(:"4$S%MO:C*RE]55F965N:?^J(J2?,DG3/(Y[/X M76E`>P:>@#[$AG\=F:Y#S8*Q'TZ="&SLF:A\I9_17\:,YT+L1EG_H%&%B4H% M=&=-/`-_/9BYGX3+>0+T$262PO&OV`RB99^QG+IH`\JTPA\H(G!N/KWH:J)[ M%FSL?I*'?;9&GZ&_E"49106L^23\/G;2N9],./:@.9U2K29-EAV9`/F_23Z- M>TAE@I=Z8\9.8&?DAD7TPM[@@+"GK='9Z4397C`C"#S([R1V7W%`?^B:7.-^ MWI%KN1;WJY*U#L^<7E`1&Q"Z5$*JD%RSBFI?J%!"UW4Q[X2>L`';T'E=SGF] MP$WA.JWK!PS]F6MG]6TX5I M9AF,9B/.U00!A2`;-YA8(;.CF:>E1S4HNI%9S"$L!,PAS?04IC-D3":P5X6P MU]('9YMTGI6I+X^9J6;.X*?(^![H:JRBR?LPSOP0R9C20^-W2%^BES;Z8E(. M@-MAOC4FXZ,;*R@]H3\W;=Z9$TF)AG3[YY?;\=)>G#*1-YC9YWO9XL,MGWH>TLDVV"Y,PY]\&VX[8 MX#"<[>HB._B*6&8?,`T%E MX)3:;P&0B MO;*#)3;Z*=C&S,+/_2+G?@GGC&RMCO;[S)_'AA9[F1[!\/`3^1RF.HU)0?;( MR(DR185I(Q/?)FY:R2G1N5[]'H5I"JZ!P#>M\:EP[.3JVIOTD8#T7.'*N1ZG#"D8'0\X:8@W#AS,'5D8"\U\]TB0"CE>VCN=J)`MZR"ITL9%#KC="=URF$>;JG,5>SJ^> MXTJ8:,ML^29'?=-)P"<8Y(I'"O- MI">_B:Z5GD'!#Y_IBJ,;S%G2%5/9$HKL610+;1L.DZE4CDAVM#WS-Y20MB67 M5&W"5ZM5^/97A*\9CL\\&_Y<4:Y16&"70M%;S+V\Z"W#.!2\)9WHE(M,16,O M5\!8"D>$F'1S9QH$U-D/"?RK^QI.3J:(F2:6( MP*QS70)VYK93\ES8C!^(>)<0EV5Q8&@(+'?`=G\I5[*\FZX/!,JZ[PEC.!M8 M/GYNKR*RMWQ\U1["4>.H.SWJ=:)LY\:66I=PNR-PA1E2C;1#FC=#O MHIZCA*8USP#CVCY8Z+NRMFNTO&I33KY[`:HG^YK'&E:5YAMAW*0.%GI9%@T- M:[-RC'#W%_=:?TK7BP[Q6=T1^8A\1#[RQ\>]NK9K.[=[\"/3Y=1L;/HD6AF( M0[06.02V*^XLQ'7#!:N*NH)%9?D#MBL+EFOSCM>JD\A)Y"1RDE=.+HODV?L- M:\KF,K:4R<116[Z6?JWY6O2%A.=WQ'+-,'1&CI7D#\,\+<5-[:TSLV"6WHW>R M8K,6.12DY=B5RVNU(:<*)2@'B8$&TI:)@=3VY()!X M?!K.)7.XV>::9WQS:>4.G/$XXP]NQI<\03B$K%4W.:_?*KLPZ&P'H0Z&V!]B M6AO^<-5%0\70)/YP531Q,,0@40Z!E419D3L`;"73MV%%XO/:4LRL_""<8G*J M8VRIE>]NCA_+8M]H_LKDS_Q)K]9`K*K]QO%%>.MO_(_+S=5G"KF4*_]*X77_DMSB]>K_[J^Y=5_K3VW MO9%<)'<[9V#'+TJM7+?=[T6IE0NYPN'>66L8BGLRC+3G*MLAK,B& MKRZRPLJFQTI[/07""7R6TVX.(0\0V7 MLBP.#(Q#X`_8[B_E2I9WTX%QH*S[GC"F"GL^`7?+%9&]G?Y5>PA'C:/N]*C7 MB;*=&UMJ7<)M?NS8FRZG9V/1)M#(0AV@M<@AL5]Q9B.O&*2QT!5-8\`=L5Q8LU^8= MKW?0DKYQ<%LFS]SO(8%$ZG<&V62R4K;)8J$NI,%8'B)%G-P'$KJBHQ/A:DKUK-HFWP5`[V]^2H&V^:K*/O\GG_4`7+7Z9*ML"'X MNQU96.(\N[IZN,D5&D:E.+G"$C3MR;/PCH)Q")=:[\Q786+2&>*8+EYAK<<5 M,A!EK?E**ZV46!W'51ET(7BEDEK2L%SZW0_^H`WVIH%OD9!7R=2:,!U=U/4N M3&4$N'H*>+D+QRQ\'/%_=CPG'!-;>/9].Q1Z@N.Z\<1Y)AY4L`BC(.8Y94AK M)KU"I1H&`W`,L";*@V$'`.ZB!K8BP_YPHA"2@PG^+",5RJ[ZSL^I2J9UH00$ M(ES]9I.B=$'IYCI$@L](6>0C1AQCQ/$^I+BJBK+2A4`W!'9#8*GU:'3=N.C\ M]LQKC!-RL@O18NLCB"J'B"U'=U4*?=(^#!&[)\_@9KPC4S^('._YVAOYP<2$ M&*SSM_3+@XL8T]9%C&W$L6T"R&1):F\$F:YL&4&FMBPE'CJ''4G1MU)=.S82%_0^@SIDM_T$.9 MC3,:1XVC/JA1KST'[DSAEX>Q$]B]J1E$;RV7XE5'V'1@@Z*+BHIE^/@#MB\: M0[QGRA^NLB1*,H:8\0=L,O0N)T='Q#>\L*2(LB9W`-@:'0"UJ8[7X.+OA4F8 M#J?*XY8G(SO4(D5-1R628X#[""Z_X,HJ7BWD&-YC1=2EYJ\6_HP0H^U02<7L M3FC![90$)L2*"XYG^1,B'"L_H^Y9[]P?BAI6C>,:X"&F;>$87D6490288X#[ MZ!G@&%V96A=R%_;?+D8Q_<7W[5?'=85C"$P5LGA4U"GKGM2B:G3!,8\`'ZS! MC-!7U3=E:C!V(94'(HR+&Z'?<'$KHJ%V(3J&$W\G)/\4'"\RO6<'[H:984BB M4*2_CU!GW?L9O(+G>!P#C-O:P4)OB$HG?"P(,*YMA'[C@&Y=[4)\51<=J"SI M0JJ5HD*ZYTU+%HE$Y1EC6Q6$GK&U$N&KLQ4"4^X@PQP@?JQ3B0?,W!3$\ MM$8YW3=$0^Y"&`8?;E%X$FIGR4S3*VM?MPJK11S.;3P(1PUCKK3H^ZB:P$S M3.&,QE'CJ`]UU'M5U3'#5.41-IWE0E%%0\%X._Z`U3L2^(^X;GJA4L=C&PYQ MQ1B#0T-V3!:H(I%>-8:[]\H0Y1/>$8X.$`\P]Q#.\`ZR#P#.^Q MUORM5U0]:[T?):M=L!^[&,0T3S!U3Z81F3R1(+L@):-B6??,QBQ3?`/U81>L2#X-75,-U5Y MA$WGO#`D41IB5"U_P,J&J"HZ`LL=L*HL:IVXX('`8J0!(KY61BM#T="Z<)NV M1A<`9IQJ;$WN,II`U)0N3&0$N.I1,X+++[B#3IP^(KQ5@P@,46E!X3F,(4#C M@??8@M6,4U@YM>ZY3ZTHM04E^5"ZU8>PJ`[1NN`8X+[81V##ASORY;[$O=[2$_#5XGBF"R0"*:?R M],>?4UV3*J.GLC)_GPSQ5)K^**)V42MDG0D6<=UP:EI4H_SU2#IB[Z>F;6?O M7QT[&M.)*$D_'0E/?F"3@'V>4I5\TJ/*LVM.0W*:O4@U7\;Y4P%4XMEDL`CX M38]6>'-.Z`A2[OR5F/8R=PHT2N25% M7]'B7A8`1>*Q2V8Z//@$+TI>`<"*TQALAZ/&41_JJ&L\_\E1[_5`#:\`5!YATU&(`T64I.:]L_PY9YL&5C;$(9ZJ<`BL,A`UK!'((;#= MC^)!Q#>4T7!/:]#%@[,=N@#P"D!C:W*G5P"&*@;I<`RPC+HDQ^AJ?;SBP3&\ MQX:HR#N\.`%:=KGON*[HX,)J_XH32K3[MDP*,/B^N`=:P<#S7 M`"O-ZY\(;WU7`"11-KJ`<,DXV/57`%9U2T8ANP&@+]X`D+:Y`%`AD#]W#6#Y MNL#R=8+\]8%EA7L%M?3'VD]'"YIV-H58Y]O9J$557PJF3[[#%:6_VZ8__I.JZ8-+5_R=9E&05D+?\,`J%@+AF1&PA\MFL\%W' M9I,$?A&-B?#5A!AR/S'Z8.[0">.S;QZ(YY$P)$08421<)WH3[#@`PQ"^C<8! M_09Z]*"!B<^"T`D$H3,>%.>B%RD]X930"?A"W#><@55G8)%)OK<9^/W3_2?A MTC&?/3K#'"MDL^`J#N@D,KV%+]+I";.SG\Q.8]!?G`,B_1&;4"O3Z)V[#/D9 MG03(0L-TA_J#,*^%2TP*:CAVIHP3`? ]-S_IW,>K8HMIIW__D?OYS$8>_9 M-*>G]]:8V+%+;D?WB8"](U,_`#*NO9$?3%B?YV_IEP]T`IZ[OO7';]#L+]E^ MS3ZBN_;S,QW4C1^19`<_%5Z<%[\'JT;25>G1H]]HCXP,N=>;-Y%<;-F@D?Y2 M(ZN#^>QX3D2^4'SLZUDAWC-6[.S\[:OY3S^X<,TPG(T')`NLKCLR^O7HUHIZ MD@Q=RH\4P9XJL>Z/?DMUE,O;BX=_?+L2QM'$%;Y]/_]R?2$<]4Y.?EGIR\OKZ^NE5_42A/7FX M._D!;_&1']M'[5X(J<$[H"=LS;?G^T287)H=*B^]+2EO>E^RW MY\X9DHOD;A="LD_3>V?-4GD.4HA^H"\+BB51DUJ$\O2'P%1+X;\E]E]5!4.> M/?@$+S8O:-02+PA_4,QJG*YJ9(WA<8@K4FEV&OPE\,.0O0N$$_C@P@R"-ZJ> MY#_[7].-R6&NTH;A.;.L>!(S^R@/R-D$K)+$!$)<<-FTI-G6P-/F95/2WW\( M>2^^FEX\,JTH]4(2:^Q1PI\=$HIT*@5$F`:^'5M1XA("VUEP'8^$JZSE(GRE M^>A_45?ZI8C`0]$N`3L491FO5/*'*UNP&`;/'["&V->Z((@K&>P-*QT/@6D3 M.%ZB2H;K4/4T3(^E8O6!.9HHJ$I'9C;"'#ER$E=1VV#8X!5L8]7 M*WD&6!95M0LK>)WZT1TOR$4<4EZ1@&HC8>KJ"./IU'T3S.>`D`DJ)?L(!A<5 M&E!Z M:L<*2!0?V:V[.M*>;I&/R,C8AG@UG;)]=\[G>1Z8;D MEY.5I^>-7L1!`!\ZH66Z_R!F0`F]-"EII=KO]:0A?9?T\%Y3\\XN?2N>S'[R MC02.;W^FGX7E>ON[FG3T;C/O]03$;-`/_%O4TZR9U7X2(C;B'?S;D_09^PJ; M6NWIX6U:L@-9ZOU]L6EX=M[BE1]J>H%(1F,JT_T);7M,O)"J@\GR^>*'X0V) M;D=T'6V]+K05P;%)]W717@J2GM9_=P96(-ZVTWPZWTR'"JH+<^I$IIO;VK?E MM4R)A?_S%'_8Z0Z)+">Y)68A;$?D/^,P8F%Z#_X[#S,UZ)2"LP'V]-@&8=Z26Z005!"/:F@S@JH MS^?!X[SG1^CZ\=I[3#M__,HR8;2;B:[KO\+L_NP'E]30CT:QF^E@]$GBO.Q0 M\527U^TFG==#=ZG5K"WO65O0G=O+;D?+?HE24^XC^3@8+JE$:[NL3%Y%D2$9 MU8FC]I+MN#%D!+PG5APP_>[J!TL>:'\._`FLACA*&[LR`X]:CB%=!FR]T*[B MI;E0AL6K!FS"Y<'B.'9!6]W#?8!DG!7'JTO=&^_'4[1XL*HT[-Y@WP6WQ'AE MM?;QK@J0*KI?OZ\-EV@M$A0E.WL\CT-(_!`^LAIZ:?;CQWR.Y%)[.)U8BJSM MCJPL2>IC+DEJ.65BJ`ZEW=$!.80?TQS"I?H?*IH^V%W_W\&!;S_>TXE&PHV9 M,5"-_@Z844[?[QO&+F9`IE3N;&(.5C:J;L'1D_V?QXX+IQWAF6=?3Z:!_Y+N;:[W5!6 MBDV*KJI:52'-0;#%4(^[':WE)8R9Y5^7U>;IK3D^EH^KFF.TD?FN:7: MPPM)?4GEMFEI25PV-BL^DAB#8<%":H;2UO$Z\?M=>U9`S)!;BY23&KIZ9T45=)4>1%PZ+XY-/'MFT5,^N/2/764.7?U_>U?6W#ANA/^* M7_+H#<&;J=16^9C9FLJ3BR-!$K,TZ9"4/=Y?'X"D+`HD1;#1T#&3 MIV36-OOK1C?0:/0Q>6AE?QB_.%YC)20H*V*5BGSU@B7!7L%*Z?=QBU4*+)I8 M_T@G85;MUFKV5^+LMPL(G7YY]-.IHG07JV*99M%?@LR'V.A)N/+:YTT_00QD M,L%'=&0W>;["D9?-CCJ/'1D[4%7$5!%)RXDA<@/#->&(,$QDE]YBF$;7]\7T M@W7JP4TY-XJ=B!/^B)0F%T611=]693;N8\HOV8QVEL9Q.6FIH$Q"X]]_NKQ/ M(S`L46,Q0>Y/`K('8RNX:@CQI).5`,B;-"U?>&4]6?[[,QNVJ#Y59*6N-C^0 M=&0]G)9]..Y>)9#D;+\!RY!?L=G*BAY?N>P$@O+0Q0:]LW2<<6]<(N(/`+H;DQLSR`X$&"7:\\S353TDB9T'J%X">?$%80R0!2.$+1HY\0.B#H^]FOUHP8M MD%ZK3-_I%EP'+0Q0^4BS!GK0]9)$`V>Y.M.H(1NDQ2. MXKL[IBBL#0%)TC"7T152J'807D=`&G>KUO,3T&^UR?9QWD<+@*C?D[RG!9\? M/7M:IPI)NI$PL&(^TF681U.$T"6OI?O%;@2M.@F-Q0(,399@B(<,!A)Z+)&X MQK[$(@'&)$I@KGGJ&TJP>U!C:E+C\>C2&C`@+9J#+QY%[>D&-)_3*7,U/WV? M+L-D0>_#@MXEW>]+*!<.9_L$&T,?"3G,X71='POX\TN`SZ>7A:]TU_^IWW37]B MFOCT4/9-?[KXZ)LNY;ZXCN,=/[M;P_*>'AO#\IZNTHP^3>I9>:4@KF@<,[DD M5#+1T;&=XY?`9G(/8ZT:W%,R.ZD&]\@E_ M9%K-,R#D!"2`8I[N'M>Z\4=U_$Q+6=\X"&CPH2%J)Y`_"C3"QZE:/#;9#W7) M&'$,*\#'R5+WJJ1]*;0=#SSJ^/".&&*:P@O`WGG1>7Z05G^:O;.'<3A88D[^ MWKB0"Y_[[J$,`MWG8@9!I*^`>GC1;1#2.ZT>]C`,PA:+849RL6+"I1T'R3T# MQB><9;PWX[I'G_KI[`C-=\;1E\1>MA-D`E"'*];^#9(<@S!=(0B4$*$CT"#- M$1#O$@09FL237/.:Y`B`I9.%($1;='@'B8X!^98B0/3L$>O,2&X#_(T9$V\$ M=9=<1_E+FD=5-P"\3B;GVW>VG?2@T&"!;%-(_QP#C28T"V/>UFSVS/95WOJ1 M]UG`O"H&!MGV:`:(PA%";X.NXP3[00BSC,`4$LSV+\'!SIFNJ8`P36=O41RK MUSP2+`)V13^52SIGU[]&9]W;*$FSJ'A?9USS3@1;7^&/ MT\7[+2V6O&#TH_@70X\LPQ7T:(\,'(?DP*G0!A'R-'\ZT8'LV/(K`">@F9MFB5`\$7=%)=@W[L'Q(-M-V M+?%H.@S.\:K"W>/C@*ZF*J9MJJO\*SNPTNR=/R?D2SHK2[,DE/PFCE?/T8+M M5$\W99F?_(.3+0:*NT$@`?U75+\;51V!I$S0%I^(M2!<*X&"*$TQ>UOVK,X`E.J*4;F, MC7O)N@H+)6+6UML!JFHPP>&U]F)JQ0E[%FWK_F&$.?@VJH;S]S`9U^.GI^7G M%@K^T5%D)#L5"#MC!YE-I0;CN*QI7*;QC&9Y=>57YK3=-'V()!I`:/-L,$"D M\A_BF&XOHLYZ&OP*'^(Y0HG/$`9>@![F2[:?ZQ^\C=H M[-ETIE`JVDE$#8=<%K60-BZ+HZ.A]>+/!_&6./:OC))0IU[*8+1@=U6=Q_H8!%$ MHV-A]RBYP\J MXD6!VY452)?@+GR]-%4@PFKG+&&&B2K$"8^R9<7[)`X3GDG*\P9?GL5X"31K MV16F>\F31X$-4]/`'Q"Q+.BLGN"B?_BJ.JG^MO\[2>D8P=J:<[J;)!*\M@#V M!:\>?:J@%6ND$DLUEEB_6'82TS)"58E$S^G>)O$21K/Z_$;*DG;%.MA.*FI` MY!K<&D)>BA20=$KIK*RM?PAC>C>O6S\R%QOK5+-;%C5$LX5Q'A5865$EZ((S*WW!+Q])%W;!1M"G:OI.L(DEUW44'#)/64JX+JG4QJ]\I&[ MF(,L;5_(&NHDHX9$3C3LI';'(\EIF$WY-*9K^DKCM!0=8C3)LTQ?`+6#(A0< MO.93*)O3@@YTN'FV30XHN+&C+L>A*[)H6M!9]QPPQ+&IXGU'GK0^R'5XOM'@ M22[W^:AXD>SJWUR'*OE7GJ!)3I\1\G_'FI8+,,4]^%3$P4\ ME?G$&0?4IHGN^JFQK%B?X'LGH>SZ:W)\TQ)=Q1.3Q(]M]8CE0UXK?'!B'"N> M]78KN'.4_.NO+CHW7<,\<5&`K?XD]GW,4BABG839:ZNO,FU7C'GC"8"_FN;U M!\47`VAN%/$M;QNQ0`4!@L(5V0^$*E0-Z,;7^[4BT!I0*9X_;,OU<"!"7Q"8 M5CFF;@APU7+%2ET=Z,9W5W<)DF;IN\Y8OAG@8`1.&@A\V]=K?@I'/MM0=6]9 M@'/9(K:E>T^'N'R&(F0 M:8WQPVS/ZDC19>*#Z79XA:UDL/A`MZ8CN!T.4>&1=P4*M8_K`O M:0WE7?I"`J@T+IYK>QGF=,9SZ=C/R]LTBF8%0BIH-ZG1<&`+YPK]S:7!K/.9 MAQ,&JL*2IS)UN+T1M'.]RTV>F);7!E83!<%IY$9"X+B!+)Q6+^B;I!X[,N%S MB]/DHBBRZ-NJX*E-CRE_:6>@L[14S'5K<>7<$GJ_`E*MB_9?-"1,?@E,4!2S)NIYRL'T@PJCL#_\J/(P[@SM!*]-(FA,J7N%YE_$ME8XW*Q[A*DU=&BWWX M;LXO6"-J0$;[.1WK+0UK!$N;Y,/RUR[>PFS&[G=W\\]I-J=1L<)@U8(MY*9WLAX#) MP8[^)6J;+3*77VFT6#*=O6`6&B[H'RN.X#J*5UR/R\6^6Q5Y$29\U]KT]1E] MN^U6.M?;UCH@&GR6I$(N/3P)746.AJ=AH^IFR!&2?(Z&(:E(3P]/P;X4C[?- MZ/X,D@W9Q'(DF.G'@<>$@M4P+H0BRH-Q`;43F[C";>GX%D**"U__0K3^ZC+, MHRF611BN+[%E]:'`8D#%&@S/DCA%=',`MP3#D[*$`RV`%`?"XR6`@]?H-?W' MQ72:<=\LRJNK7II-V"V!;LX0Y;IOFWC5O5.2'A8XN?(GWR-0S]E,'I%;=:``&8NADXVL6%?0Z?4OX MMS[^[G,XY7,0WU%Y,$DG$R,0-#E8+#*Z8+][R\,B6[_%O[.6Q$/$029)NF+_ MRQ?S;M[/$ZP-AN$UV<*!U63TF8=E_BK_,SO@ZD8VF^'B_+,HW4O\IDW($%4" M"9*UXWMPC%?+,%DP$V'VSL1>Y)/PG8>X:O-?C\^Z2&95R/4Q_$[7OX,AWG/3 M=AH25D"C@2?@H$^[3NO4R-&FB\+'4&WVB>WV0SC3/XFQ=6:!@*`R`@LX^9@\ M;';DK>WI;EYN;W5:,?O)3?*8/M*$I_)3NMZZ$9[WC;IP%P&-'K80T^>.GUEP MZU/7/57&`%F06ICM.=[PFG58Z_:Y-HF:8SAGC*>&`WW+LY7-/D2%XQL01]H4<04$&R>K#+:1,^D:OSB?"#'0-3@\#:<+IE$ ML_>/KEGL-/Z\RI+R84[9HIG4_8W8=Q/#0"5GS(Y?E^6/1=5SGXI7,Z[H_%^\ MJBG&<*(<(VA"E*8\`J^&&<7$<8D\[)[!P>7?K@-)M^%_TJP1&+E:Y05SW3,4 M%VC]L5:?7+/F8`@%/N`1">"8Z*L1!&&^_!RG;V45W\?B],RN!V[$CMWP3:2H M*J$$^OR&IP#RE;*]8[%DGW]99=-EF-.+!7/NRCC>17$59MD[^]NJ!;!JCBKQ M_(;/-(8T/F*YY#G+;KHJ0,23,"^N5[2F7[D3G]/LGKY&].UNOG9Z;I(9[\V_ M"N/X_39*HN?5LZ0?$QC7-4(XJ2;>QF%=;M/,U5Y&V6P29DA]B#K=!F*OF=A% M'QGGB!ULMZ^##QI<00%7%:WM[UXFA8[@3IZE/#5!.WV[A!OM7"9!T M"3D$4&7Q^F-1\Y[`+0\4Q45H1LIZR(P$@A+;DH!2-ZCGL^D^[HVE7[/.A>.] M&1HIO\A6VS&4^%Y_,;T[Q\0\YO:9BS+4LZX//K;QEES&5GQ3),SASC M;V?Q1VCG+)V??>.!G#/V.W$Y^V7UDB9GJSJ2`L``00E#@``!#D!``#E75EOXS@2 M?E]@_X/6\[`S#X[M]('M1F<'.1L!DG;@I'?F;(R2B'O(9Q2<]RGJ__OOO?_ORCW[_][/)C>,Q-UA@*AV78R2QYSP1.7?. MV!/%S@.:S3!WPG*7%#WZ\.;Q)?[RGDWE$^(X>;XS&AZIO]'QL-^/GW"&!$B$ M[T(1QT>CZ!N?T!^/\)4#\*DXZ#)Z>GHZ>'[E_Q/AL<#PW+MSO$!]0I7"[KJ6$J.K-_KTZ=,@_!:*"O)9A/5O MF(MDV*"EN!QC"?6NGQ3KJX_ZH^/^N]'1L_!ZT`:.\X4S'T_PU`D!?)8O2V!' MD,725\##S^8<3T]Z*[)B(`':]>.[H:K_TT7,V2GU+JDD\N6:3AE?A*A[CI+[ M?7*=PE]@3CR"Z"-A8`Y@'_C(98N!*C8HEC1X+=!["2:EY(OQ=+S$/)0KZD$T MR=@IN',DYE<^>WH%M@T1KX9VAGQEP/=SC&5-2%M5=POE#OH[E7,LB8O\5^#: MDO-JD-=T!?(8)[AF:V4J[LZBP!KFB,ZPN*;W<]!USGP/1LG+_P;0Q1J:6(G, MUX,G,TJF0`B,!J[+`A@.Z.R.^000B>1_3>S51.X7^H.:MW8)/!&X7]@76"+B M[Q)W*G&7W:U)ZVJJ[Q)2HY;3U3\(P:/=,SPZ$/0'_"R#NO-`+<&O5N,6_2`D`TP"O)Q[/%.#Z062J(GI5I&W5]!Q"QWO#O9:XB&`-[*9.G)WX/`(`N[< M'<<"'M'`I]8*V,$`!VN:&0$3.Q6BME>8K[US0,UF`KV,G8-K."<8A.P+7J/. M429K;[VZ\:*SDL#]SF`[G+-2J+"4<0,_A'\#P#*0@0Q,/>PEH)78'2S0XT<0 MJ:0-AT[?2H/1W$$YZ?XXS_N.)L2><-$JIJ/'K$?/C/SY:`% M<-<4Z,`/Z/GR>:G:]`Q3#(`T2(TE4]@;1G+*LQH@[B8BX67&0O)QL;C$0`2+ MR`S[P-TBJ3_E;)%ON_AAK`0KX[`>/NF]'_:<0``&ME3RU1#XA,EL+D]Z_5&; M1"AEKD!!,&P8/P(80M9V?(:A7^)4-2QN"87%B.KN$H,CH?I_5DJT[K_%1G(/]'1K#>9`^L=&>&PVPI9L\!NC+%*8SB)=XOZCL9B"LJWQVT(? M2@RHH#G*QYR6Z![+.>9U."^KT!KQI4HD-)5I8"U7:].+$&_8ZP59$?"'/.VP M7J&6_:Q54L/:476<> M^R!S!LAO$?^!-Y34L%14V&Z"BI#'W'RTCIL)%AA:8:ZF6;S"/ENJ`=M,3TEY MNQDJ`6^M8_B5P_`=+6QUX]KFM[9..#F@UL[VYTS(\?0K8YZX9[[.X\Z5:*W1 M-8:1-'8.I+UAL7OD8S&!#DD#_`WK3#Q7PL86SX&TUL1_"Q^/O=,5]-D9_A8L M'C$?3R^('\"G85:1&`%'JTAI+8$:]0T03SU_@RBU4I5=:M(:LU.&U*< MV')CA2O-H:TO'@RMD]-,;>&[UM= M0GBDFONV%^G%1>WU6XMQM]3D-QBIG-,Y64XPJ(PH^5]QPY=4L+SY2]`G)'RH M2<*7P=:6^X'VX3VX8\;;<,K>4XHL.UM>(4$%G?JGXI$KL`C`XQWT"XJ M'*E.M@A\@:/_.L>^5O4V)J[+Z12[X-=?/KMA$O@$>!A3/6Z-@O6JMS9M-:$Q MF;/JJ6AMS`P6$`HLK#34WH=W]O(=.N$UO2(445?Y7*XD*R))+A@=;KK4J-Q) MDNLH:&WHS:!$M&W2D&)MY;=$L59!:P-W!B52CZ,)Q=K*;XEBK8)[B*68EA.< MN1A[*A_U`3W'6671YN8SYBX!!Q&60)*Y/\;+3#)C9J%17TA[6_2UIYKUNJ2^ MFMT($-RAE]A93I(/Q#E;+!@-E='E>)94Z!B[550J[Y)M!903Y`_LU(5!2:4P M;!][,!)84,/CFJ8/,//VCTMVA8!/^OE,S=L9&&,%5RU*5P*CN*V%>H#0L MB)55J&0;>U5B*A74VG?XVK!:RPZZ:S]'2![>[6!,O*E8T3:VJJS&*JH6,_:I M+F.'S,[9NJPQEIEDY;RKF)432W%B,2V,)C<$/1(_I$M=YZ+V";:N)\R-)>55 M6G''$'7GC?"P][AY2\[$MQ: MAZU*<>KD[TAA:]W*4]<-%HH![$617EC+<#R'_@G3QOHP#`QTXRDL276+A+H2 M6B-_M]TB75'4U=_B!:+GD0C*'2(P%YVC)9'(+]X[KE+IK5%>065K<_,FZF8U MBKU+Q"GH*#;L%[P0XFKC;54JO3&2JZAL[;"^88K_07Z@31?.%7EC!.85M#BJ M$/O_A8QI2[TQTK0Z6GL4,5FVP;R^X5DJ30/.]9D=Y54ZXQR7JV)MA]O`>VZD M2E>H,^3HP%O;C^)L@TJL%)2U@9PMX!NK!!-J:YV(R\729R\83W#H]51BIT(= MBUFJ@-[:(6TK@:>P`VD+6LR+";*]`YIQ2W5[@^'@H`J]DWR1UJPBVX2I)>0` M6CM\AM&@"FUN*-=RP^Y?_&Y:7S_%215TQ\T1\7\-+M6K6 MTE0-OK5AJ@)B.M#XN0:V;W@RIMSK+S$J+F[9+%$,UF87;AUB7*?#P&L?ARU* MO.*W2"V3(EK%T2J&0' MR54^#J/7RN)F'`MAXJJPM'U$9=18!^`+=-B#XV'(/KI%[IQ0S%]2M(#\*N"4 MR(!K#P&5U>A`^U?2HY)OTGJ2WUE`?"_<@:/>]6+)V2JZO,?4=4K*=X"\"EI8 MZ\/<(.T]_]'''6G["*RU,TGD\Q8$^++?6^:;;Z&SMI4W=K?2!;2YS0M+M\R` M(:A:"-G>:$[V@**9$4,Y.[DP@+4V.I.>&-4'"[)?V]GD68S6AFG6IW2+!R!# M.3O;W@#66J=&?T_4J3Q'G+^`DV;,L:I6STZ2*H*W=@*?8%A]$E=B3Z])X:9, MGW>ZC:A/ES(Q'`U$G\=$V#]#%^(^'[]2O M0Q/A^DP$',.;3.E]PDI;;3R-+E41US2\#D"?D9>T^/NZ]U.'UU-'#W`(=38? M\4\G>DCK=U;G3[LD)UUV=.9LYT]H+1?$<#)(?ZRJM$9[EZ;NA_),>DF1XM6N M_&O=53'I<<4XP*31K.Z^/'!$!7+C3[:(75R/<=`?S0`S)5/PTJB,\V=#_7T"!47R?]M)>3\<;;M5 M&W*8?QJS\Y@H3X/83!I6YL/P^/:VD22VM3E0IT\]'/*?&R@3"PJ M=@T/:7T;SKB)FR('_D`\;#S1V.K%,+,MW(4H?!L`K]1/_LZQ%_ZB8Q'4K8*M MS26ZILWM'&R![<:=22GZWQC_$:;EN%@[IYL*VLW)%MAT'[,;G$S0TRTL_CE! M?B$EV7)V,Y+%FA!B]<^-59B=1YKIN;[K%`MS1A;]X-CNM[4.K)(!L76_,V-H MZ,W]MZY,*F]_KZT1A0TVX/8V4YE^\V"%.57R)W@9<'>.!#Z=<1PE&Q8/!0WJ M=X>^!LJ]E:GM`:0'^1TCF.`:+T"=6.:>EW.WZ$_&SP,A&90*[TG`,\75!9+( MM`I]OZU3*,1)I3B(>DXL!Y9^4\8C0SO0"K5(I;AQC_-,-5++"4!6R,+E5!?)@^:8!L[(&UL550)``/KK"-0ZZPC4'5X"P`! M!"4.```$.0$``.U=W7/;N!%_[TS_!U;WT.1!EF4G:>.>>Z/(SM53.?;(NMZ] MW4`D).%"`2I`^J-_?1<0J4_PTY0`RIK,))$$+'\+["X6NPOPQY^>I[[SB+D@ MC%XVVB>G#0=3EWF$CB\;H6@BX1+2^.F??_[3CW]I-G_[TN\Y'G/#*::!XW*, M`NPYPQ>GWW>N&*78]_&+,T#C,>8Q5:=]>B+_M#]__H?39;,73L:3P'G7?;_6 MJ]F,GO$%":`)_=3#SD[:\U]\0K]?R+^&\+L#J*FX>!YRWPLN&Y,@F%VT6O+C M">/CUMGIZ3I_.X9;OUVVWOP9W@*6H2*@)$71SU6NNQ M2OV\%2.)ZMT^>A=>`(7:<^2!SYN,^'CD*Q47P,L.7#4&F,U^B5]]-.!Y=-A[) M(P,R[;/33^>GDL@/#P'(@Q2-NU%W@N@8BQOZ,$$<3YCO@31<_S/$(A7Y0&G#>(U<@TIW@ZQ+P@VO6NNT:*?+\8 M/M4A0@7ND?.O6(*=*SPBE$B_P'G7(Q0[-[!2"B=@RS;OE?,4\^,M.D#S[VL\ M@9'!U,->S)5\=*7K<_0P$DBZI^T/IT[36?2%_W<9/)Y*UP_^)V!Y])1ON6S" M1D[T`(=09_41?W7F#W'>_4)1Z!'H]W[NT,2,^\Q=X]:7_A3CVBE4$S%"8JAF M`US@,4(SF,MVNX7]0,3?2*O:;IZV(P?JA^CKWQ>`!VBX%!(?#;&O'&IMHY9Q MM/,1[++IC%'X*#K/1&2!U_=9YV4I;J^V.>%KW]'4,I=K>548T!JQ^3&18L8BA ML_HPE&31(D[.Z\-)`5,6,?>A/LQE,_,QI]^MWPQW?/^X\3UN?'.AE8$3%3?) M0KS2<)=ZIL(]J6OM%F+MMC8:X*4-GP>B+ER?@:Q=-@(>XN67C`:@"->^ZGK9 M$/,H=$XEO*%@H(A*G#DCQIUE+.K"<2)@%]OPCQI:7YG?*VKPL=9F#%8,/_14 M%HTKM0L"3H9A("5^P+XQ*L49)`"@C&]`L#D602*GU1`W-SI2V,2-$.%2039Y M7&MB#.D5>22@1IY8<9V[2$P24"')# M`QZ"JM'I8UA'!*ST#Y@_$A?/.>QCEXWG#H[2\\2XXJX?:U/@2TGW`#UWAB#Y MR$U:I'/U-,;7/6ST>HEPO2R[*3&YLM]DT4JV3#H M9\*:L&5^>=O:#&FFJ!)783_5B_4PA7:X!;E0;&T1DY'T#)42YD$MQ3QY\(R7 M$TIH%PDL')5FS^):#1H9&AD!YRRA#""[>76H[AXQI_)^FCZ>A=R=(($[8XZ5 M'(M.T$6$PL3@_(_%6'JG_D]O<1^1*I#$RI@%Y2TK8(`7/Y MZ^3J0L.5A/I!2Y>O@GT-^56%EIABVF(\6YR7MS)*8CR#7)2YM<2WN;1P&=@Y MM*?@,20C`?AZ."/'8,9>@AE&(NR[BP?4*\:NNS5M4^_.-]5NI=-"Q2KV]B/R MJ?OC]38FJVB]T`WN>%3"D*+B^J9VQ,UU([Y1TJ#!;GG8W*AX6RE>^T<^OQM0 M`1*I^=B4]A5NWGT_G)(Q!D>+@H\;)@>ULYM7A^K?1+&M@K/)8'2MS(?6TP14 M8T!TTVM-3#U39)-=" M^^L#9D][$L[+-QQDG.G3-S6/O(^>;F&'R@GRTT(,FK;F ML?_*^/<;"JL5+%"9X#<:FT?_%31;3+#W,V->)OJ-QN;1@QCGD'3S8=*TM2%# MP.V)OQ=B8D/0[0FT%^)B0^#MB;L7XD*I0`UBZ\>(QR%&/(S$R'>PL:]7<#S? M:SHVM>O#IG8I,LZ"CH.HYT240/-@/S%%3C0*/AQL,6FO-C; M\WW>Z@XF&>-6?$OO/F5T-7-Q>`&NUM:P,G-G/)$8H;_(P_711]3<8?(8U_)&J006M2V-X9:IJR>R7*4VP"Y_ M-IC-77^M,4C]]7-T@5,&^GQ=S5UGK4`E8(]_M&-G4=Q/V;13MNWR"G/T6M-D MVV:Q\`!H#9?QG/=KN5K:`7NN&BW)2CYS9\_]HB79C"WCYDVB%I8LO+VMQC%! M8[BTH>JH^,'5-0R`>(A\C=IM'<(MJG=.1/L8)#PXNW,L<["ZS.&PE?JXJ!YZ MU<,>:PSV6G=QK`LXU@64S*I;$RDJ7=&0]Z9XN[/HA[VTOE5_^9A4/R;5CX:D MM@KU&D^O"XM5'_ORC1[+MWL0^8JF6UCG%E(82S26NBQ34/"\">'>/>)ZZ!D=JD/V+92^@1P1$&T0]ODK9Y8Z MHP.7W:?"R@O)/.CM+>+?L13#'D;R?2X3,NMC4`E$H]O!Y&1KS[T7I6"'=Y=[ ML:A$TFWSRHMQGZ$LMCGNQ9C+5K;:9G!+J6?!4F!+TVN'[70<`X/';)O1*S;7 M"PX2C^5_W#Z6'_=TYEUMR%TO=H'R7H<`]\@C]C99_/(R-SH^$MJ[KUY+S)C^ MY8298ED*4;`LNU9FQE?5NA#OEJ?;#DNKCH#="64^&Q/Y$FF.5R[BZ&+?ERM>2GJJ-*GJN!EP<*ZGX&J+'G'E MJU3E\^[!64B]DS5/KPH#09&KVX/-CO*>P]G,?UF^["$99]Z>YI.!)=0_IUW7 MZX,U&_R2]F"Q72RM0PS+(N)LUG0V31S*>T;646.P;*J M@V5&$E:FXR%)*AQ]+_\:(H'AF_\#4$L#!!0````(`(Y#"4&6-"9"A#H``)S- M`@`5`!P`=FEV;RTR,#$R,#8S,%]L86(N>&UL550)``/KK"-0ZZPC4'5X"P`! M!"4.```$.0$``-U]>6_D1I;G_POL=XBM&8S+0*I<9?=VK[W=,TA)*3O1DE*3 MF66[82P&%!F9HLTDLWGH\*??N'AD,B(8O.+1@T;#)2G>X_M%O'AQO>.O__%Z M"-`SCA,_"O_V[M.'C^\0#MW(\\/]W]YER863N+[_#B6I$WI.$(7X;^_"Z-U_ M_/O__!]__5\7%XO7%(<>]M#/E^M;=.L\X@#=^N%OCTZ"D1MC)R5_>_'3)W09 MO808;9W]'L>\]2)T'@/RP^.;^.,FVJ4O3HQS<="GCQ_H_SY]_?'B0GSPDC#V M$/D;8_'UAT_\+T'^38(F3/[V[BE-C]]]]=7+R\N'U\$_^D]=M/7_U\=[MQG_#!N?!#BM\MJ2@;&=VG;[_]]BOV5](T M\;]+&/UMY#HIZ]]&N9"R!?WI(F]V07]U\>GKBV\^?7A-O'>D#Q#Z:QP%>(UW MB`GP7?IV)(.5^(=C0`5GOWN*\4XN11#'7U'ZKT*\IZ-&O_`M_<*G/],O_(OX M-1OB=XBV_+Q>*@%]>\)+$'UE3@/Y$E?I$8BPT/Y>9,M&, M+_L&TPO&E+*-W!.&`562*);V`>.58/?#/GK^RL,^X?GI$_W'!?W'Q<=/0@_^ MA?SJOZXC-SO@,-T2MCDWAN%O[^I__JH0A[:8QZWZOVJ/*)#ZA\E$YS\D1H_ M'%Y\WKS[]_S/B/[]KYS+Z&,X)U_TZ%=O`FRZB<&4TTX23MM"Z(!%3]+8 M"=-[YR!;%N3-[&N"3MQ<"4QD'6W\%0*>#SUOALIVB#:T.^A71/5B)UB2X\/K MW_&;7)(%ZRRE-VL^J'LE&]"!+8F M&$`Y6R!:X!A[M=`+KUHZ&!5B9#/$"5&%LHLN/?O/$=67KS_^^9N/3%OH;XK= M[#ST^,>7X2Z*#^P6>?Y(=RYN>H:N!9U=G6D-B*J-,=%_!8^!%>UI*9'ZT$&4 M!0F-JE"C7W+Z_W>N1X-`\L3GV,+7_[4,W>B`-P0U9MCD4Z>QM=T)8RA\;ET-I+;7X0]QM//3VR@Y MO]N0-8#IUKJ(>4_*9;.MK5OG=?%ZQ&&"+W&(B4!:;96TAM16I?"GVJJ5VG:' MTP&_(5BN(F*ZPHRLY*LCCIGI2BXQ,6.X$!HG=WX8QBL5$T'JQ)`*H;53CY5-I#>'6T':[<[SY=Z3H?>4\HO$1UH M5(J`2AG0(Q,"<`,KLG6DFD(OT8T#_E MN$?96*45CX&)#=9BOKY?WG^_09>+F]5Z@9;W5ZN[!=K.?UYLX/9DJ_0)QV2$ M(MX'X9[#$^N!PDXV$<&8-C,HN35JAV$T`](H]+D:,0)4IC\YE3?6=GA%;Z,;]K5;NVZT$9VYK*&(35)? M2(X5DMO<6N_LIQ=^\^^AT-/H?)&E%!;66-0Y1:T-9H1MXXFXM>W?#F5 MF!BS8D/%+GQR4H@UH"LB(3Z?+E/="C7<5ID23W%KI+K+ZH8):*M4`=%ARS3V MA6^OW9,.VO:'Q3H_2KQ?_/RPN-\L`!>:U2D`S=6CM"70[%`+74R%9FG'TWNI M>#5-J.DVNQ6POULR%/=AL9YOR7E8*"_(K&O9L>`+5"Z)L`N-4ZML!SRQS@6N M32N5I.-/JHIHZI'/&P'.)HV"0IVCCBER2<`A)7NA\,YH8&;$1O,;K\) MBCLG_@U79K1B,N@(8.9!,X1\"IC);J_SUSC!!.@3/8CB9QQ$1WI(U?=_`PW, M$!@!R4>A%8+1S%"3R.>3-V_/;S-*"D@3U`N#5U(`+L@QV=QRCPK5XEMM`;30 MUH4L%E6U=.,MH"?BU!89^E?$_VQ_6]@@VWJUV:"']>IFN873N:LH25>[[Z/( M2S91H+I@KK6"T3V%L(5#O5I*>QVZ<.*0+*7)`XZ9O^NED_BNHEL5;6$Z5RMX MX9?<)#%<1U_[099BE08K6T^CL\^$5W6W1&I['?X3]O=/Y.MSLA`[>WR?'1YQ MO-K5W,%U&M^2!\S@=`*:#UEGA,`#*52K)N?<^S7C[T5MAM2$VX0&UQR\=IC; MH;8WX/,P]3TJ&SE=;[";Q7[JXV3QZ@:9ASWN9W4X9MS3?;4[MSKS`_484PS_ M0+QAE&'0CBER>8S1(Z-MH(?J@EKND`I?5#)&.>?<$[+@3?T4<^XTOIR'"\T0 M_P+D#KF(?,H?R,OU&+L!^8]ZVVQ""K67-H=5;K#;XQE-<0T!U")93T+2"LI9 M5>5R[*29YN@NBE:3+I28",E@&,PH(9RF]Q MBT7$F(<>_0\-U7@F)C9,DWEZY<3Q&U&-'YT@4ST!&=(";;+:`"MV65T0C;?- M,H10VV<1`O:TPOY1(9TA)T4Y-6+DH^RSCGFJ.^5.JR^R"A7%1/.AD#,,3XTU M(B0R?^/4%JA+O/=#>B8;&9KV(:4K*.9S`[*)[SL*N*0"//E*47`E6(8T5W5" MCR3LOZVLLXK%E(RT'J;>5IOALVRRE8!:6&Z1]B]G@M[G;`!<6'NB)&L`LW@FZX%OM%G8$E`M M$IF1LTM1P0!1#C21OW*"0BQU(\',(]:CJ4U'8C>H0`]Q1"_GO,NWSPDF]N;& M#YW0I6\];NH_LZMNQ61LPP`H8+4UQ"*"M3.VT:9A*S"R18*I7TY.2V^\IQS( M.O$E*IB@D@M`Y&M?A"Y%F%%0NRA&NP*4HP0%/MUX%&./Z29E,*GIIH'8,-T: ML($/7G&GVW7PI`PF-7@:B`V#9X#-MJV4@VEI*\LXG0G:2G.$S%8>*PC+B)Y^ MYE*1UI)(ZF+L)60SM75>1>HOGM3F%<>NG^!DM6.OA:LCRXYS!KHK$X"$EYVA M%MDO6W.PFPJSHW@U/CI.\8ZB%(FW]^+1S6&_&V,M<_J,?,HX\)>D729X>):5YMLA?G!0Y,9$= MO3SA$)$_T4=9[K[C1DF*WK-/AU%X\<_,"?R=3Z1)Z$O?Q2,K0U>E^)(*'.U# M_W=>G^[DNW2`8YQF<4@`\'&O?XU]3,6^RIV@$MM:)Z"%^?C[5_(!;9]\TD,! M^Y$0'(DJL)OO]*S7R9^B..6(++*=LR`&5P?G#>&CCZU"@>2BE.) M8J?51`24>-0(2I&,U!B#_<'81G/WGYE/\]:E9'K[CP&>)PE67MD9T,$.22.@ M\U$Q1C+:]M9$]-JJ(VA0&B%!A4HRQ.F&76&DE2"'`4-D>'+$&ND7[?DBP--A M.5)`@/.%K*-DAYV^/1`D+-,V^>U1XX[>AL%$9E`C1.54,L+6X_3!4MX43B)T M\])\=F]#"'#*:`6I.%D84=D]3;0029%LB9W6&37?28U_1&\V;<-`DZ:LM+/O M[R,[W>N'])*!/X1X62QV[6+_27_B/B#Y/E3L_+T,L],`^6T48O1&R_.\CV+V MPV-&]OXX(?OG-S?`7U+3SP\*3F'ZC\X;_X%M\%\P6>.BV-^3;6T0O#'FC_@M MHFM$$W-V-FN%@B\[E5L4M@`Q1H'O//H!#QL(HY0W?:&G#X\>!]1'Z,,^P5WJAYJF&6B%BTD:E%+W8`9G(`^(7Q M[,'+KDGM+6C=EX+/@3+O=H($`1),RN<$4QL$77`=,L>>J3-#!W( MD,6^$R0SE&3'8^`+K4EP_.R[Y(-N5"LB\65OL.%A,T;T:`'(@WI$T52 MN#Z,)K`XM(*L7!:,N,`N""U$-%D*2G:HX,`X;DJ[IHO[<<#GQE]^T0!C M]_L@:[]G9P^4)COWWDGD3Y>\N7`V>]CMD5`S]17F2UV3-%VCO?L$)/'EA2^0))_%*LJ$_*1?0B[]*#ANY7')^HR MDZ59G"]HD%?_U_0%@_9[7?'E36!NP&1B%G71%?)9S)9PH'KTNPAX-[RO;R(" MRF]@!*5(7-`*PVC7](U"UU(-5`CH/!_Y?M[,+[8WBO)^'OQ2/D_UA+VKR@.K M8B:H&@,%1FI%+T(B&V6V:<-WF)ZGVI4V;*2"LO1&8$KC;XS"8EI&QP]IVO%5 M>.TGQXB?S5<[[7+00`.4NM$$2)',L0V"T=:")I%K215)^[S4'C&C%2)J4N%> M:]OBH&TI`*\"@&Y_7V(_Q1=>],+P[/Q7ME\N;LRG\89K[F39$&G?A='4W8!5 M4?G]L%K<'1>YS!):,Y*(S"I/;J,U/1NY?D"SHI2U&K;1,*HP_F>!=NB6NK/8 MXUOL1W"+(PF$Z&9QM(PF97$,(+>/'IGDX$KBF[H-KI;1I`;7`'+[2#S8P:TD MH[G)/70?Q(['/`^/AA0\'T\C+$E>'B,\%M=\MJ%L6J'/&@&MIU)1B]5/*^-X M-UKG0M7N?C:;Q7:CJ6]G>ZRO^"N-T9#7VD*.O$+P4P702&RQHX,@>J&O#C=1 M?!UEC^DN"^H/4D)4U0"TXP$T,%V`%@/6%:'-PC6%-QU==;4#IF@+5:A&(WA9 MH,9`XM$LITK$>C&7HMT,D98S)-K"5*(Q$[KP`RC],6M64`Z;P^_$G>$4`UZGLA)S.0$-HF3E_;$9?G$ MK=EZ"04=4S>UJVZ3@+Q>S#,GR(HSV9OMIA MT%)`U6=I!%&693&6?C2#JQ>W7H2E;$W];_/V,\0H8.JN]`%P%.TACR**4'"= MWC<101U.3*"4IY0V&$:;`(U"2_(9,8(98B1%AE-&-.9$T.Y+6L/89(^I[(K` MXC[9=;-#%E#WJZKS./EW@-G;6>A5?6O;)I08CCW0[GS@[BDV]B/URWAG@N$Z M0G*3F[-&5=ZTE)C@SN9WE?\,G5F`V:D)`'%:'Z^+;LGJ^!UR*AWE5;[`H#L5 MUA-<2-77WGJ2B2VBDFMQ4_DM^EQ'D??B!^+5-SPC/@`9`:B_<)R%,;'[5/2^H$4Y\3C5 M-QK?9SJAXJF':L%-THP]%@LJ4JD$CBATM7>NBK9`A11U@A=%%$TD'DW]52+* M-:-0]:(IA'*WDQGZ>M90<:>BLTWJ"J:I!@-N23T-W@ZT8O+G@VF$`^GCIF'C MH^5QT);CG941P>,%+QOHETRK5MOY+>+.JB#'4Z5@/*4&]"M9F<^*'*)8TF&1 MA)L>J-*W!F]:;O\Q"3?N"D8S7VX=`;B^-7AUF\EN]4:ZFD^NP85# MT1CLME@C>N7NMT%FJYU-L_75=4#=WZKV8%VN!U#I]6;)+1:F/!R#Z`WC-6;W MN<8#8$`'5(+2%%!1=[(-$DC;;VSSIV/KFVT\Q'Y![;!5:03H5F8DZJEOF28+ M*XA_;P5"XXU&,QFXIZ\6CL3=MQ&'S=C8Z9U9S$\I9K);#2W@.L$$RPO& MRWI=VA(LK$`E="6HH$G:T0RY7+RZ8T[N!\Z:S1!K.$/+)"&[+XA[C[9R)USN M,**)0GD"SQGZ-/OX\2/]/Z^8E>2YE'_''FT:8N1+`=KTVRR*->GTO=X,RD-3 M+F[IEJF7H8(Y$MQ1E3TM-7/Z`91_8133S4L&+$)EXMC1>F?!ZR`\ M.@'-,S(BN$WJQ*EU>)=X[X?AV`BU=[&C8>/WM^SL4J@W9A\`S811N:)@^=23 M>7$&,[JYJA--X1)+!45^G]6$P=+5ED3HQELN3H-*(OB;KE8PQ*57[?P_B?LL MPPFAI0"_Y6J:"H;23\2;5P3!VOH!XV%,%]+!G03B[12/36U M0@(<`]$P*`TT$XJ)4`V&,8(>)2+O'/>)',WCMW*D0^\F(^=T6C?LK&N-*`"* M/IJ!**H[ZIO;+>-H(DMM9U$0E2&Y[/F@H`,IRM@/RHR=$THLNU&Q--9A[`3F MRHEC5DA0%/9S6(Y,6NE/G/3(%A#C%'FT>"'Y2Q"%^XO`?Z8//'G(<1EW5I3, MK93+)?]T67G>2/P62ZKFLA\D_%RV"0K>"L;1;E>T)WM4TI$?T.+5.1P#7CR7 MG`AI0?/DMV1&JQKZL:ATR-K2$B^T+R"+"F[\?>@3#'2QXGZ?[`0;^"[96&SQ M:WH9J-^D3(F!+N!:0:.VK1WEN9D#2-9Z[2=N$"5$AYJ&2D\"G,Q5`Z,Z++KV MUM8<=`;``NI8N,%[NJZL\^*PYM/!B!+(;)F# M.K%9S61P!JM2_:*#WZ$1+7@ID#;>B!T0C?A$8P9!DB7-HZF#/43SI9'%T6-/ MR`4[NCWCM;CI3HC?0)X]V*#WGT,G\WQ"]^4D`JOXS19WE5*IXTD3P+JG9V*> M5#M5R&?A1>M4,OV[5'XM#?8^I1>V]LHTJKS*Z:D7^_`9R6_:^X"-_G=$2]@]6 M^8L3>\P-Z":*=Y@=PE5Q^P/P!?2Y&*)#3MPMANR)$9?Q_M"E3A;"M"#.%7&V MN2F%X>?4WO$A.R,]OP*S'>;[2.Z#YD7'1._.-_%KR>ZZC=*:GG:J4?1S-. M%CJNYM9:?I+>]98?1?2K]$0BOBM,V07[-*I^FQHW\74D/B_,'ZH(("(L0)Q_ M[7,S,>/8WX<\5M9]V\8.$=D5J4[93P%#4';C)29F M&V^=5]X?A$V,2===8_Y?W3NIG>\#OKG:[."3]UN(GAW-$MKL2GD^.UDPPPR) M[Z-<`%21@+U8561`I1`S],C$@`I_@.S.O,O/IV456^UT9OM1( M-2T;=`:FR7(H4%B?[Z78YK.T"#D:?+*9'::Z8I'%$T'7WY+`R&.D!HQ@&?PK M8&ZB8W16Q;5TS%X:;6X/WRV2N&C)6EU&'$XMXD4;,F&[NZ`#%RM7Q'?X$AC MM9$X;P?N#7XJL,0'7"[IF%.M)IHN[0'ZA3>S[E+15E@>T`#]>J.X.]"J;0/- MI'(1R-79&`%LUYWE#E+<$M2C=Q9Y$Y2[5 MP4%O7\SI)YM`0V%WNB`#/1HU[5^F-3#&`V$LNWV<` MNGOEOFI;>M!H\C\4C8`=#4]$K7D42F4?@3*CZ:U'N#/@+:P+IVI>+PET/ MJ3Y&(7TYF[_Z:C\8+0VP)NB`U!3#!,'X>J(06:DVL]Q1M"1!OU`B0$4ZPW`= M'-M<+D`]VC-Y M`MFXJL5!48B>Z'OW!?H14F:L'#$MZ8X)V-JN)-:"W#5 M_+((JYG/LHTA> MHO#FT)NN5I0`R4S:@2J2FIB1V4UNTD8FLSLW2CY#OP@S"&@%1\(GOU,:*YQXL;^(TLF@LA7R`'W"_+O(O\$.O(AVT4QBK$;QH"9V@5@,77;$-N=R^TEJU]RE2Q0R0/E3-![P4:7 M0L'*C/_OA+711`P,]GR=]T&S@A4)@>YQ4Y)(>5/@A%(2L:M'OB9Y1SWT2014 M)HKBOKYPT[J#S*`)H0I9;_S03YZP]SU-[=>DN6>-@757*GI->[4R6U.)[W,G$!U/BG*/YM&3[PE)5-:GS6&%B-I:+7U%@K M\_BZ<2ZD1C=H4QHU+AJ#6N(FL>G?+_SPXBB7%4"1U\[+G9/BV'>"1CT^;0NL MQC+!:UJLDWA$3X34:/#I"4JFH)J<(/,5-"#2E#8NB?:Y'`Z@NG4.Y$GCC.7 M?325U@IK6N-D*I5\C<4_K6T"7:>W3(I$W2'F(?L/];=Z=@+J?]=8MKT-`ZA( ME;80R^B5KMA&FS.MP-3#18KT5L`[<^A9 M*]UY;%B'H0;*E3A-];A8WCJOESC$.S]-1/J?W[%W0^;+9S*/8AI-Q)P4$A8I ME]QAAZ84/M2G?U]F`%?.O:$7]\^=.=F]C.XI9KU6G?.*NN3XEM: M1&1)>BS<^X\!YD6#[IQ?H_@J<)+DWCE@K:M_:RXP>Y^.8/,-4$^4H^V"VL.2 M756F^(*Q0"4/Q)G,$&.#&!]$&?4*.5"LQ9^I"!YS:D^N?6_GA$;34],88&HVBEY,2V5+NU.R08QZ5)AH/YV9.'T$C3.Q,X21)N"M MO\,;U\=$U]433]((8,(I12TF6JV%W0FF^'QM3&D[)!K"3JCI2=PX@5J)G/"& M0TX8OO_-DC0ZX)C5"N:5HI;A+HH/3&P#_\$N7$#JF'8%6ZEMVI:%[7JGW>23 M%`YE)YJ<$[O\%;Q0A=ET_`O_^R(W**8Z*'3W!'HBH/LE,\B*I.X3]K(`KW;G M)>TJ8"_?Q!\;"_UUY084DM\/?!&WWQ]U'U_U5E_7>JUWY`3AO]X+=.G)WHF- M99_V'C+6G:`%,YK1-K?!!;\3:_SX5C2`=G0?M`/JUI?%>-&BUS[-=>L?$"]F M-X[+3K.G^UC#G:\[<3'<_NEPBP:`B]%EEO@A3A*6=%B(LPC\@Q\ZXF%$DQC/ ME!AFJ6D'+5]9VF.:[,Y!E_.M"Z<_Q(Y!FCVN'UJ`'$NY%@J1C'*XR6F`,R_I M@-22,)D@&.V%K4ED30ZWG")?ON%SN>_+8I?9<1Z31*A^M@%=K5`<]X2F8& M0+6%DN\;^Z8&4YQR5F27&/K[)RHMP?_D)'B^CS'FDR*]02K5)`PB$)2MP4N*Z&(/#*2VZ0'_C,,,5XIAFF5R,Z"#\GM"%[`^65*D%]6]H+'8TO=./DZ2CUH`8]"+*# MO\=DZH9)&C-Y-5Z9VN80YKU9_-+*J]M:-O9-@M1-9T&!*B2P4ZX7"M\6BN8% M;"`8@*?+U:[#*POEG>T6Y4%0+6H]%9L]P5 MBC6%OZ:GUP)^RN]U0N\J8OG1<$B3HVFN/Y04<%<@#2"HIA@T/[?PUF:L#>@+FEHW3AI8 MUP?)UY6/8?"C+JX1$QI6O(V=,'%P?;LBJHB]N-H77.'$%>2%8,S190KJK)%E*\XU!><2_^#U0Y1 MYHASMWWT&+5/:,+0Q`E(IUP@YJ1U(;RTIE(ZY,I)\3Z*_=_9<4;K0&=".(72 M(CI(U3G;3&5]7IJ*U%B:Y)14N?J,OT0VY676U6!H2C\-635H&(#9X>#$;\S9 M6H\5M'#X&:J&%-0Z`K#2X`T0*K7`#62'\XQKZ'IU\VEXP*FZW41NFWZM9,9R MEX?K+*:ZP/S]N2L$^^/JR'8&BU<TIB82KL'YXW]>O[BQ-X,B:_,4/Z=A&4P M9L)`I,`;I%_RO[$($DJ#HAPF9V0US;AQ%,4YC,(INDI)1JI""_8VT@N8/03* MZ=YRN=EOGM6&#:40)5[S8$%2U<'%+-*-.GF;Q6]1@_\J[?C(]1*SI89472@IF M"`MN/-EJA1]TG/R@X.^WRXOKY>WG[?+'!=HLKCZOE]OE8E.;B'9<;D#'=0J5 MX:[]Q`TBFK[7M$"G&UOM7*^0\1E=^4`=\\ET\+ M3M!1^:U!UZ/R.Z.U<.)L`T]WVC2I1"$.UY!%RX<#;U+LV.J;2W;(V"&3O3PK M*ID;'MHZD#OO*4,P3JT29M=YBU#4O)2?A8&!X+@8]_P_6`T9%PU-&\ MQD0`U\\WJ.<"5O\,T=4MQ*.Z<:1)@^/T;8:.`2N'3,P_)H;T*/-<&;5?Q1-* MLMI=^\^^AT,OJ40G2Z#D!!1&03)#G(C7)AL6P+<<0(CW5)%5`]`:1]$,'1T? ML`!9N;PJIB?;!)CO%0VY0.\36X&M[Q$[H;2P/S2%I=L;:A:7R6T)N^*5+2B@ MV\$XHZ54J!AD)<3)E;;FGZ8]V)9.#Z"R:3.3?,QMF5)4R<:+MLWG`&M-EIH1 MB_,U[ZB,A1="I[0566/>Z)2PNK0+86]]Y]$/V!5;*&:(QUOKG6`)O4D$A75$>I<.Z._Q0*^XK@C/*/`]MG(RQR[9,[.R*8#/ M1H/8A5>&HIU=OPNM$/4[/';I>-*<>P/".!=T$=X]$9YM,&MN`E:@J_2%O;OD1<8?)\:2\OQ/"BM+PTH<[3E&Y@LS[&[T79%_"/#AV MAN)7+B9!WAJWT=S]9^;'^$$\@[)5D2C1(G\"U;T[IA$2Y.BA>$9E'&9,M1;C MO*.V>X;L!E&DYDXF]D0<8_I$*A1,?0%6R*%1%CZ:XC.M"V.JELN,S_PR)I!\T,M#V2"///\]=_'42);[(OV;%2K M%#/$:&`"#?N`\"L4EHV`PH[=8_F\.K',IX:9N4B-(GT:I4Z@M@FM(%`WKND8 MX>^CR'OQ`]F9,O\3A#9#B:7J)I%?(GG@[ZW:!RO6$(F6T*^=+:4&>4_V/%8< MP0D>R)*Y#*^,D#UC@-!3-A.)T<7ES0#OC6 M0`0*R(:=)7IB[QCZ6C:&-`"O#Z9`BF>()@*[[Q%FTD@F]!D9^D6D)P!\Z1X4 M$,P+RU#26W]B80:H3>SI:I>O(`\X9O?"\P.U-]*[8+;]2&BC_-F3[?"KU\+L M9IG]5GHW;#,GM;B_8QN3^^C!B66U%IN;0V6DUHM?9H\WDWO,VRZ5H)++(W&E MRMJ28RW+^P!3`[&S[`F7_4@$?Y8)#E+ZKU&_%6W!R_ZI-=M(XM'4^B=,ZS]B M;TY4R-GC^XSFJ:+!,L2N8O&`MLK2)"6FCEA/B<;D')!@@3@/ECN)6\D*_0P) MSO:O>?HCG?^X6,^_7Z#[SW>7BS5:W:"KU=W=ZAYM?IBO%QNT^KS=;.?WU\O[ M[]$%8DD:%M=6CQX*C#5PET[BN_W'DK&!,&A]<;8;R9=OGQ/ZI,>#I>G#JDLV/6R[H[B@9#'C.3E-4O:>>=H0R9&O MMYIKN"K2XZ,*T62RVPV$AQU$)!=$<'NV5;QW0I$%_<0+;AYZ9(^9Y*?2U>[& M#YW0]9U@0WXCJE?K\RH,Q!MF3SAHQ^1[R%%Z9+1)/%07U)Y$R6K/?"2J3":1 M_*<7XC+=45,`S_"?^0/.$4UW#3)=#/IIFC-'WC&UJ,G*)V9GON!TE3F96V2N M%1]"Y9=0^2GP%=9"ETGMSA2B``DB/\6W_C/=6I,CT=XG>X(Y\UNZ?+MS?HWB M*WJ/:QX7V)XA=*1@URZHQP[VQ3Z:4>@%5A=?R-E=,'ZH9(@X1WJJ9#P18SJY MT,,A.J,L$^-PMTUZA"[Z@7L`HB1[_!6[*75`=0XTBOCWS@9`\7JYC1T/4]?H MY-9WF3\B-5[$2&D+/)M0`;Q@FH,IWC";2>R^8IK*4U.HDA#EE'Q1Y;2P5:`' M0#5#0176T0:LQD?.T7`-6;S]*DO2Z(#C6S_A=4ZSXS%XF^]CC!OJN)M2`DSU M=J"*Z6Y&9G?*MY&I?FLFB!&CYL6E&3TJ&<#._6'@!06\A,-S+,%KM`&CXP/, M1:W9Z-SCM.$NS9089A_?#EJ^9^^&:;3]N3&(<[W3[[]Y0E'83**=H4UE9WTN M-3T-9$Z@JR[12`*PT!K"*%;8AO9VEU8C822)8L[/H^\%X9=C3XK&U:8W(J[_ M,(D+;`[')!;)><6TE%'*+1=+*9/)+9H:J`:+IP%&B$54#JKM8EKE`ADZWQOH M"1`1ORI\),[L"^!LS-*,>>">X_D'=N)5J)Q_C61`,\X03C''6N(8;U8U"UZ; M1XQ$.EUFB)(A0@IL[E&19;ZIL@FYRNG<`QT+,:CDD,2B7/ M5W5_VN%A5L5H<@/7`-GD@=8,ZV@&A">=+L)GM(6#0X^>%[Q*A!'+EU*$$)%M MU^J(XSS=T[@>'?0R3PRFM[H/BLJ MA(HX?-'UU3A\#>Z&C`,%LTK&`6#'M4%@7\TW/Z";V]5/&W2S7MVAU<-B/=_2 MG!'SJ^WRQ^5VN=A,83`E216Z#Z8L?<0T![,=[//!7-[_N-A,<#!%E.(P@UDP MF_Q@MH-]/I@WR_OY_17@8-+:/ZL=37V<;*)`EC6=MJ#+`VN#:".(WC>0<[79 MTH0YF_FMY3XLC+.XI-0I0+GDY(V!U;J5\,4ZLOCY87&_L=S/YJ5#IE;\I(7D M]U>KNP7:SG]&#^O5C\O-8FTN'\*"KR/FNL7.YX6Y2N M!;7/IE)??5ZO%_=;--]L%EN[=EE9IT(CKK;>!G"7=\*SIHOC]A\$S^V<#L,] M4?O__+Q\N".#,D-.RNI5VMV6T*I`(N8I"MU&#>)EZ8L8KH($>H/2%L;V!V)E M`*9!O>Z\1LI*XZE8FE;RY^;F=CF_7-[:/[?DQ>'(GJHB=ZD@LM4H3R!,MX4G M_5^205;&:P-E<;,@_7^-RNVBQ?ZO9A'V4Y[\+/2NHI`>(S`Y#&-5-=D*!2(D MZ(3&=M_W@$&V,,LMM>P;9NBO5O?T5+0@)WG+TX"EQ'PB!V(<)W292M]TL:V5 MQE\@WAS-TS3V'[.4Y%/4#A;=2?ZPNKU>K#=?L$5W^P\HPT\C^&NR MZ\T_S[H@&1K[N6\[`-FNMO/;ZBK`)@3XD%02QO+4TVZU( M*%U2P-QW=0`@,N/G-2#&!6#<];S\L6&WST1=YTGT>9/DI_WMCR>X05]KBR>< M]C1TU8>64@]1[T&19>'!2=+K#%\Z`:WWQ&MSWT3Q&C_[^&6URQ,7+T.663IS M@N#MS@_]0W8X@]6;&T!NAO[@B[0-W5G9S>C05TY)D>3(@%VE3$2G$%R*0S?$1PWJU&?PRXJI_D5-C")+\89>(\,_*,8^&,Y\`T] M@`Z<\Y!9V@@BE^+?X]5NXP0XV4;;)S_VB'5EV[9ZA^@)(,R1"832XNA:6S8J MS:+(IHN@825,*!4]?#$ZQ`AAS$)O*"EM?G&D[5%".0#-]]Y`$KRG7_@BJ4.B M(Y6^1,@5Z=<&S;?(G4/HI[>$5A;DH6X&DN!)*6XEJ5.MC>U$3@H!)`_'>4M$ MFZI")NPH<2>QJ3SCZ>.MP@U>WQ1<+VMB*W2S:`>IGV="-.OHK=J/'4)16\C? M65D'JGY!GY9*<>2Y;)L:`U6BT(I>U),PDGG<%TB9D/*GQTI+L*2S'<0>5515 MUTH+S:E*!LZ]7S..10)"55I/,)/4UT,EO\G4V.L$?7%SL[AB3H/,4V7YXP)M MMJNKOZ/5PW:YNN=WV>O%9KM>7E$_%E&$C_[V\_W2\O,RV\:*$EOW6%Y=GOV1 MY5\=Y_&`['75;S:-\E&?7[Z!ON`G';ZI!GE@:A9VL05P):T$RC#C0@M%Q_@) MAXG_C+D7H=(:56@1MTPGU$@X14):5@OPWM]&23*.DZ=RT#R/%;MS@@?']Y;A ME7/T4R=0(RG:(TIPX8=(D,`.3D\8RP*&7;O(#^IK?*2!9<3BJU^*1:QQ?FSG M+Z^#2 M/@C&[X/&BS];G:#M@R%ONV_]WW#@/T615WU!VCJO(F+K$A/11'WKW['W^1B% MGP.>=VR#TS3`XJ:AUE,#,08P;(-V26'F!N%JU^@-*++$'S3GC4Z?(:FONN"/ MV`=0^05$/X'R;Z#R(R`&T5+W'$^?FTGW/(KN>63=$Y?=D]'NR?+N2<;MGD9; M^!*!1UZJ9.S;8>I.1J;Q0Q3XKC[5 MQ,8GTWSGNS2ZLB1$.2547A_2F<08W@+PESQFMW/G$2LT M4BH*4_+5@#8CAV-,!![I!407/J&'MM@6<=!`FJ_O=RS"NH>L'1LEZ1JSVX:3 M"O>KW9U#=NYE&JUEN(VV."2;^03C&\>E02A2M\6^'"%JS0[2"64-VE[L+->F M'4!6>3X:P16=L*56F3&N)FCS0^98F3-'.7>8:K;C=,A9'Z1/6/1#5.T'ZK5( M_E)VQ6[,KFBN?#N:0'8O[[`"\O7E9%=F]=/2MTC*]/MG"$U:H_LT9OQ+`PB^?4)6Q`S M-UX?N+0/\&D?^((GC!F#P5K8./+K$S,WI,GBGE74'O\:Q==^PK?=49P_Q,JZ MHYD&P`29`BE,31.!79-B)DU]4\_]^-BFB+Z?5RB+MW00\]`;3Q%X`3/E>\M_ M8./A5<8C1P1X]7;^J"QQSU#GXCFRF5? MG=$UO_@PJEV9L2W@'RKG-4#WDN]=.2*54M96375;D/`PO>"5^#!Y0]L! M8CHI#!:`D2>X08185P#\F:6V+QIW(HH'3[ZR*4A( M@['0-)^*$-K5"-W'C08[-&O4DW]<8P+""86;(3TB2T-'&P@@W%Y,()3N++K6 MEMU4FD6I^P\4-.B4B%TZ67^I[8R#)U*@[F$')_X-LVU.4&*+3Q@!N8%T@+5] M\A.$N7,&`7$D@K$@27I#E)1W0F3S0K0ZQ"X;N1<_?6+WVJ>HZ?ESD=$,MT[( M>NK[('IT`I&#XM^H-`.^M16"6Q8[?+TNLN0;#D9>*55,22$ M>$1K`ZE\,3.ALOP\9BY2_4ZD6M>9+&-%0N>2'-!.#(G,RY'Y09`=_#T.Z=-/ M`1+0/HR#\@S:D,9`(>))>NT:2@,B`"-@#*4P`(T4=B>_H3CJS.WG$QTP<_LP M@#3S>T9O(F$F>7]89UA06)`.NM#O]S'>.REF3CTGS^M4X/P!?D-.2'@>AE%& M_BN*9C:ZV`S%&F*S,&RWE-N)8?A:WG`,*71]2V.*N82#QX33V_2T&\..!BBJ=<;(5BCWORY/KI]3 M(BJ_<^)I_V6=940&8&E:P"ELBP&-76MB+%`]/V?N_%ZY]ZG0BF(;(.9B`%"5 M2Y*L`NHX'JA&HS$V*D#WYILLS6)=2A^\9/7"?X!W94.:#; M,H%Q>NX&E1J0;ARLF9,^XM5SOS$F)UG0BF+Q!1^TVB'."5%64*D3!P&\2'BF M#P\Y5=J)JSQB[V MGVF8?UZ05GY9;48)\F#3!E3EU<:$S/;3C;E,DG>!DK@LAE4ASRL@`SWB](!6 MH(D+"IXF9)DZ@>^$Z"E*>&I?X*"EX0;0J4-.T!BO.T4HY$^QG^+KZ"6LQ(QO MHSP4O$6X="M&H+'2'2!+`J5;<(&*DFXMHBYDEC%#E!LZ21.QC8J\#Q8>7%K$ M#`^*_H6A]RAZMYH'(8T4)_9QO.K-H\.MC'UJ.O;VSB(T?HEFQ23_H865GYV` MNO.RS$QO3<&6AK0P)X]6P/*`RTZ(1C%-+:2IOS;0:#*6H);^HT(ZXRFWWM`O MXK_``9B#`QQRR7?=.,->):;Z(?9=7`D0E!H4`RJ(Q=P83+ER-Y)87J8-Y9%M MBRGA2=#1E'0``)_,!`!4`'`!V:79O+3(P,3(P M-C,P7W!R92YX;6Q55`D``^NL(U#KK"-0=7@+``$$)0X```0Y`0``[5U+<^,X MDKYOQ/X'K>>P/0>7+5=7[W9'UT[(KPK'V"6%K=J>.57`)"1AB@*T!.E'__H% M^!(I`B#XD`C"CCJX;`&I3'R)1"*12/S^MY>U-WJ"/D4$?SX:?S@]&D'L$!?A MY>>CD!X#ZB!T-*(!P"[P"(:?CS`Y^MO__/N__?X?Q\?_.+^_';G$"=<0!R/' MAR"`[N@9!:O1.7G&<#0'RR7T1U&[*PP>/?;+XVORX0-9!,_`A^GWC\:G'_B_ M\=GI\7'R#>>`,HKLLXC$V8=Q_(F'\(]']M&(L8_IYZ-5$&Q^.SEY?G[^\/+H M>Q^(OSPY.SW]>)(V/(I;_O9"4:'U\\>T[?CD'W>W#\X*KL$QPEQ@9]N+DQ'U M&__ZZZ\GT:>L*46_T:C_+7%`$`UH)5\C:0O^VW':[)C_Z7A\=OQQ_.&%ND=L M#$:CWWWBP7NX&$4,_!:\;A@Z%*TW'F<\^MO*AXO/1T_HB3`*;%Q_^7C*^__E M,L%L@MTK'*#@]08OB+^.N#X:<;K?[F\R]M?01RX"^!$1I@Y,/^`'AZQ/>+,3 M-:63MHP^!$RE.'TZ74PWT(_HTGHLRFATRMP%H*MKCSRWX"U'HC5KY\#C"ORP M@C"HR=).UVY9F;'YCH,5#)`#O!9\[=!IS>0-?F+TB(]@S=$J=.Q.HY@VK`!> M0GJ#'U9,UA7Q7&8EK_XO9%.LH8I5T&S//%IBM&"`,&O@."1DY@`O9\1#C".: M_JS)NQ[)_;(^Y^M6EXRG!/?+]B4,`/*ZY#NCV.5T:S*Z@NY=LM1HY$3]#P+P MN'N$QP=B?0Y?@K#N.E"+<&LQ[L"_B'\1TH`PGBCSX7EWITSU&PE$-/HG+F&:X*$R+[8:S0YJFCM;58WWG1J$=SO"M;AFI6QNLE- M^%O&68%GA@;$+G13KCG=#G;HR5>@@%,[/1T=C]+V^?\"[([BSJ-\[XAMQKA' MG`*O'@^`$+]J@/E?OJO8FSS2P`=.D!+RP"/T8DJ:_4YJL9B,9A2(H=#YL"1/ M)RY$)XSK,?\/9W]\?#I.PC!_87_Z'G_Y/5PB_ITX^`K6<(=?]EV29AE[>>@G M?I%5X#LI0?;?`N[EL%'2XF03;9"/G17R,I59^&1=:_02+HA*!.*S3>3GH[/3 MHU%(&6=DPVEL[<;^Q_Z"R>$#[X;-CI>_PU?IX)?:#7#T2S(DP_]S>?@W/F*[ MD>#U\]'X$%BD,LT960$$Q8\'-?)%UI,!_Z4/?4\YF3%S3Y@`+O-?58.]TVZ0 MH[XC0S+\_]W'\$\8/R[GZ=H#2\&P[WP^J.'>X3T9YO%IGVI^C:@#O']"X%^S MOU"%HI=:#FKLI5*D*/2RN!:YBJ>A'@Z%M@-&HB!'BH5@I=T_%A>A[Q<41&[[ MY4T'A81`K")51)Z`4W_LJN;R9^_WV`F,QM+*64NXBP@`?"BEIUMI]LJV!R\ M7+UL^+PXAQ@RD:4*)FAI.(92OA5+?CU`GZ#_2"@T"U*NM-=LK)B9"Q`.F0W? M6K5SR)8$F`T,I'<(1SS?X``R$/GB4:02IW/C60N*]9#W8Z&JY"N&(I-?1MC9A[DM:'N M#^)ZNJN'N#HV/RR@ZV!L#;S5R+;V1_(&O!\')%V68@%S:]DE>D)L_^4*'0>- M7L/"6DLD^5'GT.;SM#@XDNV?L)7IJ["(9\5IQI`=KE341+>IRL>2MQT*H&7. MY6>!@YV/J9`Z$/9H8ZLT3PI>A^ZO47/Q"\1,4H\M%Q-WC7"4(1.@)X6;5-G# M>'`K)>C*2^I_?CY`C]%<,E'O@/\#YD9'@*RJL?&@JIC?SWZF][E[SY!@H[CB MOAY\@A[9\/5(CF]%>^,AKN!_/UYN[RA_\9DK&)\2B*QQ_E/#/:("K[;L1"$ M#::++X2X](%XHEUGJ87A,)7XM2<<]``\2.^9[<`A_`I%\ZG4PG"P2OR:L->7 M9,Q/<(!Z\?G%>A,&E2GT#0D9#&4;L1+$/[8. M$ABV\-4:CNGB"OB8.1%T!OTHMV2RYM=51-FNW=#M+?VFU33*TF:[&02#KI#EK=)&& MTQM%!/N^2).O5Y@*J1Q M(H5838CT-7%U$,N2*AO(94)T;*^J$6^_,NG_%WBAL!2`7K\A*("F M*)TE%VZBT@^,0S\P94.W5RWX/K9(#[@PG=VQVZ3UA\S6@[A6"=L)^Q!0?HP1 M_=16!UGWX>J$3"([[P)<+1;088-U]>)$-=[OV?!-L7AD1*<#M;H/02GJ263I M*:^^V]3*E^Q/(YH[S?4]R_WD6IJJ(X)=5ZNMJ'$ZHK'GKK\Q[0Y>$GJ;,1%"UZ@[R`*Z70194A,-X5R/85TG_I$#-,!33O15%I[@A,S M$K$G;.,F5P6C<`P5'48IB+H2-8Z6/EK##J&2QZF-P#T.9DXS%GR(1LUMAL* M7J-D.5ZUC/UU(SEGKM/9,&6HL3+4D=(BQ3"]9ECS$QA%.3';$HVV21#T*\$. M&Z\;MKMBJGP/'?8[\OA%B.TM^CEI?ZBU_Z\/8084G+/+5 MB`L?]Z42AYI?6>WB@M2V&JTU\8,DVV.Z*#]*5#8Y%1W>BG94C8/F.Q)#LQ1I M$CAT^3T$HMB62I>>BO9O15\JAJ']D7T'^V))F#1^+_D&)V^V439"$#WQ)P;3 MUUY?V1Y_YL,-0*ZD=%,;0F]!1=J,3V>'_)U9&DU%FH%7+AS[U0]A)E!603BJ M+YRTT5&G6N3>K%+5&J7V)P2&Z;0R%IM*77Q:6SLZ#H M6)P;3UY$B3];3MR0#Y("?HU.`\9?0SKC2BG*:DT5PH;;K3^3/'J[2GK'4+/C M6U@FZHS'?BXM]'YS\1QX@/WA805S!B&[L?A1\\9B0F64D.GW;F*2,@*\61+2 MT+NCJ.C6RWE*9(]41[8[#0S(_:T<^>S,8X?W?3Q5WGSH;Q%X1%YL-;`;90^M MB,?O-<\Z)+CTI9*OGOW-H>3!TLJI5&K7VQ(HG/K%N5-BUIZKN-), M+06"&GW,1%.#<7NR0Z*H3CP>W+>KG)<5[RZ_YE:%:A.K:MP7CG77 M><%R:+$9KN7WF.CI-(57P[^QX&&;LI1L4^V%O+[2C&^(&41!X*/',.#'+G/" M;1G!`>/>B]YPBE_ATE*%9H3[U\>&?B..$Z]'A\(#[-(6LFS0IB MBI[@-H#S%;*=R!R\B-SRNA3,5YG:(NTI9:>?M'87Q;S/`')O\`78(*:OZNM* M.IT&`+N&%`<+,![Z#9\`(`S=M%QL;@9 M*`M<(\L"DL)!T3UU'`B6$MXMBB+NINQ^A4'\J!_"2_ZDZS/R/`&H>MT&@;&> M*)8NK`J(!P9C"2H+SHREV2SBMXC5S?M"43O_J#*')_]>S""!KOY7.HZ-E.Y,Z\-8/MQQ=?6M-,V6$PZE`ER%Z"7OV< M#$4W*QS._0U7ZR5#ALKP5;8>#+A**>Q)*3H/V7!%!YW8O5EO?/(4OV(E`[>B M_6#@K9##HH,&@$4OV,9_'@Q<,;OV.-V%"P'2L%3OD47E90SAY88]!:)Z/I/- M-NURQ)2MC<9/R;E%4:ABP1LYDI)V1F,HX=D>/R6K7"2.2A0_-AJJ(JOV7"W9 M5IE2&TI).Z,QD_!LCY=HZ:-X6N#6>PVO5^=34E?B#C#Y,?1?MWXT=J]#'Z,@ M](4US]0]OI\-9&N@*8M-1I8-`G("Z(JU5GE(6J?S((YCZ@AD:9X2SVY&<>D5 M+C_!O((*Q(ZXYIBRM0'I*[72197"V#/ED]R[7%G%RB1#45L#T-5+,A0Q;$^ M1K+V2HH/20VQ;B?C#;"N();>EI&_D=!W16J-2B3[>5G/Q+H_HM!W91<#;&73 MX@82B0Z5?]]C(;19-+0K&"`'9*E&VZIHXR95T48_%:C^];U*6A>6T_/(,Q_D M:^)?DO`Q6(1>N52YPLFIUW](1;MJBF9"2&(?%QF_$C;M]&XSYIL."6FY%/8$ M%8LR1F_BT$D8K-BB\2<4'4I7=1@NP&59+(U'B,2^H334QCMM/'2L4SE,V+IV M7A]`::`E[88$J$0$BP[#E'MKV]1-3Q"`U]R'[)M^XS=V/+E&+CJFS=:^K) MEJ$Y`^[<$U>_4C?O:R)I8%!*4!$*<+"KPH>=4#E#$[]T16]P9#V$T<0LK/2S M9K'];1.R&"5?,$)XE/^*_QS%7S+ZZ1L&H8M8O[X#3C7KB6KUZZ=P9L+:7/`( M7('W>;_/NM4:^VU-RR+S9E7FS[B+A>#5$PF.#FU?D.C\I*)][\@45*@$@9AI MLQ#9X?&2K`$2O>(L:=<[`BI%RLJ8B'DW"XB*K#50-H0CC>0X]2L5[;>7Y*H M`K:DB7MZ0:*U5[R!/B(NX]L/^KPLB_ACGMBE.?^?9^,+5$3>U%S0Y3S;\_AP M)%1\5G(9^ER=8\V*SE"V5RVB9I-GX+O1BQ?7Q%_`Z*:-V&:WIFFN4G0@7/LC M1V/4)_<($Q(-H_1T#P""EWNUS"G)@+S'C(S2E$`'Z#_A!P8#R-_.WB)(RJR M3(/]?Z6YRK=_V5/=M&"+6''L;=A9M]S@B(ZS6T=@S'`@#/=(OX^-5HS.9,R\ MTFZTZ@KWZM'(I[VH29_7GM48R[A-T>IH$]$O6H)01_JFFN+46:N7F:AJLY^N MQ';&[%)Y.[+WG7]#7\I38SYH:%.K($6GUP1[SX>41]>^,G1&6T)C5(*HY_2__5RP:`LFB*^HVK<3[;@$\0AS!V71'R]JJX$:?3I MK5I0)1;;1,)*(8SSW20UNR0[!360M7J:#65-S899S;NE M@9#B27>4$1N5I*N&6;NG^:AKBV)<<3Z)Q6:KC@W)_^Y_(PI*^:MQK]C4;_YK"I'HP%NE!#DNK]D11^G5I1_3I]*SVCBBF]+X? MJAVX<%;0#3TX7515XU:MO8VHF#U]&XMEJ<.]'0OI00T_BM92$DT*0U(039%L M+;^A,O*7_`JC5[+ROS2P\@FI=S._ATN67%TU$K8:4S)_-C<6S;C`V7NRU^&5 MK,W\VG<"V'^]B02P`2;+=*0WN@DTG[I-H#%6$]Y3`8>@G?M+#_QHV4IL?-98 M1YHBR"0;?[)KJY0KYBF+?JD*@/8:Z1IX)=#M;CUC+7F+H4;LHJKK`"J$Z@MC M:;@B-Y^DP0GU).PS$-';+)0<[NU:--%A7KF-X?-$PG57$\(SQ[%P0R>8^LEE M2I:-OC.[]2Q=F!0<1V5UC( M3)+GA6NTA!AN7S84%P:L;M[S",L59&NF5.P;%YN40/9W%(D:[1[D2(E:F0^0 MB&OCC@FK5_=;274W13LCEP@%OUVA8LKZGGD[;.>MXR06FID`7DGG2L\<%%@V MSMIU#V,%?`9XU@)=$Z%FZ>E$)N(UPHBRG?870ER14RUK.`C\=GAN?;Y@^+S[ M@_@_;C!;\=DBK\1RI^$@L-SAV=(8>B;N/7B^`P'T$?"44!;;#0+)(LO9;5N[ MHGIU.?"Y18J<0(B;DW*S@; M16JV;,O?%)$U-`,,E785DC,$$ICPZH_64E09E1(V-=6BJ;DV)SQ5"0U/4URP M59=(G);JYH9`)(Q`57.ON00-K=")^/K+)+@`OO_*'"WIJ^)Z_0S`7*JX69*N MGBA=7=`V*K@E>1.BO_)_H(,*S3>0A(UY$G M-=9M]2&`_AZ/XJ9,W3!:KH)[N`E]9P4HG"Q]&)5CJC#!#?J;CG$#D=(H]=N+ MA_&?O=$:%>FA478MMI`&?4>OR:MN66&^6N8F>9SK1 M0N`]E0WM7D-F@`:7(3P''L#IRSS7Q+^'3P@^3Q?)H-$;[/('R=AH>:]W"*-U MN!:I2!MJP]21-A(;5Q!+HB.WZ`?TT(H0E\GG<&B6,+H4D\R.<\@&;#M#OFT( M_N8%:`WXBT\!6[=E%J4CPL/4G(Z$;_^@VX&TZ.IE`_G>9IOQ^2U`7A+IC2>. M2$>TN@U3`[1$&TK6)?.Q.<<^OU"76CVFO9!M7OGMKPOA+KY6SV&"K"M=@O.O MIN/,9/!YH61$X]O\Q)_Y/)M^^SJ@"&.=7L/$5T8^(C#(J(X#=44)G=(,7Q%]'7/=ZBS3AYQYN>"4+O%3L MW.5-^[T_NLM7;FC/7Y,/]:Z3UJ346]GW"LS*5TMK"F;I35/5I$[B:&?EH%SS M:=WGO=2W,J\%J6\-5+_?S+@]S>>JM+E^GN9(7JPX#RG"D-*$62K)?ZMHWQMB MS95T^S*'4C+#8$L,I>Q.[,[GO;^'HM*N#(`BSWN^!,O?5^'/US,&Z24"2TQH M@!S%-=B*#CW;*LG=R@JF#4YCNPI]LH$`:V&C:&PF+@J&AQ*$N44+^!![=')@ M!(W,!$3`J'$A\VZ6CM041V40:3PH5QY:(PR2LR5)-J]N1^,`KL.\18^NR1VA M6TE2L,CW%7<;LI^G):#<"G>3$U%+#F5V1$-*INRM5&JYS9AH**1QN1,=36W@ M09H\62:^\UYJT5_`NY6F9Y-V5YZND.TH)[&K#-5(0,KS/G+U/ND?*%A%-U&F M&^@#/G;I/HJ-*EC#*QPPMH59J^T(#EQKVHIOG"O>T?VM5.IMZ5&![@A;#5PA MA#)9ZN?SVA//R/,$T&X_&CB>6T&,>^NMJ_NP`GU5M\I;G6 M;R^2-);:O'#:>_Z8T)$UYSA#E@+!UQVFO7?`_P&Y+;N%@'%.5VAS#QDK`">W M$[F*"B]ZU:5@BM'62WFH*=Q08)\LEW[T3.H=TVM8L"Y?T2^RI9W17K0IKVK05!Y`[V4Z),Z@1(YO=#E]YWY;XF7*_;^:G0?LF+4 M$E1E388$?G;@SWT<3)NI@("(S8H@$->XTW6).G!!$L^U(.!T$0F=2,8^N<%L MQPLQC\-">`T92L+LY]&:C@,`?S#%@)?D&>=4=TY2C:RQ^Z]%:,C6OZ'(Z=2VK:[$.:"( M3A>S'/'=?`NF?[OI%E&O$5F,"OWZ2.4L;`1SB#'=R/,V75PC#+"#@)<=1*J* M0G9$MY?LUC:L;U%6%:CH_BOZ6CLZU9\LR[;SX;&T_L5N!F/9\GPJO[.>=ADE M?;IYF*#(B/I5`EE;$Q)D]2:P5J\>2SRKT9`EP+[EJ2.K`54]@1I6>[)N)FT/ M]OGKE0&\14\\&E!D\?PU=D$]0*E>":?ZQ(R?=VV$>R/3,4DS+J9=D(=?JW7_26!-53N&N)>I@,-XR_A6LH32-N3:% MOK!NH,X:`(MEW'-B]!W`X8+9G=!'>#F'S@H3CRP1I!?$AS.?N*$3\"C)$=8M^=04=:5S[B$I+VOY*73-KWE M^]:DI/X]^6>WW>?U[QW.KU!6>*E"V$)'`Z>Y\%2XCDS&+=%[UX4OOKA(2G47 M`_$7*+:&!B3RO#WL)XX3KL/H>'RRYBD6?XKR"2I&3TK$&OV02G@PE\^(D*>T M:,.G4A:!//39L#R#02%0358TKF=5=C$Z3*DGPALTJCD3D>29UC2H(@+&J((B M"ZN)7+;J1Q@P2RB0^)\0^/-G(M*(RBZ#T8%*26S=02L%9]\DM`0:G>Q`/I;% MN(S[`V!_34)1W7&-/E8@'XMBW@7;0R#/5L+:R$=][$`^$L6\UU7WC/P]Y`%F MEU]#N&;[(N#QL:BC!A("@]<)B5R)@GQ\*_K!I9[BVH8AZC)X'<@D2<,GG^P* MGVA<92FG0S=]^N^]RF4+QO52JK5ZF7)%3II0IB.$I2F)RU/Q;''-D550)``/KK"-0ZZPC4'5X"P`!!"4.```$.0$``.U<;6_CN!'^7J#_ M0?677H$ZMI/=!39([N#$26'4V1B)T]ZW`RV-9>Y2I(^DG/A^?8>49,EO>G%> M[$.%!0)9G!G.\"&'P^%H+WYY"9@S!ZFHX)>-SDF[X0!WA4>Y?]D(59,HE]+& M+S__]2\7?VLV?[UZ&#B><,,`N'9<"42#YSQ3/76NQ#,'9T1\'^2)8PF'1"J0 MB72GTSXQ_SJG[68SEG=%%/)CFZ4_/>E$+E\_?JU95L;CB;2!_V-!*!FQ(4E>0"2>I3P,14XH#C"<.**`#O" MT?ARUD[ZF-.YJ,K#!>=AL-T03\N67LR@A41-I$*)+@+,P.!W*V30@PD)F;YL M_!X21B<4O(9#M)9T'&I8(0AYAB0=<$\O>\X.W^=6U+A4LEC#1+N(`:>>>9W" M/R%J;#F2%C,0G6:[TSSK-'#2.,X%X5QHHG&NV=_FS6Q&^43$/_&%0>E<"@8C M%.&8AZ>'?M&(&[+6(_4Y6N\2KKNN*T*N<8D,!:-(J!H.]2X;^21+)1(U/)A0 M3JVZ[=/VJ=-T>E2Y3*A0`O[(2'-2<4XB[Z*U+F1=?HAKZY[_;)]G$A1";@=G M@"]B[I@DC],ES`W9'HRI9KOYXK<)(&^!TQWY+N1UJ+1`*M7EWB/X9K;W<1[( MP-H1H56&L`"S3^N869G.4JA#N.?$8IV,W!J[[=CUT4KNTS&#KE*@50\TH4R- MX$6C[XE@*Z#)1>Q+^W-G';)4GA,)='Z*13JQS'_4<%6"*Q>G0H#*XU/C4A*7 M$<''';#$;;FH?"Z%2B2I!J4D*-OA*-IQBH&HQW_[^.-1@ZK[R3!C<`3!MH8" M%#8V$2O#$1,G*Z5&HEJ$UB.:;-OQ*]`7;"Z?-H`K&;#5,<$;@GM:&M;30D!? MBV>-XQXX9N.)$G0%L<7^&-81Q_X9BVV.M@I#P<(\K9K.J#WL6\+:*0]HIQ#* MC4VS-)2=&L2=IX$Y&BIDBD-R'MAX7P#/V>:)8"FBWN8JX+!Z2EY_7;")Y:-0 M;U2O]FCE'5JA/]O7G=7X[8-?=EF5(2Q8:-71JQ??_N!5N-\J=\_U:3-W4@A@ M\E1#N`M"--+>Z-Y/KJ>$^Z#Z_'%*)$P%\_`$=?-[2/4BQK`<;2Z(G4]M@ULB M"9^O!?>`F[M\?%*(EV<+`U(2,7'B[AS*G6R'?W>B+IV?GC@)/8I\-=#%T]3,K`M@6I(G!*>K=5<&HP"C8GA3L.4=-;)I[5VEZTTI0/SFG5K<=> MRQCICA5?;S/5(+N?@;2:;\$LTY8/6F)E0]%@QDS%J'TWE3"Y M;)B:SF92M/D;FGOR$K"$Q,C/J4&UR*Z/4-QQ(H)(=T/*1F4J"A&XG#0&>ZU$ M^40`XF?8LU?7CNE'_=,A##5MO9GQC(RK&H\LP-[1ZH&1_T[FX@2M:N[:G'XG MHZ_37M[)=%QB54U?797O9'EOV*8MK\V.Z?-SI>3%^4ENI949:WPO8P.EL7\:B9\1H4SH\)9 M9U\54CBJJ9#P55;!RE+@GOABCE.+9JO%=^FPE<<\-%/F]_* MV`*F5?*FLB[;R_)+PI`PF/'_O`?XF^7]U9;!GFL@]V.!5P!@9>V'0#*O;()3 M+BK/QRQ?\F.7)O$''C;J,W[YM[S0KSM66A(7YX31/#],3&E)_'39T#+$91UM M#/83G'-LH=SO8RAO0BUNI4BN'D!Z5(%>%YYU,+]<3^+3S.1 MM7LP9DT-!`=-Y.)=C(W:QE&:`1M@3/7N(;C74Y#+8[2Q(#Y`<;_K:CJGVJ8- M([-+$A_*5%>"EV=KE$ON\_B^0`W)PO2$/[$G[^9E9@Z7!M,^QP,2(+*0T"0C M\"H1?Y9Q>0`7Z-QTEF1[%V@11OHS0I#7$KG:"&8GU[RB4YLETI_[X[JG-;MZ\:SY$9 MG-E"T7L(M.0/\,SN\H336FI".5(,A;(G,'4'Q-Q%&1&)]:\0HZ3H MJLY;&@ZM:XE/3W=XAWTXC\Q'F(_VO9`!AM61[@]@SDU&C=2(JT7]^0^ MLD&XGP/&&/[4J!]*=TH4='T)T>5'5U\3*1>HTW\("Y>Q2C6>XXQ`5==Y;:6 M0_O*/F-A0'T,"OHXY:1-3:SM2KDDA]:_BP&<1QEV,8='<$-IC]8W+RX+O2BT M,?%YJ+?F8O9D/K()-T3?H-.+7J2]QM@A3<'L:C[2DR4&IHPH98-T&X;N.'<5 MTQW!B6LDB0G&*BM#>>C%ED1&`ZJL)WL,9S.V2'?)58O* M4A_:JHUO]K?'AH5DQ^86B-*]$.(RJJ'EO17R`>84GN\G21JJSSTZIQY:PA9W ME-,@#):>XQ42LL8GNGZL^1B8F/MVW\2RA&'@(T93*G%)25.L&UN83Q3/3)R6 MLXCP0-D:P[$1SVTT'75(EVJ[-:K;VGQD"^J.\'""ZH2FYQ&X4RZ8\#%@N!82 MAE)XH6O]W#4P4U(!:^YP;_9#^\9H(_,4WQ MK(A!E=9L)0/U1L(.NS)-`/4`S!35K016]Y,[!`?2RKH^1X<"',%4`+?$I8RF MSN>U4CXL?ML9>WN>31029DPQ5Q8NVC(25R8-'DH)7FS>2*P8N`R_]^8_T.F[ MZ'[H6VA6K,'ONY`]JJ+_Z"_-*"6&%]-E#:1<@P_RH#%143!TM%'0`(CY#&9* M9P\@I$_0JVP>D0J(CO2@9`,6W##N\-``)D57RM:J7$=J?#;B)QDNK>6(#S.M&77QT.ACY[>;GP;N8ID-WBD**S+ M.9XZW.0CNZW[REN).]()L=,LF[;JVU_Q>28-/BNP_$G-7I;8K%=>[,%XI$.0 MQ$CI"G_2&`U&GBTZH"_O$LN0'OR4W@-MZ*6)\C8+8]3UNH,K1WVD7FX9[OY7 M8E<]\78+R\+A> MM*)B4GS\'U!+`0(>`Q0````(`(Y#"4&.8E?,:ET``*(6!@`1`!@```````$` M``"D@0````!V:79O+3(P,3(P-C,P+GAM;%54!0`#ZZPC4'5X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`(Y#"4$)J"2PI0T``(BM```5`!@```````$```"D M@;5=``!V:79O+3(P,3(P-C,P7V-A;"YX;6Q55`4``^NL(U!U>`L``00E#@`` M!#D!``!02P$"'@,4````"`".0PE!0,YV'.`,```&OP``%0`8```````!```` MI(&I:P``=FEV;RTR,#$R,#8S,%]D968N>&UL550%``/KK"-0=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`CD,)098T)D*$.@``G,T"`!4`&````````0`` M`*2!V'@``'9I=F\M,C`Q,C`V,S!?;&%B+GAM;%54!0`#ZZPC4'5X"P`!!"4. M```$.0$``%!+`0(>`Q0````(`(Y#"4')GG0T91T``"?S`0`5`!@```````$` M``"D@:NS``!V:79O+3(P,3(P-C,P7W!R92YX;6Q55`4``^NL(U!U>`L``00E M#@``!#D!``!02P$"'@,4````"`".0PE!2BS\?G$*``#<70``$0`8```````! M````I(%?T0``=FEV;RTR,#$R,#8S,"YX`L``00E#@`` ;!#D!``!02P4&``````8`!@`:`@``&]P````` ` end XML 38 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 58 149 1 false 15 0 false 5 false false R1.htm 00 - Document - Document and Entity Information Sheet http://meridianbioscience.com/role/DocumentAndEntityInformation Document and Entity Information false false R2.htm 0110 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://meridianbioscience.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) false false R3.htm 0120 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://meridianbioscience.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) true false R4.htm 0130 - Statement - Condensed Consolidated Balance Sheets Sheet http://meridianbioscience.com/role/BalanceSheets Condensed Consolidated Balance Sheets false false R5.htm 0131 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://meridianbioscience.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R6.htm 0140 - Statement - Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited) Sheet http://meridianbioscience.com/role/StatementOfChangesInShareholdersEquity Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited) false false R7.htm 0201 - Disclosure - Basis of Presentation Sheet http://meridianbioscience.com/role/BasisOfPresentation Basis of Presentation false false R8.htm 0202 - Disclosure - Significant Accounting Policies Sheet http://meridianbioscience.com/role/SignificantAccountingPolicies Significant Accounting Policies false false R9.htm 0203 - Disclosure - Inventories Sheet http://meridianbioscience.com/role/Inventories Inventories false false R10.htm 0204 - Disclosure - Major Customers and Segment Information Sheet http://meridianbioscience.com/role/MajorCustomersAndSegmentInformation Major Customers and Segment Information false false R11.htm 0205 - Disclosure - Intangible Assets Sheet http://meridianbioscience.com/role/IntangibleAssets Intangible Assets false false R12.htm 0401 - Disclosure - Significant Accounting Policies (Policies) Sheet http://meridianbioscience.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) false false R13.htm 0502 - Disclosure - Significant Accounting Policies (Tables) Sheet http://meridianbioscience.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) false false R14.htm 0503 - Disclosure - Inventories (Tables) Sheet http://meridianbioscience.com/role/InventoriesTables Inventories (Tables) false false R15.htm 0504 - Disclosure - Major Customers and Segment Information (Tables) Sheet http://meridianbioscience.com/role/MajorCustomersAndSegmentDataTables Major Customers and Segment Information (Tables) false false R16.htm 0505 - Disclosure - Intangible Assets (Tables) Sheet http://meridianbioscience.com/role/IntangibleAssetsTables Intangible Assets (Tables) false false R17.htm 0602 - Disclosure - Significant Accounting Policies (Details) Sheet http://meridianbioscience.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) false false R18.htm 06021 - Disclosure - Significant Accounting Policies (Details 1) Sheet http://meridianbioscience.com/role/SignificantAccountingPoliciesDetails1 Significant Accounting Policies (Details 1) false false R19.htm 06022 - Disclosure - Significant Accounting Policies (Details Textual) Sheet http://meridianbioscience.com/role/SignificantAccountingPoliciesDetailsTextual Significant Accounting Policies (Details Textual) false false R20.htm 0603 - Disclosure - Inventories (Details) Sheet http://meridianbioscience.com/role/InventoriesDetails Inventories (Details) false false R21.htm 0604 - Disclosure - Major Customers and Segment Information (Details) Sheet http://meridianbioscience.com/role/MajorCustomersAndSegmentDataDetails2 Major Customers and Segment Information (Details) false false R22.htm 06041 - Disclosure - Major Customers and Segment Information (Details Textual) Sheet http://meridianbioscience.com/role/MajorCustomersAndSegmentDataDetailsTextual Major Customers and Segment Information (Details Textual) false false R23.htm 0605 - Disclosure - Intangible Assets (Details) Sheet http://meridianbioscience.com/role/IntangibleAssetsDetails Intangible Assets (Details) false false R24.htm 06051 - Disclosure - Intangible Assets (Details Textual) Sheet http://meridianbioscience.com/role/IntangibleAssetsDetailsTextual Intangible Assets (Details Textual) false false All Reports Book All Reports Process Flow-Through: 0110 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Process Flow-Through: 0120 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Process Flow-Through: 0130 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Jun. 30, 2011' Process Flow-Through: Removing column 'Sep. 30, 2010' Process Flow-Through: 0131 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) vivo-20120630.xml vivo-20120630.xsd vivo-20120630_cal.xml vivo-20120630_def.xml vivo-20120630_lab.xml vivo-20120630_pre.xml true true XML 39 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Inventories (Details) (USD $)
In Thousands, unless otherwise specified

Jun. 30, 2012

Sep. 30, 2011

Inventories

Raw materials $ 7,147 $ 7,272

Work-in-process 6,662 7,016

Total 33,120 32,689

Illumigene instruments [Member]

Inventories

Finished goods 2,668 4,179

Kits and other [Member]

Inventories

Finished goods $ 16,643 $ 14,222

X

- Definition

Carrying amount as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InventoryNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. Also includes purchased parts that will be used as components of a finished product.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of merchandise or goods which are partially completed, are generally comprised of raw materials, labor and factory overhead costs, and which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Inventories (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Sep. 30, 2011
Inventories
Raw materials	$ 7,147	$ 7,272
Work-in-process	6,662	7,016
Total	33,120	32,689
Illumigene instruments [Member]
Inventories
Finished goods	2,668	4,179
Kits and other [Member]
Inventories
Finished goods	$ 16,643	$ 14,222